

GIP/GLP1 Co-Agonist Compounds

The present invention relates to compounds having activity at both the human glucose-dependent insulintropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus ("T2DM"). Also, the compounds may be useful in the treatment of obesity.

Over the past several decades, the prevalence of diabetes has continued to rise. T2DM is the most common form of diabetes accounting for approximately 90% of all diabetes. T2DM is characterized by high blood glucose levels associated mainly with insulin resistance. The current standard of care for T2DM includes diet and exercise, treatment with oral medications, and injectable glucose lowering drugs, including incretin-based therapies, such as GLP-1 receptor agonists. A variety of GLP-1 receptor agonists are currently available for treatment of T2DM, although currently marketed GLP-1 receptor agonists are generally dose-limited by gastrointestinal side effects such as nausea and vomiting. Subcutaneous injection is the typical route of administration for the available GLP-1 receptor agonists. When treatment with oral medications and incretin-based therapies are insufficient, insulin treatment is considered. Despite the advances in treatment available today, many patients with T2DM are unable to reach their glycemic control goals. Uncontrolled diabetes leads to several conditions associated with increased morbidity and mortality of patients. There is a need for a treatment to enable more patients with T2DM to reach their glycemic treatment goal.

Obesity is a complex medical disorder resulting in excessive accumulation of adipose tissue mass. Today obesity is a global public health concern that is associated with undesired health outcomes and morbidities. Desired treatments for patients with obesity strive to reduce excess body weight, improve obesity-related co-morbidities, and maintain long-term weight reduction. Available treatments for obesity are particularly unsatisfactory for patients with severe obesity. There is a need for alternative treatment options to induce therapeutic weight loss in patients in need of such treatment.

-2-

WO2016/111971 describes peptides stated to have GLP-1 and GIP activity.

WO2013/164483 also discloses compounds stated to have GLP-1 and GIP activity.

There is a need for T2DM treatments capable of providing effective glucose control for a larger portion of the patients in need of such treatment. There is a further need for T2D
 5 treatments capable of providing effective glucose control and with a favorable side effect profile. There is a need for alternate treatment options to provide therapeutic weight loss in a patient in need of such treatment. There is a need for an alternate treatment option for a patient in need of treatment for severe obesity.

There is a desire for compounds having agonist activity at the GIP and GLP-1
 10 receptors that are suitable for oral administration. Compounds with extended duration of action at each of the GIP and GLP-1 receptors are desirable to allow for less frequent dosing of the compound.

Accordingly, the present invention provides a compound of Formula I:

$R_1X_1X_2X_3GTX_6TSDX_{10}X_{11}X_{12}X_{13}X_{14}DX_{16}X_{17}AX_{19}X_{20}X_{21}X_{22}X_{23}X_{24}X_{25}X_{26}X_{27}$
 15 $X_{28}X_{29}X_{30}X_{31}$ (SEQ ID NO:3)

wherein:

R_1 is a modification of the N-terminal amino group wherein the modification is selected from the group consisting of Ac and absent;

X_1 is selected from the group consisting of Y, H, D-Tyr, F, desH, and desY,

20 X_2 is selected from the group consisting of Aib, α MeP, A, P, and D-Ala;
 or X_1 and X_2 combine to form desH- ψ [NHCO]-Aib;

X_3 is selected from the group consisting of E, N, Aad, and cTA;

X_6 is selected from the group consisting of F, α MeF, and α MeF(2F);

X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, E, α MeF,
 25 α MeF(2F), I, α MeY, Q, D-His, D-Tyr, cTA, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X_{11} is selected from the group consisting of S, α MeS, and D-Ser;

X_{12} is selected from the group consisting of I, S, D-Ile, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X₁₃ is selected from the group consisting of Nle, Aib, L, αMeL, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₁₄ is selected from the group consisting of L and K, wherein K is conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally conjugated to said K via a linker;

X₁₆ is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, αMeK, R, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₁₇ is selected from the group consisting of K, Q, I, and an amino acid conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally conjugated to said amino acid via a linker;

X₁₉ is selected from the group consisting of Q, A, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₀ is selected from the group consisting of Aib, Q, H, R, K, αMeK, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, I, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₂ is selected from the group consisting of F and αMeF;

X₂₃ is selected from the group consisting of I, L, A, G, F, H, E, V, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₄ is selected from the group consisting of S, Aad, D-Glu, E, Aib, H, V, A, Q, D, P, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₅ is selected from the group consisting of Y and αMeY;

X₂₆ is selected from the group consisting of L, αMeL, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₇ is selected from the group consisting of L, I, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₈ is selected from the group consisting of E, A, S, D-Glu, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X_{29} is selected from the group consisting of Aib, G, A, and $K(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}$;

X_{30} is selected from the group consisting of C, G, G- R_2 and $K(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}$;

5 X_{31} is absent or is selected from the group consisting of $PX_{32}X_{33}X_{34}\text{-}R_2$ (SEQ ID NO:4), $PX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}\text{-}R_2$ (SEQ ID NO:5), $PX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}\text{-}R_2$ (SEQ ID NO:6), $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}] X_{32}X_{33}X_{34}\text{-}R_2$ (SEQ ID NO:7), $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$
 10 $X_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}\text{-}R_2$ (SEQ ID NO:8), and $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}] X_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}\text{-}R_2$ (SEQ ID NO:9);

wherein:

15 X_{32} is S or $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

X_{33} is S or $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

X_{34} is selected from the group consisting of G, C, and $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

20 X_{35} is A or $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

X_{36} is P or $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

25 X_{37} is P or $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

X_{38} is P or $K[(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_q\text{CO}_2\text{H}]$;

X_{39} is selected from the group consisting of C, S, and K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_q-CO₂H];

X_{40} is selected from the group consisting of C and K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_q-CO₂H];

5 q is selected from the group consisting of 14, 15, 16, 17, 18, 19, and 20; and

R_2 is a modification of the C-terminal group, wherein the modification is NH₂ or absent;

or a pharmaceutically acceptable salt thereof;

wherein if X_{30} is G- R_2 , then X_{31} is absent;

10 wherein no more than one of X_{10} , X_{12} , X_{13} , X_{14} , X_{16} , X_{17} , X_{19} , X_{20} , X_{21} , X_{23} , X_{24} , X_{26} , X_{27} , X_{28} , X_{29} , X_{30} , X_{31} , X_{32} , X_{33} , X_{34} , X_{35} , X_{36} , X_{37} , X_{38} , X_{39} , and X_{40} may be a substituent that contains a fatty acid; and

wherein no more than one of X_{30} , X_{34} , X_{39} , and X_{40} may be C; and

15 wherein if one of X_{30} , X_{34} , X_{39} , and X_{40} is C, then none of X_{10} , X_{12} , X_{13} , X_{14} , X_{16} , X_{17} , X_{19} , X_{20} , X_{21} , X_{23} , X_{24} , X_{26} , X_{27} , X_{28} , X_{29} , X_{30} , X_{31} , X_{32} , X_{33} , X_{34} , X_{35} , X_{36} , X_{37} , X_{38} , X_{39} , and X_{40} is a substituent that contains a fatty acid.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein q is 16. In an embodiment is a compound of Formula I, or a

20 pharmaceutically acceptable salt thereof, wherein X_{31} is selected from the group consisting of SEQ ID NO:5 and SEQ ID NO:8. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the X_{17} amino acid that is conjugated to a fatty acid is a natural amino acid. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{17} is selected from the group consisting of

25 K, Q and I.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein K is conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally conjugated to said K via a linker.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{14} or X_{17} is selected from the group consisting of $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{16}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{14}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})-(\gamma\text{-Glu})\text{-(Trx)}\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})\text{-(Trx)}\text{-(}\gamma\text{-Glu)}\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})\text{-(}\epsilon\text{K)}\text{-(}\gamma\text{-Glu)}\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})\text{-(}\epsilon\text{K)}\text{-(}\epsilon\text{K)}\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})_2\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2\text{-(}\epsilon\text{K)}\text{-CO}-(\text{CH}_2)_{16}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2\text{-(}\epsilon\text{K)}\text{-CO}-(\text{CH}_2)_{14}\text{-CO}_2\text{H}$, and $\text{KDab-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Dab-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{14} or X_{17} is selected from the group consisting of $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{16}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{14}\text{-CO}_2\text{H}$, and $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{14} or X_{17} is selected from the group consisting of $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{16}\text{-CO}_2\text{H}$, $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$, and $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{14}\text{-CO}_2\text{H}$. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{14} or X_{17} is selected from the group consisting of $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{18}\text{-CO}_2\text{H}$ and $K(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO}-(\text{CH}_2)_{16}\text{-CO}_2\text{H}$. In an embodiment is a compound of Formula I, or pharmaceutically acceptable salt thereof, wherein X_{14} or X_{17} is $K(2-[2-(2\text{-amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_a\text{-(}\gamma\text{-Glu)}_b\text{-CO}-(\text{CH}_2)_q\text{-CO}_2\text{H}$, wherein a is 2, b is 1, and q is selected from the group consisting of 18 and 20. In an embodiment is a compound of

Formula I, or pharmaceutically acceptable salt thereof, wherein X_{14} or X_{17} is $K(2-[2-(2-$
 amino-ethoxy)-ethoxy]-acetyl) $_a$ -(γ -Glu) $_b$ -CO-(CH $_2$) $_q$ -CO $_2$ H, wherein a is 2, b is 1 and q is 18.

In an embodiment is a compound of Formula I, or pharmaceutically acceptable salt thereof,
 wherein X_{14} or X_{17} is $K(2-[2-(2-$
 amino-ethoxy)-ethoxy]-acetyl) $_a$ -(γ -Glu) $_b$ -CO-(CH $_2$) $_q$ -CO $_2$ H,

5 wherein, a is 2, b is 1, and q is 20.

In an embodiment is a Formula I compound, or pharmaceutically acceptable salt
 thereof, wherein X_1 and X_2 do not combine to form desH- ψ [NHCO]-Aib (hereafter a
 “Formula II” compound).

10

In an embodiment is a compound of Formula I, or pharmaceutically acceptable salt
 thereof, wherein:

X_{17} is an amino acid conjugated to a C $_{16}$ -C $_{22}$ fatty acid wherein said fatty acid is
 optionally conjugated to said amino acid via a linker; and

15

X_{30} is selected from the group consisting of G-R $_2$ and G;

wherein if X_{30} is G, then X_{31} is selected from the group consisting of PX $_{32}$ X $_{33}$ X $_{34}$ -R $_2$
 (SEQ ID NO:4), wherein X_{32} is S, X_{33} is S and X_{34} is G (SEQ ID NO:297), and

PX $_{32}$ X $_{33}$ X $_{34}$ X $_{35}$ X $_{36}$ X $_{37}$ X $_{38}$ X $_{39}$ -R $_2$ (SEQ ID NO:5), wherein X_{32} is S, X_{33} is S, X_{34} is G,
 X_{35} is A, X_{36} is P, X_{37} is P, X_{38} is P and X_{39} is S (SEQ ID NO:298) (hereafter a

20

“Formula III” compound).

In an embodiment is a compound of Formula III, or a pharmaceutically acceptable
 salt thereof, wherein the X_{17} amino acid is conjugated to the fatty acid via a linker (hereafter a
 “Formula IIIa” compound).

In an embodiment is a compound of Formula III and IIIa, or a pharmaceutically
 25 acceptable salt thereof, wherein:

X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, E, α MeF,
 α MeF(2F), I, α MeY, Q, D-His, D-Tyr, and cTA;

X_{12} is selected from the group consisting of I, S, and D-Ile;

X_{13} is selected from the group consisting of Nle, Aib, L, and α MeL;

-8-

- X₁₄ is selected from the group consisting of L and K;
X₁₆ is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, αMeK, and R;
X₁₉ is selected from the group consisting of Q, and A;
- 5 X₂₀ is selected from the group consisting of Aib, Q, H, R, K, and αMeK;
X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, and I;
X₂₃ is selected from the group consisting of I, L, A, G, F, H, E, and V;
X₂₄ is selected from the group consisting of S, Aad, D-Glu, E, Aib, H, V, A, Q, D, and P;
- 10 X₂₆ is selected from the group consisting of L, and αMeL;
X₂₇ is selected from the group consisting of L, and I;
X₂₈ is selected from the group consisting of E, A, S, and D-Glu;
X₂₉ is selected from the group consisting of Aib, G, and A;
X₃₀ is selected from the group consisting of G and G-R₂;
- 15 wherein if X₃₀ is G; then X₃₁ is selected from the group consisting of PX₃₂X₃₃X₃₄-R₂ (SEQ ID NO:4), wherein X₃₂ is S, X₃₃ is S and X₃₄ is G (SEQ ID NO:297) and PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5), wherein X₃₂ is S, X₃₃ is S, X₃₄ is G, X₃₅ is A, X₃₆ is P, X₃₇ is P, X₃₈ is P and X₃₉ is S (SEQ ID NO:298) (hereafter a “Formula IIIb” compound).
- 20 In an embodiment, is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein the linker comprises from 1 to 2 amino acids, and in a further embodiment of these particular Formula III, IIIa and IIIb compounds are those wherein the linker amino acids are independently selected from the group consisting of Glu and γ-Glu. In another embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically
- 25 acceptable salt thereof, wherein the linker comprises from one or two (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties and in a further embodiment of these particular formula III, IIIa and IIIb compounds are those where the linker is (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_a-(γ-Glu)_b, wherein a is selected from the group consisting of 1 or 2; and b is selected from the group consisting of 1 or 2.

In an embodiment is a compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein X_{17} is an amino acid conjugated to a C_{16} - C_{22} fatty acid, wherein the amino acid is K and wherein said fatty acid is optionally conjugated to said amino acid via a linker.

5 In an embodiment is a compound of Formula III, or pharmaceutically acceptable salt thereof, wherein:

R_1 is absent;

X_1 and X_2 do not combine to form desH- ψ [NHCO]-Aib;

X_{17} is K conjugated to a C_{16} - C_{22} fatty acid wherein said fatty acid is optionally
10 conjugated to said amino acid via a linker.

In an embodiment is a compound of Formula III, or pharmaceutically acceptable salt thereof, wherein:

X_1 is Y;

X_2 is Aib;

15 X_3 is E;

X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, and Y;

X_{11} is S;

X_{12} is I;

X_{14} is L;

20 X_{16} is selected from the group consisting of K, E, Orn, Dab, and Dap;

X_{17} is K conjugated to a C_{16} - C_{22} fatty acid wherein said fatty acid is optionally
conjugated to said amino acid via a linker;

X_{19} is Q;

X_{20} is Aib;

25 X_{21} is selected from the group consisting of H, Aad, D, Aib, T, A, and E;

X_{22} is F;

X_{23} is I;

X_{24} is selected from the group consisting of S, Aad, D-Glu, and E;

X_{26} is L; and

-10-

X₂₈ is selected from the group consisting of E and A.

In an embodiment is a compound of Formula III, or pharmaceutically acceptable salt thereof, wherein:

- X₁ is Y;
- 5 X₂ is Aib;
- X₃ is E;
- X₆ is αMeF(2F);
- X₁₀ is selected from the group consisting of Y, 4-PaI, and V;
- X₁₁ is S;
- 10 X₁₂ is I;
- X₁₃ is selected from the group consisting of L, Aib, and αMeL;
- X₁₄ is L;
- X₁₆ is selected from the group consisting of E, K, and Orn;
- X₁₇ is K conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally
- 15 conjugated to said amino acid via a linker;
- X₁₉ is Q;
- X₂₀ is Aib
- X₂₁ is selected from the group consisting of E, A, and T;
- X₂₂ is F;
- 20 X₂₃ is I;
- X₂₄ is D-Glu;
- X₂₅ is selected from the group consisting of Y and αMeY;
- X₂₆ is L;
- X₂₇ is I;
- 25 X₂₈ is E;
- X₂₉ is G;
- X₃₀ is G; and
- X₃₁ is PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5), wherein X₃₂ is S, X₃₃ is S, X₃₄ is G, X₃₅ is A, X₃₆ is P, X₃₇ is P, X₃₈ is P, X₃₉ is S (SEQ ID NO:298).

In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein R_2 is absent.

In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein R_2 is NH_2 .

5 In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{13} is αMeL .

In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{25} is Y and X_{13} is αMeL .

10 In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{17} is K conjugated to a fatty acid via a linker to the epsilon-amino group of the K side-chain wherein said fatty acid and linker have the following formula:

(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) $_a$ -(γ -Glu) $_b$ -CO-(CH $_2$) $_q$ -CO $_2$ H, wherein a is 1 or 2; b is 1 or 2; and q is selected from the group consisting of 14 to 20.

15 In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is Orn, X_{13} is αMeL , and X_{25} is Y. In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is E, X_{13} is αMeL , and X_{25} is Y. In an embodiment, is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is E, X_{13} is αMeL , X_{10} is Y, and X_{25} is αMeY . In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is Orn, X_{13} is αMeL , X_{10} is 4Pal, and X_{25} is Y. In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is Orn, X_{13} is αMeL , X_{10} is V, and X_{25} is Y. In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is E, X_{13} is αMeL , X_{25} is Y, and X_{17} is K(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) $_a$ -(γ -Glu) $_b$ -CO-(CH $_2$) $_q$ -CO $_2$ H, wherein a is 2; b is 1; and q is selected from the group consisting of 14 to 20. In an embodiment is a compound of Formula III, IIIa and IIIb, or a pharmaceutically acceptable salt thereof, wherein X_{16} is E, X_{13} is αMeL , X_{10} is

20

25

Y, and X₂₅ is Y and and X₁₇ is K(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)_a-(γ-Glu)_b-CO-(CH₂)_q-CO₂H, wherein a is 2; b is 1; and q is selected from the group consisting of 16 to 20.

In an embodiment is a compound of Formula I selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, or a
 5 pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:10, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:11, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:12, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID
 10 NO:13, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:14, or a pharmaceutically acceptable salt thereof.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X₁ is selected from the group consisting of Y, F, and D-Tyr; X₆ is F; and X₁₃ is selected from the group consisting of Aib, L, and αMeL.

15 In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R₁ is absent; X₁ is selected from the group consisting of Y, F, and D-Tyr; X₆ is F; X₁₃ is selected from the group consisting of Aib, L, and αMeL; X₂ is Aib; X₃ is E; X₁₀ is Y; X₁₁ is S; X₁₂ is I; X₁₄ is L; X₁₆ is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, αMeK, and R; X₁₇ is an amino acid conjugated to a C₁₆-C₂₂
 20 fatty acid wherein said fatty acid is optionally conjugated to said amino acid via a linker; X₁₉ is Q; X₂₀ is selected from the group consisting of Aib, Q, H, and K; X₂₁ is selected from the group consisting of H, D, T, A, and E; X₂₂ is F; X₂₃ is I; X₂₄ is selected from the group consisting of D-Glu and E; X₂₆ is L; X₂₇ is I; X₂₈ is selected from the group consisting of E, A, S, and D-Glu; X₂₉ is selected from the group consisting of Aib, G, and A; X₃₀ is selected
 25 from the group consisting of C, G, and G-R₂; X₃₁ is absent or is selected from the group consisting of PX₃₂X₃₃X₃₄-R₂ (SEQ ID NO:4), PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5), and PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀-R₂ (SEQ ID NO:6); wherein: X₃₂ is S; X₃₃ is S; X₃₄ is selected from the group consisting of G and C; X₃₅ is A; X₃₆ is P; X₃₇ is P; X₃₈ is P; X₃₉ is selected from the group consisting of C and S; and X₄₀ is C.

In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_1 is selected from the group consisting of Y, F, and D-Tyr; X_6 is F; and X_{13} is selected from the group consisting of Aib, L, and α MeL; X_{28} is A; X_{29} G; X_{30} is G; X_{31} is $PX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}-R_2$ (SEQ ID NO:5); X_{34} is G; and X_{39} is S.

5 In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_1 is selected from the group consisting of Y and D-Tyr; and X_{13} α MeL.

In an embodiment is a compound of Formula I selected from the group consisting of SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, and
10 SEQ ID NO:308, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:303, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:304, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:305, or a pharmaceutically acceptable salt thereof. In an embodiment is a
15 compound of Formula I that is SEQ ID NO:306, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:307, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:308, or a pharmaceutically acceptable salt thereof. In an embodiment is a compound of Formula I that is SEQ ID NO:386, or a pharmaceutically acceptable salt
20 thereof.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, α MeF, α MeF(2F), I, α MeY, Q, D-His, E, cTA, and D-Tyr;

25 X_{12} is selected from the group consisting of I, D-Ile, and S;

X_{13} is selected from the group consisting of Nle, Aib, L, and α MeL;

X_{14} is L;

X_{16} is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, α MeK, and R;

-14-

X₁₇ is selected from the group consisting of K, Q, and I;

X₁₉ is selected from the group consisting of Q and A;

X₂₀ is selected from the group consisting of Aib, Q, H, R, K, and α MeK;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, and I;

5 X₂₃ is selected from the group consisting of I, L, A, G, F, H, E, and V;

X₂₄ is selected from the group consisting of S, Aad, D-Glu, E, Aib, H, V, A, Q, D,
and P;

X₂₆ is selected from the group consisting of L and α MeL;

X₂₇ is selected from the group consisting of L and I;

10 X₂₈ is selected from the group consisting of E, A, S, and D-Glu; and

X₂₉ is selected from the group consisting of Aib, G, and A (hereafter a "Formula IV"
compound).

In an embodiment of is a compound of Formula IV, or a pharmaceutically acceptable
salt thereof wherein X₃₉ is C. In an embodiment is a compound of Formula IV, or a
15 pharmaceutically acceptable salt thereof wherein X₄₀ is C.

In an embodiment is a compound of Formula IV, or a pharmaceutically acceptable
salt thereof, wherein one, and only one, of X₃₀, X₃₄, X₃₉, and X₄₀ is C. In an embodiment is a
compound of Formula IV, or a pharmaceutically acceptable salt thereof, wherein one, and
only one, of X₃₀, X₃₄, X₃₉, and X₄₀ is C modified using time-extension technology. In an
20 embodiment is a compound of Formula IV, or pharmaceutically acceptable salt thereof,
wherein C is modified using time-extension technology wherein the time-extension
technology is XTEN. In an embodiment is a compound of Formula IV, or pharmaceutically
acceptable salt thereof, wherein C is modified using time-extension technology wherein the
time-extension technology is a (Glu)_m biotin wherein m is 0, 1, 2, or 3. In an embodiment is
25 a compound of Formula IV, or a pharmaceutically acceptable salt thereof, wherein:

X₁ is Y;

X₂ is Aib;

X₃ is E;

X₁₀ is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, and Y;

-15-

X₁₁ is S;

X₁₂ is I;

X₁₆ is selected from the group consisting of K, E, Orn, Dab, and Dap;

X₁₉ is Q;

5 X₂₀ is selected from the group consisting of Aib and K;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, and E;

X₂₂ is F;

X₂₃ is I;

X₂₄ is selected from the group consisting of S, Aad, D-Glu, and E;

10 X₂₆ is L; and

X₂₈ is selected from the group consisting of E and A;

or a pharmaceutically acceptable salt thereof.

In an embodiment is a compound of Formula IV, or a pharmaceutically acceptable salt thereof, wherein

15 X₁ is Y;

X₂ is Aib;

X₃ is E;

X₁₀ is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, and Y;

X₁₁ is S;

20 X₁₂ is I;

X₁₆ is selected from the group consisting of K, E, Orn, Dab, and Dap;

X₂₀ is Aib;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, and E;

X₂₂ is F;

25 X₂₄ is selected from the group consisting of S, Aad, D-Glu, and E;

X₂₇ is I; and

X₂₈ is selected from the group consisting of E and A.

In an embodiment is a compound of Formula I, or a pharmaceutical salt thereof, wherein:

-16-

X₁₄ is L;

X₁₇ is selected from the group consisting of K, Q, and I;

X₃₀ is selected from the group consisting of G-R₂ and G; and

q is selected from the group consisting of 16, 18, and 20;

5 wherein if X₃₀ is G, then X₃₁ is selected from the group consisting of:

PX₃₂X₃₃X₃₄-R₂ (SEQ ID NO:4), wherein:

X₃₂ is S, X₃₃ is S, X₃₄ is G and R₂ is absent (SEQ ID NO:299) or

X₃₂ is S, X₃₃ is S, X₃₄ is G and R₂ is NH₂ (SEQ ID NO:300);

and

10 PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5), wherein:

X₃₂ is S, X₃₃ is S, X₃₄ is G, X₃₅ is A, X₃₆ is P, X₃₇ is P, X₃₈ is P, X₃₉ is S and
R₂ is absent (SEQ ID NO:301) or

X₃₂ is S, X₃₃ is S, X₃₄ is G, X₃₅ is A, X₃₆ is P, X₃₇ is P, X₃₈ is P, X₃₉ is S and
R₂ is NH₂ (SEQ ID NO:302); and

15 wherein one of X₁₀, X₁₂, X₁₃, X₁₄, X₁₆, X₁₉, X₂₀, X₂₁, X₂₃, X₂₄, X₂₆, X₂₇, X₂₈, and X₂₉ is
K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-γGlu-CO-(CH₂)_qCO₂H (hereafter a "Formula V"
compound).

In an embodiment is a compound of Formula V, or a pharmaceutically acceptable salt
thereof, wherein:

20 X₁ is Y;

X₂ is Aib;

X₃ is E;

X₁₀ is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, E, cTA, and
K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

25 X₁₁ is S;

X₁₂ is selected from the group consisting of I, D-Ile, and K(2-[2-(2-amino-ethoxy)-
ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₁₆ is selected from the group consisting of K, E, Orn, Dab, Dap, and K(2-[2-(2-
amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

-17-

X₁₇ is selected from the group consisting of K and I;

X₁₉ is selected from the group consisting of Q and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

5 X₂₀ is selected from the group consisting of Aib and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₂ is F;

10 X₂₄ is selected from the group consisting of S, Aad, D-Glu, E, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₆ is selected from the group consisting of L and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₇ is selected from the group consisting of L and I; and

15 X₂₈ is selected from the group consisting of E, A, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H.

In an embodiment is a compound of Formula V, or a pharmaceutically acceptable salt thereof, wherein X₂₀ is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H, wherein q is 16 or 18. In an embodiment is a compound of Formula V, or a pharmaceutically acceptable salt thereof, wherein X₃₁ is SEQ ID NO:301 or SEQ ID NO:302.

20 An embodiment provides a method of treating a condition selected from the group consisting of T2DM, obesity, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), dyslipidemia and metabolic syndrome, comprising administering to a subject in need thereof, an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. An embodiment provides a method for providing
25 therapeutic weight loss comprising administering to a subject in need thereof, an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment, the condition is NAFLD. In one embodiment, the condition is NASH.

An embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in therapy. An embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in therapy to treat a condition selected from the group consisting of T2DM, obesity, NAFLD, NASH, dyslipidemia and metabolic syndrome. In an embodiment, the condition is T2DM. In an embodiment, the condition is obesity. In an embodiment, the condition is NAFLD. In an embodiment, the condition is NASH. In an embodiment, the condition is metabolic syndrome.

The compounds of Formula I, or a pharmaceutically acceptable salt thereof, may be useful in the treatment of a variety of symptoms or disorders. For example, certain embodiments, provide a method for treatment of T2DM in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In an embodiment, is a method for treatment of obesity in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In an embodiment, the method is inducing non-therapeutic weight loss in a subject, comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

In certain embodiments, the present invention provides a method for treatment of metabolic syndrome in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In an embodiment, the method is treatment of NASH comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Also provided herein is a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, a growth differentiation factor 15 modulator ("GDF15"), a peptide tyrosine tyrosine modulator ("PYY"), a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and oxyntomodulin agonist ("OXM") in the treatment of a

condition selected from the group consisting of T2DM, obesity, NAFLD, NASH, dyslipidemia and metabolic syndrome. In an embodiment, a compound of the present invention is provided in a fixed dose combination with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM. In an embodiment is a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM in the treatment of a condition selected from the group consisting of T2DM and obesity. In an embodiment is a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, and a SGLT-2 inhibitor in the treatment of a condition selected from the group consisting of T2DM and obesity.

In other embodiments, the compounds, or a pharmaceutically acceptable salt thereof, may be useful to improve bone strength in subjects in need thereof. The compounds of the present invention, or a pharmaceutically acceptable salt thereof, may be useful in the treatment of other disorders such as Parkinson's disease or Alzheimer's disease. Incretins and incretin analogs having activity at one or more of the GIP, GLP-1 and/or glucagon receptors have been described as having the potential to have therapeutic value in a number of other diseases or conditions, including for example obesity, NAFLD and NASH, dyslipidemia, metabolic syndrome, bone related disorders, Alzheimer's disease, and Parkinson's disease. See, e.g., Jall S., et. al, *Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice*, MOL. METAB. 6(5):440-446 (March 2017); Carbone L.J., et. al., *Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis*. J.GASTROENTEROL. HEPATOL., 31(1):23-31 (Jan. 2016); B. Finan, et. al, *Reappraisal of GIP Pharmacology for Metabolic Diseases*.

- TRENDS MOL. MED., 22(5):359-76 (May 2016); Choi, I.Y., et al., *Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP triple-agonist (HM15211)*, ADA 2017 Poster 1139-P; Ding, K.H., *Impact of glucose-dependent insulinotropic peptide on age-induced bone loss*, J. BONE MINER. RES., 23(4):536-43 (2008);
- 5 Tai, J. et. al, *Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease*, BRAIN RES. 1678, 64-74 (2018);
- T.D. Müller et al., *The New Biology and Pharmacology of Glucagon*, PHYSIOL. REV. 97: 721-766 (2017); Finan, B. et. al, *Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans*, SCI. TRANSL. MED., 5:209 (October 2013); Hölscher C,
- 10 *Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases*. BIOCHEM. SOC. TRANS. 42(2):593-0 (Apr. 2014).

Another embodiment provides the use of a compound of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition selected from the group consisting of T2DM, obesity, NAFLD,

15 NASH, dyslipidemia and metabolic syndrome. In an embodiment, the medicament is for the treatment of T2DM. In an embodiment, the medicament is for the treatment of obesity. In an embodiment, the medicament is for the treatment of NAFLD. In an embodiment, the medicament is for the treatment of NASH.

Another embodiment provides a pharmaceutical composition comprising a compound

20 of Formula I, or a pharmaceutically acceptable salt thereof, and at least one selected from the group consisting of a carrier, diluent, and excipient.

In an embodiment is a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, at least one permeation enhancer and at least one protease inhibitor. In an embodiment, is a pharmaceutical composition

25 comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, at least one permeation enhancer, and at least one selected from the group consisting of carrier, diluent, and excipient.

In an embodiment is a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, a permeation enhancer, a protease

inhibitor, and at least one selected from the group consisting of carrier, diluent, and excipient. In an embodiment is a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a permeation enhancer. In an embodiment is a pharmaceutical composition comprising a compound of the present invention, or a
5 pharmaceutically acceptable salt thereof, and a permeation enhancer. In an embodiment the permeation enhancer is selected from the group consisting of sodium decanoate ("C10"), sodium taurodeoxycholate ("NaTDC"), lauroyl carnitine ("LC"), dodecyl maltoside ("C12-maltoside"), dodecyl phosphatidylcholine ("DPC"), sodium N-[8-(2-hydroxybenzoyl) amino] caprylate ("SNAC") and a Rhamnolipid. In an embodiment the permeation enhancer is
10 selected from the group consisting of C10 and LC. In an embodiment a protease inhibitor is selected from the group consisting of soybean trypsin inhibitor ("SBTI"), soybean trypsin-chymotrypsin inhibitor ("SBTCI"), ecotin, sunflower trypsin inhibitor ("SFTI"), leupeptin, citric acid, ethylenediaminetetraacetic acid ("EDTA"), sodium glycocholate and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride ("AEBSF"). In an embodiment, a
15 protease inhibitor is selected from the group consisting of SBTI, SBTCI, and SFTI. In an embodiment, a protease inhibitor is SBTI.

As used herein, the term "treating" or "to treat" includes restraining, slowing, stopping, or reversing the progression or severity of a symptom, condition, or disorder.

Certain compounds of the present invention are generally effective over a wide
20 dosage range. For example, dosages for once weekly parenteral dosing may fall within the range of 0.05 mg to about 30 mg per person per week.






The compounds of the present invention include novel amino acid sequences having affinity for the respective GLP-1 and GIP receptors, with desired potency at each of these receptors. GLP-1 is a 36 amino acid peptide, the major biologically active fragment of which
25 is produced as a 30-amino acid, C-terminal amidated peptide (GLP-1₇₋₃₆) (SEQ ID NO:2).

GIP is a 42 amino acid peptide (SEQ ID NO:1), which, like GLP-1, is also known as an incretin, and plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in the presence of glucose.


The compounds provide desired potency at each of the GIP and GLP-1 receptors. In an embodiment, compounds are suitable for oral administration. In an embodiment, compounds have desirable GIP and GLP receptor extended time action. In an embodiment, compounds have desirable GIP and GLP receptor activity wherein the GIP agonist potency is
5 from 2.5 to 5 times the GLP1 receptor potency as measured by the casein cAMP assay described herein below, wherein the potency is normalized against native GIP and GLP on the day the assay is run. In an embodiment, compounds have desirable GIP and GLP receptor activity wherein the GIP agonist potency is from 2.5 to 10 times the GLP1 receptor potency as measured by the casein cAMP assay, wherein the potency is normalized against
10 native GIP and GLP on the day the assay is run.

As used herein the term "amino acid" means both naturally occurring amino acids and unnatural amino acids. The amino acids are typically depicted using standard one letter codes (e.g., L = leucine), as well as alpha-methyl substituted residues of natural amino acids (e.g., α -methyl leucine, or α MeL and α -methyl lysine, or α MeK) and certain other unnatural
15 amino acids, such as alpha amino isobutyric acid, or "Aib," "4Pal," "Orn," and the like. The structures of these amino acids appear below:


-23-

 α MeL α MeK α MeF(2F) α MeF α MeY


Aib




D-Glu




Om




2Pal




3Pal




4Pal



Aad




Trn




AOC




Dap




cTA



Dab



-24-



As used herein “Orn” means ornithine. As used herein “4Pal” means 3-(4-Pyridyl)-L-alanine. As used herein “αMeF(2F)” means alpha-methyl 2-F-phenylalanine. As used herein

5 “αMeY,” “αMeK,” and “αMeL” mean alpha methyl tyrosine, alpha methyl lysine, and alpha methyl leucine, respectively. As used herein, “e” and “D-Glu” mean D-glutamic acid. As used herein “D-His” and “h” each mean D-histidine. As used herein “D-Tyr” and “y” each means D-tyrosine. As used herein “D-Ser” and “s” means means D-serine. As used herein “D-Ala” and “a” each means D-alanine. As used herein, “αMeF(2F)” means alpha-methyl-

10 F(2F) and alpha-methyl-Phe(2F). As used herein, “αMeF”, means alpha-methyl-F and alpha-methyl-Phe. As used herein, “αMeY”, means alpha-methyl-Tyr. As used herein “αMeK”, means alpha-methyl-Lys. As used herein, “αMeL”, means alpha-methyl-Leu. As used herein, “αMeS”, means alpha-methyl-serine and alpha-methyl-Ser. As used herein “αMeP”, means alpha-methyl-proline and alpha-methyl-Pro. As used herein, “desH”, means desHis.

15 As used herein, “desY”, means desTyr.

When X₁ is DesH and X₂ is Aib, and the DesH and Aib can combine to form a group as illustrated above, DesH-ψ[NHCO]-Aib.

When used herein, the term “amino acid conjugated to a C₁₆-C₂₂ fatty acid” refers to any natural or unnatural amino acid with a functional group that has been chemically modified to conjugate to a fatty acid by way of a covalent bond to the fatty acid or, preferably, by way of a linker. Examples of such functional groups include amino, carboxyl, chloro, bromo, iodo, azido, alkynyl, alkenyl, and thiol groups. Examples of natural amino acids which include such functional groups include K (amino), C (thiol), E (carboxyl) and D (carboxyl). In an embodiment the conjugated amino acid is K.

As noted above, in an embodiment of a compound of Formula I, II, III, IV, and V are compounds of the present invention wherein a fatty acid moiety is conjugated via a linker or a direct bond. In an embodiment, compounds of the present invention include a fatty acid moiety conjugated, preferably via a linker, to a K at position 14 or 17. In an embodiment, the conjugation is an acylation. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain. In an embodiment of the compounds of the present invention include a fatty acid moiety conjugated, via a linker, to a K at position 17.

In an embodiment, compounds of the present invention include a fatty acid moiety conjugated directly, without a linker, to a natural or unnatural amino acid with a functional group available for conjugation. In certain preferred embodiments the conjugated amino acid is selected from the group consisting of K, C, E and D. In particularly preferred embodiments the conjugated amino acid is K. In such embodiments, the conjugation is to the epsilon-amino group of the K side-chain.

In an embodiment, the linker comprises one to four amino acids, an amino polyethylene glycol carboxylate, or mixtures thereof. In an embodiment, the amino polyethylene glycol carboxylate has the following formula:

$$\text{H}-\{\text{NH}-\text{CH}_2-\text{CH}_2-[\text{O}-\text{CH}_2-\text{CH}_2]_p-\text{O}-(\text{CH}_2)_z-\text{CO}\}_r-\text{OH}$$
, wherein p is any integer from

1 to 12, z is any integer from 1 to 20, and r is 1 or 2.


In an embodiment is a compound of Formula I which comprises an amino acid conjugated to a fatty acid via a linker, wherein the linker is one to two amino acids selected from the group consisting of Glu and γ -Glu. In an embodiment the linker is one to two (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. The compounds of the present invention utilize

a C₁₆-C₂₂ fatty acid chemically conjugated to the functional group of an amino acid either by a direct bond or by a linker. In an embodiment, the fatty acid moiety is conjugated to a lysine at position 17 via a linker between the lysine and the fatty acid. In an embodiment, the fatty acid moiety is conjugated to a lysine at position 20 via a linker between the lysine and fatty acid. In an embodiment, the fatty acid chain is any single chain C₁₆-C₂₂ fatty acid.


In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the fatty acid is conjugated with a linker, and the linker comprises one or more (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties, in combination with zero or one to four amino acids. In an embodiment, the linker may comprise one to four Glu or γ -Glu amino acid residues. In an embodiment, the linker may comprise 1 or 2 Glu or γ -Glu amino acid residues. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, comprises a fatty acid conjugated via a linker wherein, the linker comprises either 1 or 2 γ -Glu amino acid residues. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, comprises a fatty acid conjugated via a linker wherein the linker may comprise one to four amino acid residues (such as, for example Glu and γ -Glu amino acids) used in combination with up to 36 (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. Specifically, in an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, which comprises a fatty acid conjugated via a linker wherein, the linker constitutes combinations of one to four Glu and γ -Glu amino acids and one to four (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, which comprises a fatty acid conjugated via a linker wherein the linker is comprised of combinations of one or two γ -Glu amino acids and one or two (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, which comprises a fatty acid conjugated via a linker wherein the linker and fatty acid components have the following formula:

$(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)_a-(\gamma-Glu)_b-CO-(CH_2)_q-CO_2H$, wherein a is 1 or 2, b is 1 or 2 and q is 16 or 18. In an embodiment, a is 2, b is 1 and q is 18; and the structure is:


-27-



In an embodiment, a is 1, b is 2 and q is 18; and the structure is:



5 In an embodiment a is 1, b is 1, and q is 18; and the structure is:



The term “C₁₆-C₂₂ fatty acid” as used herein means a carboxylic acid with between 16 and 22 carbon atoms. In an embodiment, the C₁₆-C₂₂ fatty acid suitable for use herein can be a saturated diacid. In an embodiment, the fatty acid is C₂₀-C₂₂. In an embodiment q is selected from the group consisting of 14, 16, 18, and 20. In an embodiment q is selected from 18 and 20. In an embodiment q is 18. In an embodiment q is 20.

In an embodiment, specific saturated C₁₆-C₂₂ fatty acids that are suitable for the compounds and uses thereof disclosed herein include, but are not limited to, hexadecanedioic acid (C₁₆ diacid), heptadecanedioic acid (C₁₇ diacid), octadecanedioic acid (C₁₈ diacid), nonadecanedioic acid (C₁₉ diacid), eicosanedioic acid (C₂₀ diacid), heneicosanedioic acid (C₂₁ diacid), docosanedioic acid (C₂₂ diacid), including branched and substituted derivatives thereof.

In an embodiment, the C₁₆-C₂₂ fatty acid is selected from the group consisting of a saturated C₁₈ diacid, a saturated C₁₉ diacid, a saturated C₂₀ diacid, and branched and substituted derivatives thereof. In an embodiment, the C₁₆-C₂₂ fatty acid is selected from the

group consisting of stearic acid, arachadic acid and eicosanedioic acid. In an embodiment, the C₁₆-C₂₂ fatty acid is arachadic acid.

As shown in the chemical structures of Examples 1-5 below, in an embodiment the linker-fatty acid moieties described above link to the epsilon-amino group of the lysine side-chain.

In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein none of X₃₀, X₃₁, X₃₂, X₃₃, X₃₄, X₃₅, X₃₆, X₃₇, X₃₈, X₃₉, and X₄₀ is C or is a substituent that contains a fatty acid. In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein none of X₁₀, X₁₂, X₁₃, X₁₄, X₁₆, X₁₇, X₁₉, X₂₀, X₂₁, X₂₃, X₂₄, X₂₆, X₂₇, X₂₈, X₂₉, X₃₀, X₃₁, X₃₂, X₃₃, X₃₄, X₃₅, X₃₆, X₃₇, X₃₈, X₃₉, and X₄₀ is a substituent that contains a fatty acid; and none of X₃₀, X₃₄, X₃₉, and X₄₀ is C. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein none of X₁₀, X₁₂, X₁₃, X₁₄, X₁₆, X₁₇, X₁₉, X₂₀, X₂₁, X₂₃, X₂₄, X₂₆, X₂₇, X₂₈, X₂₉, X₃₀, X₃₁, X₃₂, X₃₃, X₃₄, X₃₅, X₃₆, X₃₇, X₃₈, X₃₉, and X₄₀ is a substituent that contains a fatty acid.

As used herein "time-extension technology" means a peptide time-extension technology for example, recombinant human serum albumin ("rHSA"), peptide conjugation to a pharmaceutically acceptable polymer, such as polymeric sequence of amino acids ("XTEN"), unsulfated heparin-like carbohydrate polymer ("HEP"), hydroxyl ethyl starch ("HES"), llama heavy-chain antibody fragments ("VHH"), pegylation, Fc conjugation, bovine serum albumin ("BSA") (Sleep, D. *Expert Opin Drug Del* (2015) 12, 793-812; Podust VN *et.al.* J Control. Release, 2015; ePUB; Hey, T. et. al. in: R. Kontermann (Ed.), Therapeutic Proteins: Strategies to Modulate their Plasma Half-Lives, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2012, pp117-140; DeAngelis, PL, *Drug Dev Delivery* (2013) January, 12/31/2012. In an embodiment time-extension technology is applied using a linker group. In an embodiment, the time-extension technology is applied using 0, 1, 2, or 3 amino acids as linker.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, without a fatty acid (*i.e.*, a compound where none of X₁₀, X₁₂, X₁₃, X₁₄, X₁₆, X₁₇, X₁₉,

X₂₀, X₂₁, X₂₃, X₂₄, X₂₆, X₂₇, X₂₈, X₂₉, X₃₀, X₃₁, X₃₂, X₃₃, X₃₄, X₃₅, X₃₆, X₃₇, X₃₈, X₃₉, and X₄₀ is a substituent that contains a fatty acid) or time-extension technology may be administered to a patient in need thereof via transdermal or infusion methods of administration. Further, a compound of Formula I, or a pharmaceutically acceptable salt thereof, without a fatty acid
5 may be further modified using a peptide time-extension technology for example, recombinant human serum albumin ("rHSA"), peptide conjugation to a pharmaceutically acceptable polymer, such as polymeric sequence of amino acids ("XTEN"), unsulfated heparin-like carbohydrate polymer ("HEP"), and hydroxyl ethyl starch ("HES"). In an embodiment, a time-extension technology is applied using a cysteine amino acid in a Formula I compound,
10 or a pharmaceutically acceptable salt thereof, without a fatty acid, using procedures known to the skilled artisan. In an embodiment, a time-extension technology is applied to one amino acid in a Formula I compound, or a pharmaceutically acceptable salt thereof, without a fatty acid. In an embodiment, wherein a time-extension technology is applied to a Formula I compound, or a pharmaceutically acceptable salt thereof, without a fatty acid, X₁₇ is selected
15 from the group consisting of I, K and Q. In an embodiment wherein a time-extension technology is applied to a Formula I compound, or a pharmaceutically acceptable salt thereof, without a fatty acid, X₃₀ is C. In an embodiment wherein a time-extension technology is applied to a Formula I compound, or a pharmaceutically acceptable salt thereof, without a fatty acid, X₃₄ is C. In an embodiment wherein a time-extension
20 technology is applied to a Formula I compound, or a pharmaceutically acceptable salt thereof, without a fatty acid, X₃₉ is C. In an embodiment wherein a time-extension technology is applied to a Formula I compound, or a pharmaceutically acceptable salt thereof, without a fatty acid, X₄₀ is C.

When used herein in reference to one or more of the GIP or GLP-1 receptors, the
25 terms "activity," "activate[s]" "activat[ing]" and the like refers to the capacity of a compound, or a pharmaceutically acceptable salt thereof, to bind to and induce a response at the receptor(s), as measured using assays known in the art, such as the in vitro assays described below.

The affinity of compounds, or a pharmaceutically acceptable salt thereof, of the present invention for each of the GIP and GLP-1 receptors may be measured using techniques known for measuring receptor binding levels in the art, including, for example those described in the examples below, and is commonly expressed as a K_i value. The activity of the compounds of the present invention at each of the receptors may also be measured using techniques known in the art, including for example the in vitro activity assays described below, and is commonly expressed as an EC_{50} value, which is the concentration of compound causing half-maximal stimulation in a dose response curve.

In an embodiment, a pharmaceutical composition of a compound of Formula I is suitable for administration by a parenteral route (*e.g.*, subcutaneous, intravenous, intraperitoneal, intramuscular, or transdermal). In an embodiment, a pharmaceutical composition of a compound of Formula I is suitable for oral administration (*e.g.*, tablet, capsule). Some pharmaceutical compositions and processes for preparing same are well known in the art. (*See, e.g.*, Remington: The Science and Practice of Pharmacy (D.B. Troy, Editor, 21st Edition, Lippincott, Williams & Wilkins, 2006). Physiochemical properties of a peptide in addition to anatomical and physiological features of the gastrointestinal tract may provide challenges to efficient oral delivery of a peptide. In an embodiment a pharmaceutical composition for oral administration comprises of a compound of this invention, and a permeation enhancer. In an embodiment, a pharmaceutical composition for oral administration comprises a compound of Formula I or a pharmaceutically acceptable salt thereof, a permeation enhancer, and a protease inhibitor. In an embodiment, a pharmaceutical composition for oral administration comprises a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a permeation enhancer,

Monolithic and multi-particulate dosage forms for compounds of the present invention are contemplated. In an embodiment, a compound of Formula I is provided as a monolithic composition. A monolithic composition is intended for release of all components in a single location. A multi-particulate composition is intended to achieve fast transit from the stomach to the intestine and allow for distribution of composition components over large surface of small intestine. Concurrent release of a compound and functional excipients is desired for

monolithic and multi-particulate dosage compositions. In an embodiment a monolithic composition of a compound of Formula I, or a pharmaceutically acceptable salt thereof, is formulated as an enteric capsule, enteric coated capsule or an enteric coated tablet. Such multi-particulate composition may be formulated as an enteric coated minitables, or enteric coated
5 granules where the coating is generally intact in the stomach at low pH and dissolves at the higher pH of the intestine. Two types of coated minitables or coated granules may be formulated for either delivery to proximal small intestine by dissolution above pH 5.5 or to distal small intestine by dissolution above pH 7-7.2. A coating system for distal small intestinal release can also be applied to monolithic capsules or tablets if distal small intestinal delivery
10 is desired. Minitables may be filled into a standard uncoated capsule.

As used herein the term “permeation enhancer” means permeation enhancer that enhances oral absorption of a compound of this invention. As used herein, permeation enhancer means permeation enhancers, such as sodium decanoate, sodium taurodeoxycholate, lauroyl carnitine, dodecyl maltoside, dodecyl phosphatidylcholine,
15 SNAC, a Rhamnolipid, and permeation enhancers reported in the literature, such as for example, Permeant inhibitor of phosphatase, PIP-250 and PIP-640. *See*, *Pharmaceutics*. 2019 Jan; 11(1): 41, (See *Biomaterials*. 2012; 33: 3464-3474), ZOT (zonula occludens toxin), Δ G (fragment of ZOT) (See *Int. J. Pharm.* 2009; 365, 121-130). In an embodiment, a permeation enhancer is selected from the group consisting of sodium decanoate, sodium
20 taurodeoxycholate, and lauroyl carnitine. In an embodiment, a permeation enhancer is selected from the group consisting of C10, LC, and NaTDC. In an embodiment a permeation enhancer is C10.

As used herein the term “protease inhibitor” means a protease inhibitor that may be selected from the group consisting of protein based, peptide based, and small molecule based.
25 Protease inhibitors are well known and may include, for example, soybean trypsin inhibitor (“SBTI”), soybean trypsin-chymotrypsin inhibitor (“SBTCI”), ecotin, sunflower trypsin inhibitor (“SFTI”), leupeptin, citric acid, ethylenediaminetetraacetic acid (“EDTA”), sodium glycocholate and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (“AEBSF”). In

an embodiment a protease inhibitor is selected from the group consisting of SBTI, SBTCI and SFTI. In an embodiment, a protease inhibitor is SBTI.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound is a potent GIPR/GLP-1R dual agonist that is a partial agonist on the GLP-1R as demonstrated by a Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay, and a partial agonist on the GLP-1R as demonstrated by a β-arrestin-2 recruitment assay. In an embodiment is a compound of Formula I, or pharmaceutically acceptable salt thereof, wherein the compound stimulates GLP-1R induced activation of Gα_s in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay. In an embodiment, is a compound showing partial agonism of 75% or less in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay, and 35% or less in the GLP-CHO Cell β-Arrestin Recruitment Assay.

In an embodiment is a method for treating diabetes comprising administering an effective amount of a compound showing partial agonism of 75% or less in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay, and an effective amount of a compound that is a GIP agonist. In an embodiment, the compound showing partial agonism in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay is co-administered with a compound having GIP agonist activity. In an embodiment, the compound showing partial agonism in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay is administered as an active agent within one week before or after a compound having GIP agonist activity. In an embodiment, a method for treating diabetes comprises administering an effective amount of a compound showing 35% or less in the GLP-CHO Cell β-Arrestin Recruitment Assay and administering an effective amount of a compound showing partial agonism of 75% or less in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay.

Compounds of the present invention may react with any of a number of inorganic and organic acids/bases to form pharmaceutically acceptable acid/base addition salts.

Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. (*See, e.g.,* P. Stahl, *et al.* Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011)). Pharmaceutically acceptable salts of the present invention include, but are not limited to, sodium, trifluoroacetate, hydrochloride, ammonium, and acetate salts. In an embodiment, a pharmaceutically acceptable salt of is selected from the group consisting of sodium, hydrochloride, and acetate salts.

The present invention also encompasses novel intermediates and processes useful for the synthesis of compounds of the present invention, or a pharmaceutically acceptable salt thereof. The intermediates and compounds of the present invention may be prepared by a variety of procedures known in the art. In particular, the Examples below describe a process using chemical synthesis. The specific synthetic steps for each of the routes described may be combined in different ways to prepare compounds of the present invention. The reagents and starting materials are readily available to one of ordinary skill in the art.

When used herein, the term “effective amount” refers to the amount or dose of a compound of the present invention, or a pharmaceutically acceptable salt thereof, which, upon single or multiple dose administration to the patient, provides the desired effect in the patient under diagnosis or treatment. An effective amount can be determined by a person of skill in the art using known techniques and by observing results obtained under analogous circumstances. In determining the effective amount for a subject, a number of factors are considered, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

When used herein, the term “subject in need thereof” refers to a mammal, preferably a human, with a disease or condition requiring treatment or therapy, including for example those listed in the preceding paragraphs. As used herein “EDTA” means

-34-

ethylenediaminetetraacetic acid. As used herein "DMSO" means dimethyl sulfoxide. As used herein "CPM" means counts per minute. As used herein "IBMX" means 3-isobutyl-1-methylxanthine. As used herein "LC/MS" means liquid chromatography/mass spectrometry. As used herein "HTRF" means homogeneous time-resolved fluorescence. As used herein

5 "BSA" mean bovine serum albumin.


The invention is further illustrated by the following examples, which are not to be construed as limiting.

PEPTIDE SYNTHESIS

Example 1

10 **Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH₂ (SEQ ID NO:10).**

15 The structure of SEQ ID NO:10 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, α MeL13, K17, Aib20, D-Glu24, and Ser39 where the structures of these amino acid residues have been expanded:



20 The peptide backbone of Example 1 is synthesized using Fluorenylmethyloxycarbonyl (Fmoc)/tert-Butyl (t-Bu) chemistry on a Symphony X peptide synthesizer (Gyros Protein Technologies, Tucson, AZ).

The resin consists of 1% DVB cross-linked polystyrene (Fmoc-Rink-MBHA Low Loading resin, 100-200 mesh, EMD Millipore) at a substitution of 0.3-0.4 meq/g. Standard

side-chain protecting groups were used. Fmoc-Lys(Mtt)-OH is used for the lysine at position 17 and Boc-Tyr(tBu)-OH was used for the tyrosine at position 1. Fmoc groups are removed prior to each coupling step (2 x 7 minutes) using 20% piperidine in DMF. All standard amino acid couplings are performed for 1 hour to a primary amine and 3 hour to a secondary amine, using an equal molar ratio of Fmoc amino acid (0.3 mM), diisopropylcarbodiimide (0.9 mM) and Oxyma (0.9 mM), at a 9-fold molar excess over the theoretical peptide loading.

Exceptions are couplings to C α -methylated amino acids, which are coupled for 3 hours.

After completion of the synthesis of the peptide backbone, the resin is thoroughly washed with DCM for 6 times to remove residual DMF. The Mtt protecting group on the lysine at position 17 is selectively removed from the peptide resin using two treatments of 30% hexafluoroisopropanol (Oakwood Chemicals) in DCM (2 x 40-minute treatment).

Subsequent attachment of the fatty acid-linker moiety is accomplished by coupling of 2-[2-(2-Fmoc-amino-ethoxy)-ethoxy]-acetic acid (Fmoc-AEEA-OH, ChemPep, Inc.), Fmoc-glutamic acid α -t-butyl ester (Fmoc-Glu-OtBu, Ark Pharm, Inc.), mono-OtBu-eicosanedioic acid (WuXi AppTec, Shanghai, China). 3-Fold excess of reagents (AA: PyAOP: DIPEA=1: 1: 1 mol/mol) are used for each coupling that is 1-hour long.

After the synthesis is complete, the peptide resin is washed with DCM, and then thoroughly air-dried. The dry resin is treated with 10 mL of cleavage cocktail (trifluoroacetic acid: water: triisopropylsilane, 95:2.5:2.5 v/v) for 2 hours at room temperature. The resin is filtered off, washed twice each with 2 mL of neat TFA, and the combined filtrates are treated with 5-fold excess volume of cold diethyl ether (-20°C) to precipitate the crude peptide. The peptide/ether suspension is then centrifuged at 3500 rpm for 2 min to form a solid pellet, the supernatant is decanted, and the solid pellet is triturated with ether two additional times and dried in vacuo. The crude peptide is solubilized in 20% acetonitrile/20% Acetic acid/60% water and purified by RP- HPLC on a Luna 5 μ m Phenyl-Hexyl preparative column (21 x 250 mm, Phenomenex) with linear gradients of 100% acetonitrile and 0.1% TFA/water buffer system (30-50% acetonitrile in 60 min). The purity of peptide is assessed using analytical RP-HPLC and pooling criteria is >95%. The main pool purity of compound 1 is found to be 98.0%. Subsequent lyophilization of the final main product pool yielded the


-36-

lyophilized peptide TFA salt. The molecular weight is determined by LC- MS (obsd: M+3 =1657.2; Calc M+3 =1657.0).

Example 2

Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₆-CO₂H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH₂
(SEQ ID NO:11)

The structure of SEQ ID NO:11 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, α MeL13, Orn16, K17, Aib20 D-Glu24, and Ser39 where the structures of these amino acid residues have been expanded:



The compound according to SEQ ID NO:11 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1642.6; Calc M+3 =1642.8).

Example 3


Example 3 is a compound represented by the following description:

Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH₂
(SEQ ID NO:12)

The structure of SEQ ID NO:12 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, α MeL13, Orn16, K17,

-37-

Aib20, D-Glu24, and Ser39, where the structures of these amino acid residues have been expanded:




- 5 The compound according to SEQ ID NO:12 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1651.8; Calc M+3 =1652.2).

Example 4

- 10 **Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH₂)₁₆-CO₂H)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGPSSGAPPPS-NH₂ (SEQ ID NO:13)**

- 15 The structure of SEQ ID NO:13 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, αMeF(2F)6, 4Pal10, αMeL13, Orn16, K17, Aib20, D-Glu24 αMeY25, and Ser39, where the structures of these amino acid residues have been expanded:




-38-

The compound according to SEQ ID NO:13 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1642.5; Calc M+3 =1642.1).

Example 5

5 Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₆-CO₂H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH₂ (SEQ ID NO:14)

The structure of SEQ ID NO:14 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, α MeL13, Orn16, K17, Aib20, D-Glu24, α MeY25, and Ser39, where the structures of these amino acid residues have been expanded:



The compound according to SEQ ID NO:14 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1626.1; Calc M+3 =1626.1).

Example 6 through Example 287

The compounds according to Examples 6 (SEQ ID NO:15) through Example 287 (SEQ ID NO:296) are prepared substantially as described by the procedures of Example 1.

Example	Compound Name	SEQ ID NO	Calculated MW (average)	Found MW (average)
6	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	15	4863.5	4862.1
7	Y-Aib-EGTFTSDYSILLDSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	16	4822.4	4821.3
8	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	17	4863.5	4863.2
9	Y-Aib-EGTFTSDYSILLDSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	18	4822.4	4820.7
10	Y-Aib-EGTFTSDYSILLDSIAQ-Aib-AFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)YLLA-Aib-GPSSGAPPPS-NH ₂	19	4776.5	4775.4
11	Y-Aib-EGTFTSDYSILLDSIAQ-Aib-AFIEYLLK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-Aib-GPSSGAPPPS-NH ₂	20	4834.5	4834.8
12	Y-Aib-EGTFTSDYSILLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-AFIEYLIEGGPSSGAPPPS-NH ₂	21	4891.6	4890.0
13	Y-Aib-EGTFTSDYSILLD-Aib-IAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-AFIEYLIEGGPSSGAPPPS-NH ₂	22	4848.5	4846.8
14	Y-Aib-EGTFTSDYSILLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)EFIQYLLE-Aib-GPSSGAPPPS-NH ₂	23	4976.7	4975.5
15	H-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPS-NH ₂	24	4865.5	4863.9

16	H-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPS-NH ₂	25	4865.5	4863.9
17	H-Aib-EGTFTSDYSILLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLE-Aib-GPSSG-NH ₂	26	4444.1	4442.7
18	H-Aib-EGTFTSDYSI-αMeL-LDKK(Dab-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Dab-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-αMeK-AFIQYLLA-Aib-GPSSGAPKPS-NH ₂	27	4979.8	4978.8
19	H-Aib-EGTFTSDYSI-αMeL-LDKK(Dab-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Dab-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-αMeK-AFIQYLLA-Aib-GPSSGAPPPS-NH ₂	28	4948.8	4947.2
20	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	29	4877.5	4875.9
21	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-αMeK-AFIEYLLEGGPSSGAPPPS-NH ₂	30	4935.6	4934.1
22	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-αMeK-AFIEYLLE-Aib-GPSSGAPPPS-NH ₂	31	4963.6	4962.0
23	Y-Aib-EGTFTSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)SILLDKIAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	32	4813.5	4812.9
24	Y-Aib-EGTFTSDYK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)ILLDKIAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	33	4889.6	4888.6
25	Y-Aib-EGTFTSDYSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)LLDKIAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	34	4863.5	4862.5

26	Y-Aib-EGTFTSDYSIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)LDKIAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	35	4863.5	N/I
27	Y-Aib-EGTFTSDYSILK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)DKIAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	36	4863.5	N/I
28	Y-Aib-EGTFTSDYSILLK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)KIAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	37	4861.6	N/I
29	Y-Aib-EGTFTSDYSILLDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)IAQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	38	4848.5	N/I
30	Y-Aib-EGTFTSDYSILLDKIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)Q-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	39	4905.6	N/I
31	Y-Aib-EGTFTSDYSILLDKIAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	40	4848.5	N/I
32	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)FIEYLIEGGPSSGAPPPS-NH ₂	41	4905.6	N/I
33	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)EYLIEGGPSSGAPPPS-NH ₂	42	4863.5	N/I
34	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)YLIEGGPSSGAPPPS-NH ₂	43	4847.6	N/I
35	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)IEGGPSSGAPPPS-NH ₂	44	4863.5	N/I

36	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)EGGPSSGAPPPS-NH ₂	45	4863.5	N/I
37	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)GGPSSGAPPPS-NH ₂	46	4847.6	N/I
38	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)GPSSGAPPPS-NH ₂	47	4919.6	N/I
39	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)PSSGAPPPS-NH ₂	48	4919.6	N/I
40	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)SSGAPPPS-NH ₂	49	4879.5	N/I
41	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)SGAPPPS-NH ₂	50	4889.6	N/I
42	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)GAPPPS-NH ₂	51	4889.6	N/I
43	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)APPPS-NH ₂	52	4919.6	N/I
44	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)PPPS-NH ₂	53	4905.6	N/I
45	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSGAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)PPS-NH ₂	54	4879.5	N/I

46	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSGAPK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)PS-NH ₂	55	4879.5	N/I
47	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSGAPPK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)S-NH ₂	56	4879.5	N/I
48	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSGAPPPK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-NH ₂	57	4889.6	N/I
49	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-NH ₂	58	4976.7	N/I
50	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	59	4414.0	N/I
51	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	60	4085.7	N/I
52	Y-Aib-EGTFTSDYSI-αMeL-LDSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	61	4836.4	N/I
53	H-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	62	4851.5	N/I
54	H-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQHAFIEYLIEGGPSSGAPPPS-NH ₂	63	4903.5	N/I
55	H-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQHAFIEYLIEGGPSSGAPPPS-NH ₂	64	4904.5	N/I
56	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQHAFIEYLIEGGPSSGAPPPS-NH ₂	65	4930.5	N/I

57	Y-Aib-EGT- α MeF-TSDYSILLDDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	66	4877.5	N/I
58	Y-Aib-EGTFTSDYSSLLDDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	67	4837.4	N/I
59	Y-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	68	4878.5	N/I
60	Y-Aib-EGTFTSDYSI- α MeL-LD-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	69	4834.5	N/I
61	Y-Aib-EGTFTSDYSI- α MeL-LDSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	70	4836.4	N/I
62	Y-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	71	4099.7	N/I
63	Y-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	72	4100.6	N/I
64	Y-Aib-EGTFTSDYSI- α MeL-LDSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	73	4058.6	N/I
65	Y-Aib-EGTFTSDYSI- α MeL-LDTK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	74	4072.6	N/I
66	Y-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	75	4878.5	N/I

67	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-A-αMeF-IEYLIEGGPSSGAPPPS-NH ₂	76	4877.5	N/I
68	Y-Aib-EGTFTSDY-αMeS-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	77	4877.5	N/I
69	Y-Aib-EGT-αMeF-TSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	78	4891.6	N/I
70	Y-Aib-EGTFTSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)SILLDKIAQ-Aib-AFIEYLIEGG-NH ₂	79	4035.7	N/I
71	Y-Aib-EGTFTSDYSILK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)DKIAQ-Aib-AFIEYLIEGG-NH ₂	80	4085.7	N/I
72	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)FIEYLIEGG-NH ₂	81	4127.8	N/I
73	Y-Aib-EGTFTSDYSILLDKIAQ-Aib-AFIEYLIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)GG-NH ₂	82	4069.7	N/I
74	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-A-αMeF-IEYLIEGGPSSGAPPPS-NH ₂	83	4891.6	N/I
75	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEY-αMeL-IEGGPSSGAPPPS-NH ₂	84	4891.6	N/I
76	Y-Aib-EGT-aMeF-TSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-A-αMeF-IEYLIEGGPSSGAPPPS-NH ₂	85	4905.6	N/I
77	Y-Aib-EGTFTSDYSILLKIAQ-Aib-AFIEYLIEGGPSSGAPPK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)S-NH ₂	86	4764.5	N/I

78	(D-Tyr)-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	87	4863.5	N/I
79	Ac-(D-Tyr)-AEGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	88	4891.5	N/I
80	Y-(D-Ala)-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	89	4849.5	N/I
81	Y-Aib-EGTFTSDY-(D-Ser)-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	90	4863.5	N/I
82	Y-Aib-EGTFTSDYS-(D-Ile)-LLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	91	4863.5	N/I
83	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLI-(D-Glu)-GGPSSGAPPPS-NH ₂	92	4863.5	N/I
84	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	93	4863.5	N/I
85	Y-Aib-EGTFTSDASILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	94	4771.4	N/I
86	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEAGPSSGAPPPS-NH ₂	95	4877.5	N/I
87	Y-αMePro-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	96	4889.5	N/I

88	Y-Pro-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	97	4875.5	N/I
89	Y-Aib-Aad-GTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	98	4877.5	N/I
90	Y-Aib-NGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	99	4848.5	N/I
91	Y-Aib-(γ -Glu)-GTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	100	4863.5	N/I
92	Y-Aib-EGT- α MeF-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)SILLDKIAQ-Aib-AFIEYLIEGG-NH ₂	101	4049.7	N/I
93	Y-Aib-EGT- α MeF-TSDYSILK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)DKIAQ-Aib-AFIEYLIEGG-NH ₂	102	4099.7	N/I
94	Y-Aib-EGT- α MeF-TSDYSILLDKIAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)FIEYLIEGG-NH ₂	103	4141.8	N/I
95	Y-Aib-EGT- α MeF-TSDYSILLDKIAQ-Aib-AFIEYLIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)GG-NH ₂	104	4083.7	N/I
96	Y-Aib-EGTFTSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)SI- α MeL-LDKIAQ-Aib-AFIEYLIEGG-NH ₂	105	4049.7	N/I
97	Y-Aib-EGTFTSDYSI- α MeL-LDKIAQ-Aib-AFIEYLIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)GG-NH ₂	106	4083.7	N/I
98	Y-Aib-EGT- α MeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	107	4099.7	N/I

99	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	108	4113.7	N/I
100	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	109	4114.7	N/I
101	Y-Aib-EGT- α MeF(2F)-TSDYSI-Aib-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	110	4090.6	N/I
102	Y-Aib-EGT- α MeF-TSDYSI-Aib-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	111	4072.6	N/I
103	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGG-NH ₂	112	4190.7	N/I
104	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIEGG-NH ₂	113	4162.6	N/I
105	DesHis- ψ [NHCO]-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	114	4822.5	N/I
106	DesHis-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	115	4822.5	N/I
107	DesTyr-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	116	4848.5	N/I
108	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-AOC-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	117	4859.6	N/I

109	Y-Aib-EGTFTSDYSILLDKK(AOC-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	118	4859.6	N/I
110	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(Trx)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	119		N/I
111	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(Trx)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	120		N/I
112	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	121	4846.5	N/I
113	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(εK)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	122	4862.6	N/I
114	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(εK)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	123	4845.6	N/I
115	Y-Aib-EGT-αMeF-TSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	124	4892.5	N/I
116	Y-Aib-EGT-αMeF-TSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	125	4950.5	N/I
117	Y-Aib-EGT-αMeF-TSDYSI-Aib-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	126	4850.4	N/I
118	Y-Aib-EGT-αMeF(2F)-TSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	127	4968.5	N/I

119	F-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	128	4876.5	N/I
120	Y-Aib-cTA-GT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	129	4902.5	N/I
121	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAIEYLIEGGPSSGAPPPS-NH ₂	130	4935.5	N/I
122	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAIEYLIE-Aib-GPSSGAPPPS-NH ₂	131	4963.6	N/I
123	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSG-NH ₂	132	4500.1	N/I
124	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSG-NH ₂	133	4501.0	N/I
125	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	134	5020.7	N/I
126	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEAGPSSGAPPPS-NH ₂	135	4905.6	N/I
127	Y-Aib-EGT- α MeF-TSDISILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	136	4827.5	N/I
128	Y-Aib-EGT- α MeF-TSDHSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	137	4851.5	N/I

129	Y-Aib-EGT- α MeF-TSDLSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	138	4827.5	N/I
130	Y-Aib-EGT- α MeF-TSDESILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	139	4843.5	N/I
131	Y-Aib-EGT- α MeF-TSD- α MeF-SILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	140	4875.6	N/I
132	Y-Aib-EGT- α MeF-TSD-3Pal-SILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	141	4862.5	N/I
133	DesTyr-Aib-EGT- α MeF-TSDYSI-Aib-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	142	4835.4	N/I
134	DesTyr-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	143	4953.5	N/I
135	H-Aib-NGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	144	4822.5	N/I
136	Y-Aib-EGTFTSDASILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEAGPSSGAPPPS-NH ₂	145	4785.4	N/I
137	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-Aad-FIEYLIEGGPSSGAPPPS-NH ₂	146	4963.6	N/I
138	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-SFIEYLIEGGPSSGAPPPS-NH ₂	147	4907.6	N/I

139	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFIEYLIEGGPSSGAPPPS-NH ₂	148	4921.6	N/I
140	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-DFIEYLIEGGPSSGAPPPS-NH ₂	149	4935.6	N/I
141	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-IFIEYLIEGGPSSGAPPPS-NH ₂	150	4933.6	N/I
142	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-HFIEYLIEGGPSSGAPPPS-NH ₂	151	4957.6	N/I
143	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-Aib-FIEYLIEGGPSSGAPPPS-NH ₂	152	4905.6	N/I
144	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQH-Aib-FIEYLIEGGPSSGAPPPS-NH ₂	153	4957.6	N/I
145	Y-Aib-EGT- α MeF-TSDASI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	154	4799.5	N/I
146	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIQYLIEGGPSSGAPPPS-NH ₂	155	4967.5	N/I
147	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-Aad-YLIEGGPSSGAPPPS-NH ₂	156	4982.6	N/I
148	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIAYLIEGGPSSGAPPPS-NH ₂	157	4910.5	N/I

149	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIVYLIEGGPSSGAPPPS-NH ₂	158	4938.5	N/I
150	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFISYLIEGGPSSGAPPPS-NH ₂	159	4926.5	N/I
151	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIPYLIEGGPSSGAPPPS-NH ₂	160	4936.5	N/I
152	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-Aib-YLIEGGPSSGAPPPS-NH ₂	161	4924.5	N/I
153	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIHYLIEGGPSSGAPPPS-NH ₂	162	4976.6	N/I
154	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	163	4942.5	N/I
155	Y-Aib-EGT- α MeF(2F)-TSD-cTA-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	164	4944.5	N/I
156	Y-Aib-EGT- α MeF(2F)-TSD-2Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	165	4953.5	N/I
157	Y-Aib-EGT- α MeF(2F)-TSD-3Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	166	4953.5	N/I
158	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	167	4953.5	N/I

159	Y-Aib-EGT- α MeF(2F)-TSD- α MeF-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	168	4938.5	N/I
160	Y-Aib-EGT- α MeF(2F)-TSD-Aib-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	169	4862.4	N/I
161	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSG-NH ₂	170	4594.1	N/I
162	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-HLIEGGPSSG-NH ₂	171	4568.1	N/I
163	H-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSGAPPPS-NH ₂	172	4942.5	N/I
164	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLI-(D-Glu)-GGPSSGAPPPS-NH ₂	173	4914.5	N/I
165	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)- α MeF-LI-(D-Glu)-GGPSSGAPPPS-NH ₂	174	4912.5	N/I
166	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGG-NH ₂	175	4136.7	N/I
167	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSG-NH ₂	176	4465.0	N/I

168	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	177	4914.5	N/I
169	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	178	4886.4	N/I
170	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	179	4858.4	N/I
171	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	180	4899.5	N/I
172	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	181	4885.5	N/I
173	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LD-Dap-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	182	4871.5	N/I
174	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	183	4785.4	N/I
175	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	184	4913.5	N/I
176	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	185	4885.5	N/I
177	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-HFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	186	4922.5	N/I

178	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CO ₂ H)AQ-Aib-HFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	187	4894.4	N/I
179	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-HFI-(D-Glu)-YLIEGGPSSG-NH ₂	188	4473.0	N/I
180	Y-Aib-EGT- α MeF(2F)-TSDHSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-HFI-(D-Glu)-YLIEGG-NH ₂	189	4144.6	N/I
181	Y-Aib-EGT- α MeF(2F)-TSD-3Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	190	4953.5	N/I
182	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	191	4953.5	N/I
183	Y-Aib-EGT- α MeF(2F)-TSDLSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	192	4918.5	N/I
184	Y-Aib-EGT- α MeF(2F)-TSD-(D-Tyr)-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	193	4968.5	N/I
185	Y-Aib-EGT- α MeF(2F)-TSD-(D-His)-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	194	4942.5	N/I
186	Y-Aib-EGT- α MeF(2F)-TSD- α MeY-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	195	4982.6	N/I

187	Y-Aib-EGT- α MeF(2F)-TSDQSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	196	4933.5	N/I
188	Y-Aib-EGT- α MeF(2F)-TSD-3Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-Aib-YLIEGGPSSGAPPPS-NH ₂	197	4909.5	N/I
189	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-Aib-YLIEGGPSSGAPPPS-NH ₂	198	4909.5	N/I
190	H-Aib-EGT- α MeF(2F)-TSD-3Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	199	4927.5	N/I
191	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	200	4904.5	N/I
192	Y-Aib-EGT- α MeF(2F)-TSDASI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	201	4876.4	N/I
193	Y- α MePro-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIEGGPSSGAPPPS-NH ₂	202	4933.5	N/I
194	Y- α MePro-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQHAFIEYLIEGGPSSGAPPPS-NH ₂	203	4942.5	N/I
195	Y- α MePro-EGTFTSDYSILLDRK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIEGGPSSGAPPPS-NH ₂	204	4960.6	N/I
196	Y- α MePro-EGTFTSDYSILLDRK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQHAFIEYLIEGGPSSGAPPPS-NH ₂	205	4969.6	N/I

197	Y- α MePro-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQQAFIEYLIIEGGPSSG-NH ₂	206	4456.0	N/I
198	(D-Tyr)- α MePro-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQQAFIEYLIIEGGPSSG-NH ₂	207	4456.0	N/I
199	DesTyr-Aib-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIIEGGPSSGAPPPS-NH ₂	208	4892.5	N/I
200	DesTyr-AEGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIIEGGPSSGAPPPS-NH ₂	209	4878.4	N/I
201	DesHis- α MePro-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIIEGGPSSGAPPPS-NH ₂	210	4892.5	N/I
202	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	211	4938.6	N/I
203	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	212	4952.6	N/I
204	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	213	4924.5	N/I
205	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	214	4795.4	N/I
206	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	215	4823.5	N/I

207	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	216	4923.6	N/I
208	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	217	4912.4	N/I
209	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	218	4911.4	N/I
210	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Dap-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	219	4897.5	N/I
211	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	220	4953.6	N/I
212	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	221	4967.5	N/I
213	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	222	4922.4	N/I
214	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	223	4811.4	N/I
215	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	224	4839.4	N/I
216	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	225	4967.5	N/I

217	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	226	4939.5	N/I
218	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Dap-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	227	4925.5	N/I
219	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSG-NH ₂	228	4491.0	N/I
220	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGG-NH ₂	229	4162.6	N/I
221	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	230	4940.5	N/I
222	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	231	4982.6	N/I
223	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIEGGPSSGAPPPS-NH ₂	232	4982.6	N/I
224	Y-Aib-EGT- α MeF(2F)-TSDYSI-Aib-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	233	4926.4	N/I
225	Y-Aib-EGT- α MeF-TSDYSI-Aib-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	234	4908.5	N/I
226	Y-Aib-EGT- α MeF(2F)-TSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	235	4954.5	N/I

227	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	236	4950.5	N/I
228	Y-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSG-NH ₂	237	4500.1	N/I
229	Y-Aib-EGT- α MeF(2F)-TSDYS- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	238	4855.4	N/I
230	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDHK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	239	4976.6	N/I
231	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	240	4939.5	N/I
232	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	241	4910.5	N/I
233	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	242	4896.5	N/I
234	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SILLD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	243	4882.4	N/I
235	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	244	4878.5	N/I
236	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	245	4939.5	N/I

237	Y-Aib-EGT- α MeF(2F)-TSDASI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	246	4847.4	N/I
238	Y-Aib-EGT- α MeF(2F)-TSDLSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	247	4889.5	N/I
239	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	248	4896.5	N/I
240	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	249	4866.5	N/I
241	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	250	N/I	N/I
242	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	251	N/I	N/I
243	Y-Aib-EGT- α MeF(2F)-TSDLSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	252	N/I	N/I
244	Y-Aib-EGT- α MeF(2F)-TSDLSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	253	N/I	N/I

245	Y-Aib-EGT- α MeF(2F)-TSDASI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	254	N/I	N/I
246	Y-Aib-EGT- α MeF(2F)-TSDASI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	255	N/I	N/I
247	Y-Aib-EGT- α MeF(2F)-TSDYSI-Aib-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	256	4883.4	N/I
248	Y-Aib-EGT- α MeF(2F)-TSDYSILLD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	257	4911.5	N/I
249	Y-Aib-EGT- α MeF(2F)-TSDYSI-Nle-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	258	4911.5	N/I
250	Y-Aib-EGT- α MeF(2F)-TSDYSI-Aib-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	259	4911.5	N/I
251	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	260	4893.6	N/I
252	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)- α MeY-LIAGGPSSGAPPPS-NH ₂	261	4835.6	N/I
253	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQAAFIEYLIEGGPSSGAPPPS-NH ₂	262	4849.5	N/I

254	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIIEGGPSSGAPPPS-NH ₂	263	4906.5	N/I
255	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQHAFIEYLIIEGGPSSGAPPPS-NH ₂	264	4915.5	N/I
256	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQKAFIEYLIIEGGPSSGAPPPS-NH ₂	265	4906.6	N/I
257	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQRAFIEYLIIEGGPSSGAPPPS-NH ₂	266	4934.6	N/I
258	Y-Aib-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQKAFIEYLIIEGGPSSGAPPPS-NH ₂	267	4907.5	N/I
259	Y-Aib-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	268	4864.4	N/I
260	Y-Aib-EGTFTSDHSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	269	4837.5	N/I
261	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQEAFIEYLIIEGGPSSGAPPPS-NH ₂	270	4907.5	N/I
262	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQTAIEYLIIEGGPSSGAPPPS-NH ₂	271	4879.5	N/I
263	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQSAFIEYLIIEGGPSSGAPPPS-NH ₂	272	4865.5	N/I


264	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSG-NH ₂	273	4475.0	N/I
265	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGG-NH ₂	274	4146.7	N/I
266	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	275	4385.94	4386.6
267	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	276	4057.62	N/I
268	Y-Aib-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	277	4386.88	N/I
269	Y-Aib-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGG-NH ₂	278	4058.56	N/I
270	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSG-NH ₂	279	4443.98	N/I
271	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIEGG-NH ₂	280	4115.66	N/I
272	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	281	4327.91	4327.8
273	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGG-NH ₂	282	3999.58	N/I
274	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQPAFIEYLIEGGPSSG-NH ₂	283	4397.95	N/I

275	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQPAFIEYLIIEGG-NH ₂	284	4069.63	N/I
276	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEKAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	285	4224.59	N/I
277	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEQAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	286	4224.55	N/I
278	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEKAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPSC-NH ₂	287	4327.74	N/I
279	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDEQAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPSC-NH ₂	288	4327.69	N/I
280	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-KAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	289	4210.61	N/I
281	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-QAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	290	4209.58	N/I
282	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-KAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPSC-NH ₂	291	4312.77	N/I
283	Y-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-QAQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPSC-NH ₂	292	4312.73	N/I
284	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-KAQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	293	4208.64	N/I
285	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-QAQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	294	4208.6	N/I
286	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-KAQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSC-NH ₂	295	4311.78	N/I
287	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-QAQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSC-NH ₂	296	4311.74	N/I

N/I means Not Included

Example 288**Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH₂ (SEQ ID NO:303)**


- The structure of SEQ ID NO:303 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, K17, Aib20, and Ser39, where the structures of these amino acid residues have been expanded:



- The compound according to SEQ ID NO:303 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1602.5; Calc M+3 =1602.8).

Example 289**Y-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH₂ (SEQ ID NO:304)**

- The structure of SEQ ID NO:304 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeL13, K17, Aib20, and Ser39, where the structures of these amino acid residues have been expanded:



-68-

The compound according to SEQ ID NO:304 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1626.8; Calc M+3 =1626.8).


5

Example 290

(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH₂ (SEQ ID NO:305)

The structure of SEQ ID NO:305 is depicted below using the standard single letter amino acid codes with the exception of residues D-Tyr1, Aib2, α MeL13, K17, Aib20, and

10 Ser39, where the structures of these amino acid residues have been expanded:




The compound according to SEQ ID NO:305 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1626.6; Calc M+3 =1626.8).

15

Example 291

(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-AFI-(D-Glu)-YLIAGGPSSGAPPPS-NH₂ (SEQ ID NO:306)

- 5 The structure of SEQ ID NO:306 is depicted below using the standard single letter amino acid codes with the exception of residues D-Tyr1, Aib2, α MeL13, Orn16, K17, Aib20, D-Glu24, and Ser39, where the structures of these amino acid residues have been expanded:




- 10 The compound according to SEQ ID NO:306 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC- MS (obsd: M+3 =1602.4; Calc M+3 =1602.8).

-70-

Example 292

(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFIE- α MeY-LIAGGPSSGAPPPS-NH₂ (SEQ ID NO:307)

- 5 The structure of SEQ ID NO:307 is depicted below using the standard single letter amino acid codes with the exception of residues D-Tyr1, Aib2, α MeL13, K17, Aib20, α MeY25, and Ser39, where the structures of these amino acid residues have been expanded:




- 10 The compound according to SEQ ID NO:307 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC-MS (obsd: M+3 =1631.3; Calc M+3 =1631.5).

Example 293

(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFIE- α MeY-LIAGGPSSGAPPPS-NH₂)
(SEQ ID NO:308)

- 5 The structure of SEQ ID NO:308 is depicted below using the standard single letter amino acid codes with the exception of residues D-Tyr1, Aib2, α MeL13, Orn16, K17, Aib20, α MeY25, and Ser39, where the structures of these amino acid residues have been expanded:



- 10 The compound according to SEQ ID NO:308 is prepared substantially as described by the procedures of Example 1. The molecular weight is determined by LC-MS (obsd: M+3 =1626.5; Calc M+3 =1626.8).

Example 294 through Example 381

- 15 The compounds according to Examples 294 (SEQ ID NO:309) through Example 381 (SEQ ID NO:396) are prepared substantially as described by the procedures of Example 1.

Example	Compound Name	SEQ ID NO	Calculated MW (average)	Found MW (average)
294	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQQAFIEYLIEGG-NH ₂	309	4100.6	N/I
295	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQHAFIEYLIEGG-NH ₂	310	4109.7	N/I
296	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQKAFIEYLIEGGPSSG-NH ₂	311	4429.0	N/I
297	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGG-NH ₂	312	4057.6	N/I
298	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFVEYLIEGGPSSG-NH ₂	313	4313.9	N/I
299	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFLEYLIEGGPSSG-NH ₂	314	4385.9	N/I
300	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	315	4400.0	N/I
301	Y-Aib-EGT-αMeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	316	4400.0	4399.2
302	Y-Aib-EGT-αMeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	317	4418.0	N/I
303	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSG-NH ₂	318	4400.9	4400.7
304	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIEGGPSSG-NH ₂	319	4458.0	N/I

305	Y-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	320	4341.9	N/I
306	Y-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	321	4400.0	N/I
307	Y-Aib-EGT- α MeF-TSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	322	4400.9	N/I
308	Y-Aib-EGT- α MeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	323	4458.0	N/I
309	Y-Aib-EGT- α MeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	324	4341.9	N/I
310	Y-Aib-EGT- α MeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	325	4400.0	N/I
311	Y-Aib-EGT- α MeF(2F)-TSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	326	4418.9	N/I
312	Y-Aib-EGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	327	4476.0	N/I
313	Y-Aib-EGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	328	4359.9	N/I
314	Y-Aib-EGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	329	4418.0	N/I
315	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-	330	4835.5	N/I

	(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂			
316	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	331	4777.4	4777.2
317	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSG-NH ₂	332	4356.0	N/I
318	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	333	4414.0	N/I
319	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	334	4863.5	N/I
320	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-DFIEYLIIEGGPSSG-NH ₂	335	4430.0	N/I
321	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFIEYLIIEGGPSSG-NH ₂	336	4416.0	N/I
322	Y-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-HFIEYLIIEGGPSSG-NH ₂	337	4452.0	N/I
323	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	338	4850.4	N/I
324	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	339	4819.5	N/I
325	Y-Aib-EGT-αMeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	340	4895.5	N/I

326	F-Aib-EGTFTSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	341	4847.5	N/I
327	F-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	342	4861.5	N/I
328	F-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIIEAGPSSGAPPPS-NH ₂	343	4847.5	N/I
329	(D-Tyr)-Aib-EGT-αMeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	344	4877.5	N/I
330	Y-Aib-EGTFTSDYSILLDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	345	4806.4	4805.4
331	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	346	4878.5	N/I
332	Y-Aib-EGTFTSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	347	4820.4	N/I
333	Y-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIIEGGPSSGAPPPS-NH ₂	348	4935.6	N/I
334	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	349	4877.5	N/I
335	(D-Tyr)-Aib-EGT-αMeF-TSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIIEGGPSSGAPPPS-NH ₂	350	4891.6	N/I

336	(D-Tyr)-Aib-EGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	351	4909.5	N/I
337	F-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	352	4803.5	N/I
338	F-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	353	4861.5	N/I
339	Y-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	354	4732.4	4732.2
340	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	355	4819.5	4818.8
341	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	356	4820.4	N/I
342	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	357	4878.5	N/I
343	Y-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	358	4820.4	N/I
344	Y-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-DFIEYLIAGGPSSGAPPPS-NH ₂	359	4864.4	N/I
345	(D-Tyr)-Aib-EGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	360	4891.6	N/I

346	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	361	4805.5	4804.8
347	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	362	4791.4	N/I
348	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Dap-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIAGGPSSGAPPPS-NH ₂	363	4807.5	N/I
349	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	364	4863.5	4862.7
350	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Dab-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	365	4849.5	N/I
351	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Dap-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	366	4835.5	N/I
352	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	367	4819.5	N/I
353	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	368	4935.6	N/I
354	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	369	4863.5	N/I
355	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	370	4921.5	N/I
356	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-	371	4877.5	N/I

	acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂			
357	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFI-(D-Glu)-YLIEGGPSSGAPPPS-NH ₂	372	4863.5	N/I
358	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFVEYLIAGGPSSGAPPPS-NH ₂	373	4791.4	N/I
359	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFVEYLIAGGPSSGAPPPS-NH ₂	374	4849.5	N/I
360	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFVEYLIAGGPSSGAPPPS-NH ₂	375	4849.5	N/I
361	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFV-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	376	4805.5	N/I
362	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFV-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	377	4791.4	N/I
363	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFI-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	378	4777.4	N/I
364	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFV-(D-Glu)-YLIAGGPSSGAPPPS-NH ₂	379	4763.4	N/I
365	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIE-αMeY-LIAGGPSSGAPPPS-NH ₂	380	4833.5	4832.4
366	(D-Tyr)-Aib-EGTFTSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIE-αMeY-LIAGGPSSGAPPPS-NH ₂	381	4819.5	4818.3

367	Y-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	382	4891.6	N/I
368	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	383	4835.5	N/I
369	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-DFIEYLIAGGPSSGAPPPS-NH ₂	384	4849.5	N/I
370	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSG-NH ₂	385	4414.0	N/I
371	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	386	4718.3	N/I
372	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	387	4746.4	N/I
373	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	388	4688.3	N/I
374	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	389	4863.5	N/I
375	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	390	4849.5	N/I
376	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	391	4805.5	N/I

377	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	392	4791.4	4790.7
378	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIEYLIAGGPSSGAPPPS-NH ₂	393	4732.4	N/I
379	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIEGGPSSGAPPPS-NH ₂	394	4949.5	N/I
380	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIEGGPSSGAPPPS-NH ₂	395	4935.5	N/I
381	(D-Tyr)-Aib-EGTFTSDYSI- α MeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIAGGPSSGAPPPS-NH ₂	396	4934.4	N/I

N/I means Not Included

Binding Assays

Glucagon (referred to as Gcg) is a Reference Standard prepared at Eli Lilly and Company. GLP-1, 7-36-NH₂ (referred to as GLP-1) is obtained from CPC Scientific (Sunnyvale, CA, 97.2% purity, 100 μ M aliquots in 100% DMSO). GIP 1-42 (referred to as GIP) is prepared at Lilly Research Laboratories using peptide synthesis and HPLC chromatography as described above (>80% purity, 100 μ M aliquots in 100% DMSO). [¹²⁵I]-radiolabeled Gcg, GLP-1, or GIP is prepared using [¹²⁵I]-lactoperoxidase and obtained from Perkin Elmer (Boston, MA).

Stably transfected cell lines are prepared by subcloning receptor cDNA into a pcDNA3 expression plasmid and transfected into human embryonic kidney (HEK) 293 (hGcgR and hGLP-1R) or Chinese Hamster Ovary (CHO) (hGIPR) cells followed by selection with Geneticin (hGLP-1R and hGIPR) or hygromycin B (hGcgR).

Two methods are used for the preparation of crude cell membranes.

Method 1: Frozen cell pellets are lysed on ice in hypotonic buffer containing 50 mM Tris HCl, pH 7.5, and Roche Complete™ Protease Inhibitors with EDTA. The cell suspension is disrupted using a glass Potter-Elvehjem homogenizer fitted with a Teflon® pestle for 25 strokes. The homogenate is centrifuged at 4°C at 1100 x g for 10 minutes. The supernatant is collected and stored on ice while the pellets are resuspended in homogenization buffer and rehomogenized as described above. The homogenate is centrifuged at 1100 x g for 10 minutes. The second supernatant is combined with the first supernatant and centrifuged at 35000 x g for 1 hour at 4°C. The resulting membrane pellet is resuspended in homogenization buffer containing protease inhibitors at approximately 1 to 3 mg/mL, quick frozen in liquid nitrogen and stored as aliquots in a -80°C freezer until use.

Method 2: Frozen cell pellets are lysed on ice in hypotonic buffer containing 50 mM Tris HCl, pH 7.5, 1 mM MgCl₂, Roche Complete™ EDTA-free Protease Inhibitors and 25 units/ml DNase I (Invitrogen). The cell suspension is disrupted using a glass Potter-Elvehjem homogenizer fitted with a Teflon® pestle for 20 to 25 strokes. The homogenate is centrifuged at 4°C at 1800 x g for 15 minutes. The supernatant is collected and stored on ice while the pellets are resuspended in homogenization buffer (without DNase I) and rehomogenized as described above. The homogenate is centrifuged at 1800 x g for 15 minutes. The second supernatant is combined with the first supernatant and centrifuged an additional time at 1800 x g for 15 minutes. The overall supernatant is then centrifuged at 25000 x g for 30 minutes at 4°C. The resulting membrane pellet is resuspended in homogenization buffer (without DNase I) containing protease inhibitors at approximately 1 to 3 mg/mL and stored as aliquots in a -80°C freezer until use.

Binding Determination Methods

The equilibrium binding dissociation constants (K_d) for the various receptor/radioligand interactions are determined from homologous competition binding analysis instead of saturation binding due to high propanol content in the [¹²⁵I] stock material. The K_d values determined for the receptor preparations were as follows: hGcgR (3.9 nM), hGLP-1R (1.2 nM) and hGIPR (0.14 nM).

[¹²⁵I]-Glucagon Binding

The human Gcg receptor binding assays are performed using a Scintillation Proximity Assay (SPA) format with wheat germ agglutinin (WGA) beads (Perkin Elmer). The binding buffer contains 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 2.5 mM CaCl₂, 1 mM MgCl₂, 0.1% (w/v) bacitracin (Research Products), 0.003% (w/v) Polyoxyethylenesorbitan monolaurate (TWEEN[®]-20), and Roche Complete[™] Protease Inhibitors without EDTA. Peptides and Gcg are thawed and 3-fold serially diluted in 100% DMSO (10 point concentration response curves). Next, 5 µL serially diluted compound or DMSO is transferred into Corning[®] 3632 clear bottom assay plates containing 45 µL assay binding buffer or unlabeled Gcg control (non-specific binding or NSB, at 1 µM final). Then, 50 µL [¹²⁵I]-Gcg (0.15 nM final), 50 µL human GcgR membranes (1.5 µg/well) and 50 µL of WGA SPA beads (80 to 150 µg/well) are added with a Biotek Multiflo dispenser. Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta[®] scintillation counter after 12 hours of incubation/settling time at room temperature. Final assay concentration ranges for peptides tested in response curves is typically 1150 nM to 0.058 nM and for the control Gcg from 1000 nM to 0.05 nM.

[¹²⁵I]-GLP-1 Binding

The human GLP-1 receptor binding assay is performed using an SPA format with WGA beads. The binding buffer contains 25 mM HEPES, pH 7.4, 2.5 mM CaCl₂, 1 mM MgCl₂, 0.1% (w/v) bacitracin, 0.003% (w/v) TWEEN[®]-20, and Roche Complete[™] Protease Inhibitors without EDTA. Peptides and GLP-1 are thawed and 3-fold serially diluted in 100% DMSO (10 point concentration response curves). Next, 5 µL serially diluted compound or DMSO is transferred into Corning[®] 3632 clear bottom assay plates containing 45 µL assay binding buffer or unlabeled GLP-1 control (non-specific binding or NSB, at 0.25 µM final). Then, 50 µL [¹²⁵I]-GLP-1 (0.15 nM final), 50 µL human GLP-1R membranes (0.5 µg/well) and 50 µL of WGA SPA beads (100 to 150 µg/well) are added with a Biotek Multiflo dispenser. Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta[®] scintillation counter after 5 to 12 hours of incubation/settling time at room temperature. Final assay concentration ranges

for peptides tested in response curves are typically 1150 nM to 0.058 nM and for the control GLP-1, 250 nM to 0.013 nM.

[125I]-GIP Binding

5 The human GIP receptor binding assay is performed using an SPA format with WGA beads. The binding buffer contains 25 mM HEPES, pH 7.4, 2.5 mM CaCl₂, 1 mM MgCl₂, 0.1% (w/v) bacitracin, 0.003% (w/v) TWEEN[®]-20, and Roche Complete[™] Protease Inhibitors without EDTA. Peptides and GIP are thawed and 3 fold serially diluted in 100% DMSO (10 point concentration response curves). Next, 5 µL serially diluted compound or
10 DMSO is transferred into Corning[®] 3632 clear bottom assay plates containing 45 µL assay binding buffer or unlabeled GIP control (non-specific binding or NSB, at 0.25 µM final). Then, 50 µL [¹²⁵I]-GIP (0.075-0.15 nM final), 50 µL human GIPR membranes (3 µg/well) and 50 µL of WGA SPA beads (100 to 150 µg/well) are added with a Biotek Multiflo dispenser. Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read
15 with a PerkinElmer Trilux MicroBeta[®] scintillation counter after 2.5 to 12 hours of incubation/settling time at room temperature. Final assay concentration ranges for peptides tested in response curves is typically 1150 to 0.058 nM or 115 nM to 0.0058 nM and for the control GIP, 250 nM to 0.013 nM.

20 Binding Assay Data Analysis

Raw CPM data for concentration curves of peptides, Gcg, GLP-1, or GIP are converted to percent inhibition by subtracting nonspecific binding (binding in the presence of excess unlabeled Gcg, GLP-1, or GIP, respectively) from the individual CPM values and dividing by the total binding signal, also corrected by subtracting nonspecific binding. Data
25 are analyzed using four-parameter (curve maximum, curve minimum, IC₅₀, Hill slope) nonlinear regression routines (Genedata Screener, version 12.0.4, Genedata AG, Basal, Switzerland). The affinity constant (K_i) is calculated from the absolute IC₅₀ value based upon the equation $K_i = IC_{50}/(1 + D/K_d)$ where D is the concentration of radioligand used in the experiment, IC₅₀ is the concentration causing 50% inhibition of binding and K_d is the

equilibrium binding dissociation constant of the radioligand (described above). Values for K_i are reported as the geometric mean, with error expressed as the standard error of the mean (SEM) and n is equal to the number of independent replicates (determined in assays performed on different days). Geometric Means are calculated as follows:

$$\text{Geometric Mean} = 10(\text{Arithmetic Mean of Log } K_i \text{ Values})$$

The K_i Ratio (K_i for native control peptide/ K_i for test compound) at each receptor and each species is calculated. The K_i Ratio is a rapid indication of the apparent affinity of a peptide compared to the native control peptide. A K_i Ratio < 1 indicates that the test peptide has a lower affinity (higher K_i value) for the receptor than the native peptide, whereas a K_i Ratio > 1 indicates that the test peptide has a higher affinity (lower K_i value) for the receptor than the native peptide.

$n=1/x$ means that only one value out of the total number of replicates (x) is used to express the mean. SEM is only calculated when $n=2$ or greater non-qualified results exist. Means are expressed as GeoMetric means with the standard error of the mean (SEM) and the number of replicates (n) indicated in parenthesis.

Table 1. *In vitro* Binding Affinity (K_i) of indicated Examples and comparator molecules for human GLP-1R, GcgR and GIPR.

Example or comparator	hGLcgR K_i , nM (SEM, n)	hGIPR K_i , nM (SEM, n)	hGLP1R K_i , (nM) (SEM, n)
hGcg	3.65 (0.26, n=10)		
hGIP amide		0.0922 (0.0085, n=11)	
hGLP-1 amide			0.614 (0.066, n=12)
1	207 (13.8, n=5)	0.0546 (0.0120, n=5)	6.67 (1.25, n=6)
2	361 (55.1, n=5)	0.0600 (0.0150, n=5)	2.35 (0.220, n=5)
3	242 (56.2, n=6)	0.0458 (0.00357, n=6)	2.23 (0.366, n=6)
4	686 (n=1/5)	0.0528 (0.00647, n=5)	1.63 (0.260, n=5)

5	519 (109, n=4)	0.0611 (0.00592, n=4)	0.902 (0.114, n=4)
6	55.8 (10.2, n=2)	0.0835 (0.00437, n=2)	6.71 (1.25, n=2)
7	198	0.252	43.3
8	206 (25.7, n=2)	0.0772 (0.0155, n=2)	2.84 (0.753, n=2)
9	375 (87.5, n=2)	0.127 (0.0118, n=2)	14.9 (2.15, n=2)
10	226 (67.4, n=2)	0.109 (0.0927, n=2)	9.33 (1.49, n=2)
11	174 (25.3, n=2)	0.226 (0.0728, n=2)	15.7 (4.37, n=2)
12	684 (141, n=2)	0.167 (0.0853, n=2)	12.9 (2.71, n=2)
13	>1060 (n=1/2)	0.296 (0.0291, n=2)	31.1 (11.9, n=2)
14	160	0.0494	29.6
15	130	0.284	2.19
16	371	0.0841	2.78
17	261 (115, n=2)	0.606 (0.363, n=2)	7.63 (2.47, n=2)
18	50.1	0.0798	0.319
19	60.5	0.0518	0.24
20	228 (65.3, n=2)	0.0849 (0.0168, n=2)	3.30 (1.01, n=2)
21	149	0.529	14.5
22	53.4	0.624	23.1
23	>1010	0.258	6.32
24	49.8	0.232	5.04
25	81.1	0.179	4.8
26	>960	0.176	4.22
27	315	0.103	3.68
28	>902	0.24	21.1
29	132	0.377	8
30	123	0.151	6.2
31	290	0.0275	6.58
32	44.7	0.0205	3.96
33	>979	6.4	361
34	134	0.0467	3.41
35	>964	0.0358	54.6

36	413	0.141	16.4
37	255	0.0523	3.84
38	>974	0.104	31.3
39	161	0.0499	16.8
40	150	0.0345	7.56
41	165	0.0551	13.4
42	160	0.0514	13.2
43	134	0.101	11.8
44	121	0.0516	10.6
45	11.1	0.0463	5.65
46	133	0.0852	13.4
48	111	0.074	15.7
49	236	0.087	12.3
50	220 (61.2, n=2)	0.0568 (0.00744, n=2)	4.71 (1.22, n=2)
51	195 (65.9, n=2)	0.0620 (0.0131, n=2)	5.62 (0.658, n=2)
52	>1100	0.0342	5.81
53	216	0.188	1.23
54	333	0.965	1.66
55	>1100	6.24	7.29
56	>1060	0.148	10.3
57	26.1 (4.31, n=2)	0.0583 (0.0131, n=2)	3.00 (0.293, n=2)
58	339	0.105	2.77
59	292 (11.8, n=2)	0.136 (0.00422, n=2)	8.20 (4.13, n=2)
60	237	0.0655	9.55
61	110	0.102	11.1
62	168	0.0545	2.03
63	273	0.141	7.79
64	260	0.0866	4.86
65	194	0.0643	4.53
66	93.7	0.106	7.53
67	270	0.061	10.2
68	99.2	0.0243	1.58
69	22.1 (4.18, n=3)	0.0300 (0.00657, n=3)	1.22 (0.353, n=3)
74	69.8	0.0279	5.99
75	283	0.103	24.4

-87-

76	14.4	0.0659	2.64
78	215 (66.2, n=3)	0.163 (0.0356, n=2)	3.94 (1.21, n=2)
79	429 (n=1/2)	0.0313	2.69
80	347 (n=1/2)	0.0931	2.16
81	344	0.198	2.88
82	>1060	14.9	6.82
83	320	0.142	7.1
84	>1100	0.143	10.2
85	>894 (n=1/2)	0.621	1.87
86	>1060	0.0401	3.74
87	278 (n=1/2)	0.0340 (0.00150, n=2)	1.79 (0.417, n=2)
88	545 (57.8, n=2)	0.0717	4.24
89	324 (22.9, n=2)	0.045	2.64
90	245 (7.55, n=2)	0.0472	4.76
91	540	1.8	5.23
93	15.7	0.0859	1.89
99	23.6	0.027	1.15
100	44	0.115	4.13
101	117	0.0953	8.1
103	40.3	0.0645	6.68
104	123 (17.1, n=5)	0.0565 (0.0153, n=5)	3.91 (0.955, n=5)
105	20.4	0.119	0.871
106	515	0.179	1.2
107	303	0.0425	0.867
108	171	0.0732	3
109	43.1	0.0279	1.34
110	73.9	0.0395	4.38
115	9.89	0.0302	3.43
116	137 (13.9, n=2)	0.0597 (0.0486, n=2)	6.80 (1.85, n=2)
117	192 (14.6, n=3)	0.0497 (0.0111, n=3)	6.96 (1.95, n=3)
118	53.0 (7.07, n=3)	0.0859 (0.00402, n=3)	6.10 (0.870, n=3)
119	30.6	0.0925	9.87

120	93.6	0.11	11.7
121	51.9	0.177	3.16
122	43.3 (8.07, n=2)	0.190 (0.0189, n=2)	3.36 (0.799, n=2)
123	80.1 (11.7, n=6)	0.0469 (0.00804, n=6)	1.31 (0.197, n=6)
124	41.5 (9.39, n=2)	0.0424 (0.00200, n=2)	4.87 (0.277, n=2)
125	54.4 (0.365, n=2)	0.0624 (0.0117, n=2)	3.19 (0.123, n=2)
126	101 (11.5, n=2)	0.0644 (0.0267, n=2)	1.46 (0.299, n=2)
127	43.6	0.126	1.86
128	433 (203, n=2)	0.0625 (0.0355, n=2)	1.88 (0.296, n=2)
129	14.9	0.0278	1
130	>1060	0.177	3.66
133	216	0.157	11.4 (2.31, n=2)
134	60.5	0.14	12.7 (0.947, n=2)
135	454	0.161	3.01
137	98.1 (14.8, n=3)	0.0373 (0.00200, n=3)	1.24 (0.341, n=3)
138	61.2 (4.65, n=2)	0.0295 (0.00145, n=2)	0.926 (0.201, n=2)
139	105 (6.68, n=2)	0.0360 (0.00446, n=2)	1.25 (0.0904, n=2)
140	175 (40.1, n=3)	0.0474 (0.00461, n=3)	1.46 (0.0630, n=3)
142	53.1 (1.60, n=2)	0.0275 (0.00210, n=2)	1.06 (0.300, n=2)
143	65.5	0.0304	1.15
144	77	0.0341	1.78
145	158	0.0652	2.22
147	64.9 (19.9, n=2)	0.0981 (0.0285, n=2)	4.47 (0.742, n=2)
149	127	0.0708	26.1
150	63.2	0.0649	30.5
152	93.4	0.117	48
153	43.8	0.0578	22.2

154	762 (51.7, n=3)	0.0610 (0.00457, n=3)	5.64 (2.52, n=3)
157	179 (82.9, n=3)	0.0937 (0.0160, n=3)	8.97 (2.28, n=3)
158	285 (17.4, n=2)	0.114 (0.0193, n=2)	11.8 (5.32, n=2)
160	>1060 (n=1/2)	5.98 (1.46, n=2)	14.4 (3.72, n=2)
163	117	0.116	10.8
181	413 (132, n=2)	0.145 (0.0856, n=2)	7.28 (0.798, n=2)
182	565 (335, n=2)	0.0669 (0.0311, n=2)	4.64 (0.655, n=2)
183	304 (128, n=2)	0.0869 (0.0118, n=2)	4.11 (0.369, n=2)
189	146 (7.81, n=2)	0.128 (0.0817, n=2)	8.81 (0.434, n=2)
191	348 (54.7, n=2)	0.144 (0.0676, n=2)	4.52 (1.95, n=2)
192	>1110 (n=1/2)	0.118 (0.108, n=2)	2.89 (0.516, n=2)
202	394	0.0579	5.38
203	845 (n=1/2)	0.0337 (0.00260, n=2)	3.90 (1.10, n=2)
204	>1150	0.0704	1.9
205	438	0.0367	3.05
206	176 (126, n=2)	0.0814 (0.00608, n=2)	5.27 (0.359, n=2)
207	74.2	0.0786	1.37
208	>1060	0.0537	2.13
209	>1060 (n=1/2)	0.0664 (0.0267, n=2)	1.43 (0.466, n=2)
210	>1010	0.0399	1.58
211	131	0.0243	2.64
212	205 (1.77, n=2)	0.0978 (0.0730, n=2)	2.76 (0.561, n=2)
213	544	0.365	2.75
214	126	0.0304	1.99
215	75.2	0.0666	6.85
216	45.2	0.0559	2.34

217	516	0.0376	2.02
218	270	0.0593	2.54
219	373	0.0689	2.01
220	377	0.0919	2.71
221	154 (n=1/2)	0.0414 (0.00291, n=2)	1.77 (0.900, n=2)
222	71.3 (11.9, n=2)	0.0495 (0.0210, n=2)	3.59 (0.660, n=2)
223	46.5	0.0921	5.62
224	627 (267, n=2)	0.0482 (0.0174, n=2)	6.86 (1.85, n=2)
225	714 (n=1/2)	0.0622 (0.0208, n=2)	8.79 (4.24, n=2)
226	200	0.0254	4.1
227	113	0.0146	2.01
228	182	0.028	2.43
229	>1100	2.47	36.2
230	494	0.042	4.68
231	440	0.0394	3.03
232	>1150	0.0544	5.62
233	>1150	0.0445	5.99
234	>1100	0.0563	10.9
235	>1200	0.0581	7.65
236	200 (15.1, n=2)	0.0425 (0.00194, n=2)	1.05 (0.173, n=2)
237	>1060	0.131	1.04
238	230	0.0403	0.548
239	596 (215, n=3)	0.101 (0.0172, n=3)	2.71 (0.0420, n=3)
240	204	0.0284	0.552
241	167 (45.6, n=2)	0.0420 (0.0118, n=2)	0.799 (0.401, n=2)
242	95.9 (14.1, n=2)	0.0604 (0.00642, n=2)	0.853 (0.0475, n=2)
243	145 (5.05, n=2)	0.0325 (0.00840, n=2)	0.670 (0.0478, n=2)
244	87.8 (2.39, n=2)	0.0308 (0.0150, n=2)	0.820 (0.141, n=2)
246	>1010 (n=1/3)	0.0509 (0.0147, n=3)	0.812 (0.0900, n=3)
247	>1100	>55.1	4.39

248	>1050	0.0397	2.4
249	>1000	0.0394	2.35
250	198	0.0171	1.72
251	21.2	0.0249	1.09
252	26	0.00971	0.383
253	>912	0.138	2.57
254	148	0.108	2.58
255	257	0.0772	2.58
264	388	0.015	0.412
265	567	0.0224	0.537
266	193 (28.2, n=2)	0.0666 (0.0189, n=2)	2.01 (0.256, n=2)
267	349 (178, n=2)	0.0628 (0.00765, n=2)	1.57 (0.109, n=2)
268	>1190	0.0814	3.98
269	>1100	0.152	7.1
270	>1190	0.117	8.27
271	>1150	0.107	5.09
272	550 (243, n=2)	0.0353 (0.00276, n=2)	1.22 (0.291, n=2)
273	724	0.0698	1.13
288	345 (35.7, n=3)	0.0580 (0.0105, n=3)	1.60 (0.866, n=3)
289	>1050 (n=1/3)	0.0457 (0.0220, n=3)	2.63 (1.74, n=3)
290	308 (n=1/3)	0.0617 (0.0115, n=3)	2.44 (0.162, n=3)
291	>872 (n=1/2)	0.129 (0.0346, n=3)	3.16 (0.270, n=3)
292	595	0.0547	1.19
293	668	0.0775	1.64
294	629	0.205	2.92
295	>1000	0.181	4.12
296	>1000	0.444	3.33
297	>1240	0.0958	2.98
298	>1370	0.0578	3.03
299	>1040	0.734	54.3

300	251	0.0504	2.13
301	44.4 (6.17, n=3)	0.0273 (0.00127, n=3)	0.875 (0.0889, n=3)
302	18.5	0.0289	0.617
303	502 (189, n=3)	0.0580 (0.0151, n=3)	3.69 (1.86, n=3)
304	>855	0.0499	4.44
305	352 (30.8, n=2)	0.0250 (0.00586, n=2)	0.830 (0.481, n=2)
306	>1040	0.0349	2.86
307	117	0.0773	5.1
308	94.2	0.0288	1.01
309	64.1	0.0264	1.04
310	174 (8.97, n=2)	0.0315 (0.00162, n=2)	1.70 (0.144, n=2)
311	115	0.0497	11.5
312	106	0.0348	1.63
313	27.6	0.0261	0.815
314	116	0.027	0.717
315	539	0.0677	2.28
316	654 (76.5, n=3)	0.0418 (0.00224, n=3)	0.957 (0.180, n=3)
317	253	0.0215	2.63
318	730 (n=1/2)	0.0452 (0.00883, n=2)	7.52 (0.256, n=2)
319	>984	0.0349	3.61
320	>1040	0.136	5.17
321	770	0.064	4.2

322	1030	0.175	2.31
323	300	0.0516	1.65
324	449	0.0278	0.609
325	13	0.0209	0.475
326	207	0.251	2.92
327	114 (8.53, n=2)	0.0667 (0.0211, n=2)	2.10 (0.287, n=2)
328	>1450 (n=1/2)	0.136 (0.0602, n=2)	3.98 (0.339, n=2)
329	17.0 (2.51, n=2)	0.0439 (0.0105, n=2)	3.28 (0.327, n=2)
330	>1050	0.114	12.7
331	>969 (n=1/2)	0.0851 (0.00508, n=2)	11.4 (0.160, n=2)
332	397 (272, n=2)	0.0497 (0.00681, n=2)	7.87 (0.333, n=2)
333	578 (68.8, n=2)	0.0634 (0.00255, n=2)	4.25 (0.180, n=2)
334	192	0.0646	2.17
335	27.1	0.0444	2.54
336	17.1	0.0277	2.44
337	335	0.0363	1.61
338	>1060	0.0831	3.23
339	873 (19.4, n=2)	0.0388 (0.0198, n=2)	2.69 (0.218, n=2)
340	250 (60.8, n=2)	0.0507 (0.0177, n=2)	2.08 (0.0742, n=2)
341	39.7	0.0559	6.49
342	>1000	0.129	15.4
343	>1070	0.0374	13.3
344	>1080	0.0507	14.8

-94-

346	310 (26.0, n=3)	0.0559 (0.0248, n=2)	1.67 (0.911, n=2)
349	>1060 (n=1/3)	0.0800 (0.0215, n=3)	1.72 (0.0730, n=3)
352	>1030 (n=1/2)	0.0726 (0.00687, n=3)	3.03 (0.673, n=3)
354	>953	0.175 (0.0209, n=2)	7.85 (0.190, n=2)
356	>1010	0.350 (0.0397, n=2)	10.3 (1.53, n=2)
357	>977	0.316 (0.0233, n=2)	7.02 (1.19, n=2)
358	915 (n=1/2)	0.0636 (0.00684, n=3)	1.37 (0.189, n=3)
359	>982 (n=1/2)	0.0874 (0.0159, n=3)	2.59 (0.833, n=3)
360	485	0.128 (0.00895, n=2)	1.74 (0.0269, n=2)
362	>1050	0.337 (0.00484, n=2)	6.95 (0.446, n=2)
363	>1020 (n=1/2)	0.170 (0.0113, n=3)	3.89 (0.864, n=3)
364	>1150 (n=1/2)	0.672 (0.0431, n=3)	17.2 (2.26, n=3)
367	777	0.0282	0.809

Functional Activity (with BSA)

Functional activity is determined in hGLP-1R, hGcgR and hGIP-R expressing HEK-293 clonal cell lines. Each receptor over-expressing cell line is treated with peptide (20 point CRC, 2.75-fold Labcyte Echo direct dilution) in DMEM (Gibco Cat# 31053) supplemented with 1X GlutaMAXTM supplement (L-alanyl-L-glutamine dipeptide Gibco®), 0.25% FBS (Fetal Bovine Serum), 0.05% fraction V BSA (Bovine Serum Albumin), 250 μ M 3-isobutyl-1-methylxanthine (IBMX) and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) in a 20 μ l assay volume.

After 60-minute incubation at room temperature, the resulting increase in intracellular cAMP is quantitatively determined using the CisBio cAMP Dynamic 2 homogeneous time-resolved fluorescence (HTRF) Assay Kit. The cAMP levels within the cell are detected by

adding the cAMP-d2 conjugate in cell lysis buffer followed by the antibody anti-cAMP-Eu³⁺-Cryptate, also in cell lysis buffer. The resulting competitive assay is incubated for at least 60 minutes at room temperature and then detected using an instrument with excitation at 320 nm and emission at 665 nm and 620 nm. Envision units (emission at 665nm/620nm*10,000) are inversely proportional to the amount of cAMP present and are converted to nM cAMP per well using a cAMP standard curve.

The amount of cAMP generated (nM) in each well is converted to a percent of the maximal response observed with either human GLP-1(7-36)NH₂, human Gcg, or human GIP(1-42)NH₂. A relative EC₅₀ value is derived by non-linear regression analysis using the percent maximal response vs. the concentration of peptide added, fitted to a four-parameter logistic equation.

EC₅₀ determination of human GLP-1(7-36)NH₂ at human GLP-1R, human Gcg at human GcgR, and human GIP(1-42)NH₂ at human GIP-R: the peptide concentration ranges were 448 pM to 99.5 nM. EC₅₀ determination of Examples at human GLP-1R, human GcgR, and human GIP-R: the peptide concentration ranges are 51.5 fM to 11.4 μM.

Table 2. Functional cAMP Potency (EC₅₀) for Example and comparator peptides (hGcg, hGIP amide, and hGLP-1 amide) in the presence of FBS.

Example or comparator	cAMP EC ₅₀ ,nM (SEM, n)		
	GcgR	GIPR	GLP-1R
hGcg	0.0125 ± 0.0011 (n=12)		
hGIP amide		0.0979 (0.0088, n=12)	
hGLP-1 amide			0.0424 (0.0043, n=12)
Example 1	>11400 (n=1/9)	38.5 (20.2, n=12)	53.3 (21.4, n=12)
Example 2	>10900 (n=1/12)	2.64 (0.696, n=12)	6.52 (1.76, n=11)
Example 3	>10900 (n=1/7)	9.24 (2.23, n=7)	19.4 (7.02, n=7)
Example 4	>10900 (n=1/5)	1.03 (0.181, n=5)	2.02 (0.596, n=4)
Example 5	>10900	1.98	1.61

20 cAMP Pharmacological Functional Assay in presence of casein

An additional set of cAMP assays are conducted in HEK293 cells expressing the human GLP-1 receptor (GLP-1R), gastric inhibitory peptide receptor (GIPR), Glucagon receptor (GcgR). Pharmacological activity of the hGLP1R/GIPR peptides are determined in HEK293 cells stably expressing the human GLP-1 receptor (GLP-1R), gastric inhibitory peptide receptor (GIPR), or GLP-2 receptor (GLP-2R). Each receptor over-expressing cell line (20 μ l) is treated with the test peptide in DMEM (Gibco Cat# 31053) supplemented with 0.1% Casein (Sigma Cat# C4765), 250 μ M IBMX, 1X GlutaMAXTM (Gibco Cat# 35050), and 20 mM HEPES (HyClone Cat# SH30237.01) in a 20 μ l assay volume. After 60 minute incubation at room temperature, the resulting increase in intracellular cAMP is quantitatively determined using the CisBio cAMP Dynamic 2 HTRF Assay Kit (62AM4PEJ). The Lysis buffer containing cAMP-d2 conjugate (20 μ l) and the antibody anti-cAMP-Eu3+-Cryptate (20 μ l) are then added to determine the cAMP level. After 1h-incubation at room temperature, HTRF signal is detected with an Envision 2104 plate reader (PerkinElmer). Fluorescent emission at 620 nm and at 665 nm is measured and the ratio between 620 nm and at 665 nm is calculated and then are converted to nM cAMP per well using a cAMP standard curve. Dose response curves of compounds are plotted as the percentage of stimulation normalized to minimum (buffer only) and maximum (maximum concentration of each control ligand) values and analyzed using a four parameter non-linear regression fit with a variable slope (Genedata Screener 13). EC₅₀ is the concentration of compound causing half-maximal stimulation in a dose response curve. A relative EC₅₀ value is derived by non-linear regression analysis using the percent maximal response vs. the concentration of peptide added, fitted to a four-parameter logistic equation.

Using Homogeneous Time Resolved Fluorescence methods, assays are conducted to determine the intrinsic potency of Example and comparator molecules performed in the presence of casein (instead of serum albumin) as a nonspecific blocker, which does not interact with the fatty acid moieties of the analyzed molecules.

Intracellular cAMP levels are determined by extrapolation using a standard curve. Dose response curves of compounds are plotted as the percentage of stimulation normalized to minimum (buffer only) and maximum (maximum concentration of each control ligand)

values and analyzed using a four parameter non-linear regression fit with a variable slope (Genedata Screener 13). EC₅₀ is the concentration of compound causing half-maximal stimulation in a dose response curve. Each relative EC₅₀ value for the Geometric mean calculation is determined from a curve fitting.

- 5 Concentration response curves of compounds are plotted as the percentage of stimulation normalized to minimum (buffer only) and maximum (maximum concentration of each control ligand) values and analyzed using a four parameter non-linear regression fit with a variable slope (Genedata Screener 13). EC₅₀ is the concentration of compound causing half-maximal stimulation in a dose response curve.
- 10 The EC₅₀ summary statistics are computed as follows:
Geometric mean:
$$GM = 10^{(\text{arithmetic mean of } \log_{10} \text{ transformed EC}_{50} \text{ values})}$$

The standard error of the mean is reported:
$$SEM = \text{geometric mean} \times (\text{standard deviation of } \log_{10} \text{ transformed EC}_{50} \text{ values} / \text{square root of the \# of runs}) \times \log_e \text{ of } 10.$$
- 15 The log transform accounts for the EC₅₀ values falling on a multiplicative, rather than an arithmetic scale.
- Each day, the assay is run, the test peptides are run plus the native ligands GIP and GLP-1, buffer only as baseline (minimum) and the highest concentration of the respective
- 20 GIP and GLP-1 standard is used as maximum for calculations. For illustration, as shown by Example 1, the test peptide is tested in 8 runs of the assay. For avoidance of doubt, hGIP amide and hGLP-1 amide EC₅₀ in Table 3 are illustrative of geometric mean values from a series of 18 assay values, and values will vary each day compared to the zero buffer.
- Accordingly, each Example will use the geometric mean of those values to normalize the
- 25 Example assay runs.

Table 3. Functional activation of hGLP-1R, hGIPR, hGcgR in the presence of 0.1% Casein.

Example or comparator	hGIPR cAMP Rel EC ₅₀ nM (SEM, n)	hGIPR cAMP EC ₅₀ ratio (SEM, n)	hGLP1R cAMP Rel EC ₅₀ nM (SEM, n)	hGLP1R cAMP EC ₅₀ ratio (SEM, n)
hGIP amide	0.170 (0.012, n=18)			
hGLP-1 amide			0.0396 (0.0030, n=16)	
1	0.0356 (0.00576, n=8)	4.65 (0.514, n=8)	0.0410 (0.00720, n=7)	1.12 (0.0949, n=7)
2	0.0339 (0.00650, n=5)	5.89 (1.10, n=5)	0.0441 (0.00670, n=5)	0.888 (0.0993, n=5)
3	0.0411 (0.00541, n=5)	4.51 (0.355, n=5)	0.0338 (0.00156, n=4)	1.25 (0.0916, n=4)
4	0.0272 (0.00358, n=6)	5.95 (0.466, n=6)	0.0297 (0.00319, n=6)	1.41 (0.241, n=6)
5	0.0309 (0.00402, n=5)	6.27 (0.808, n=5)	0.0164 (0.00219, n=5)	2.69 (0.547, n=5)
6	0.0899 (0.0196, n=2)	2.09 (0.301, n=2)	0.374 (0.0100, n=2)	0.185 (0.00340, n=2)
7	0.461	0.317	0.470 (0.0988, n=2)	0.130 (0.0215, n=2)
8	0.0848 (0.00744, n=6)	1.97 (0.170, n=6)	0.148 (0.00926, n=6)	0.419 (0.0352, n=6)
9	0.210 (0.0335, n=6)	0.768 (0.122, n=6)	0.194 (0.0284, n=6)	0.314 (0.0384, n=6)
10	1.28 (0.270, n=2)	0.151 (0.0416, n=2)	7.64 (0.786, n=2)	0.00912 (0.000859, n=2)
11	0.486 (0.108, n=2)	0.399 (0.114, n=2)	6.89 (2.68, n=3)	0.0111 (0.00387, n=3)
12	0.300 (0.0827, n=2)	0.659 (0.221, n=2)	1.15 (0.00296, n=2)	0.0603 (0.000359, n=2)
13	1.05 (0.236, n=2)	0.180 (0.0272, n=2)	5.39 (1.35, n=2)	0.0133 (0.00338, n=2)
14	0.284 (0.0828, n=2)	0.545 (0.161, n=2)	1.87 (0.534, n=2)	0.0306 (0.00519, n=2)
15	0.613 (0.141, n=2)	0.273 (0.00678, n=2)	0.0336	1.65 (0.0634, n=2)

			(0.0000222, n=2)	
16	0.975 (0.241, n=2)	0.157 (0.0401, n=2)	0.0437 (0.00494, n=4)	1.43 (0.260, n=3)
17	5.81 (0.758, n=2)	0.0257 (0.00368, n=2)	0.152 (0.0166, n=2)	0.398 (0.0260, n=2)
18	0.610 (0.200, n=2)	0.275 (0.0204, n=2)	0.0945 (0.00823, n=2)	0.589 (0.0732, n=2)
19	0.386 (0.0583, n=2)	0.436 (0.0449, n=2)	0.104 (0.00342, n=2)	0.532 (0.0375, n=2)
20	0.0556 (0.00518, n=5)	2.81 (0.293, n=5)	0.117 (0.0121, n=8)	0.577 (0.0706, n=8)
21	0.0748 (0.00682, n=8)	1.95 (0.145, n=8)	0.160 (0.00495, n=7)	0.402 (0.0178, n=7)
22	0.0842 (0.0103, n=4)	1.86 (0.109, n=4)	0.206 (0.0172, n=5)	0.290 (0.0233, n=5)
23	0.204 (0.0160, n=5)	0.754 (0.0348, n=5)	0.190 (0.00766, n=7)	0.342 (0.0255, n=7)
24	0.762 (0.206, n=2)	0.228 (0.0443, n=2)	13.0 (n=1/2)	0.00416 (n=1/2)
25	0.230 (0.0191, n=6)	0.636 (0.0564, n=6)	0.356 (0.0415, n=6)	0.197 (0.0287, n=6)
26	0.251 (0.0264, n=6)	0.585 (0.0531, n=6)	0.293 (0.0442, n=5)	0.238 (0.0309, n=5)
27	0.0789 (0.00792, n=6)	1.90 (0.295, n=6)	0.557 (0.0717, n=5)	0.123 (0.0102, n=5)
28	1.66 (0.257, n=2)	0.106 (0.0238, n=2)	32.7 (n=1/2)	0.00166 (n=1/2)
29	0.320 (0.0548, n=2)	0.536 (0.0522, n=2)	0.999 (0.336, n=2)	0.0671 (0.0283, n=2)
30	0.114 (0.00650, n=2)	1.50 (0.0246, n=2)	1.84 (0.280, n=2)	0.0331 (0.00127, n=2)
31	0.388 (0.0773, n=2)	0.456 (0.121, n=2)	0.891 (0.147, n=2)	0.0708 (0.0192, n=2)
32	0.179 (0.0200, n=5)	0.840 (0.0750, n=5)	0.498 (0.0124, n=5)	0.136 (0.00728, n=5)
33	63.3 (6.65, n=2)	0.00222 (0.000125, n=2)	251 (n=1/2)	0.000256 (n=1/2)
34	0.360 (0.0200, n=2)	0.393 (0.00105, n=2)	1.56 (0.132, n=2)	0.0392 (0.00119, n=2)

-100-

35	0.0905 (0.00717, n=2)	1.58 (0.215, n=2)	8.38 (0.707, n=2)	0.00728 (0.000221, n=2)
36	0.309 (0.0126, n=2)	0.458 (0.00789, n=2)	2.29 (0.390, n=2)	0.0268 (0.00309, n=2)
37	0.269 (0.0546, n=2)	0.532 (0.0765, n=2)	1.15 (0.216, n=2)	0.0533 (0.00707, n=2)
38	0.147 (0.0217, n=2)	0.967 (0.0861, n=2)	2.82 (0.0832, n=2)	0.0217 (0.00181, n=2)
39	0.133 (0.0242, n=2)	1.07 (0.132, n=2)	1.92 (0.447, n=2)	0.0323 (0.00571, n=2)
40	0.136 (0.0164, n=2)	1.06 (0.188, n=2)	0.746 (0.118, n=2)	0.0801 (0.0105, n=2)
41	0.229 (0.0451, n=2)	0.637 (0.159, n=2)	0.960 (0.0203, n=2)	0.0637 (0.00478, n=2)
42	0.161 (0.00967, n=2)	0.897 (0.149, n=2)	1.45 (0.328, n=2)	0.0471 (0.0107, n=2)
43	0.112 (0.0129, n=2)	1.28 (0.0105, n=2)	0.862 (0.0963, n=2)	0.0777 (0.00826, n=2)
44	0.128 (0.0118, n=2)	1.11 (0.0174, n=2)	0.752 (0.201, n=2)	0.0918 (0.0245, n=2)
45	0.106 (0.0158, n=2)	1.75 (0.164, n=2)	1.03 (0.194, n=2)	0.0569 (0.00591, n=2)
46	0.172 (0.0231, n=2)	0.828 (0.0222, n=2)	0.687 (0.0147, n=2)	0.0969 (0.00159, n=2)
47	0.287 (0.0529, n=2)	0.654 (0.0819, n=2)	0.702 (0.197, n=2)	0.0890 (0.0310, n=2)
48	0.168 (0.0126, n=2)	0.863 (0.156, n=2)	0.691 (0.0491, n=2)	0.0966 (0.00733, n=2)
49	0.0868 (0.0288, n=2)	1.69 (0.372, n=2)	0.597 (0.0314, n=2)	0.112 (0.00642, n=2)
50	0.0794 (0.0104, n=5)	1.96 (0.179, n=5)	0.0961 (0.00519, n=7)	0.675 (0.0492, n=7)
51	0.0960 (0.0106, n=7)	1.69 (0.201, n=7)	0.153 (0.0110, n=7)	0.426 (0.0376, n=7)
52	0.0997 (0.0119, n=6)	1.40 (0.154, n=6)	0.132 (0.0143, n=5)	0.514 (0.0413, n=5)
53	0.628 (0.161, n=2)	0.287 (0.0912, n=2)	0.0339 (0.000266, n=2)	1.80 (0.190, n=2)
54	1.57 (0.144, n=2)	0.110 (0.0181, n=2)	0.0242 (0.00711, n=2)	2.55 (0.456, n=2)

-101-

55	5.45 (n=1/2)	<0.00159	0.0286 (0.000346, n=2)	2.33 (0.0282, n=2)
56	0.167 (0.0132, n=2)	1.02 (0.00567, n=2)	0.136 (0.00964, n=2)	0.491 (0.0347, n=2)
57	0.0849 (0.0107, n=6)	1.74 (0.148, n=6)	0.0668 (0.00654, n=7)	0.996 (0.0730, n=7)
58	0.266 (0.0307, n=5)	0.522 (0.0439, n=5)	0.180 (0.0151, n=5)	0.378 (0.0347, n=5)
59	0.0922 (0.0134, n=5)	1.54 (0.186, n=5)	0.0840 (0.00742, n=5)	0.812 (0.0816, n=5)
60	0.135 (0.0107, n=2)	1.06 (0.0296, n=2)	0.287 (0.0377, n=3)	0.237 (0.0270, n=3)
61	0.0739 (0.0140, n=2)	1.94 (0.158, n=2)	0.371 (0.0664, n=3)	0.187 (0.0341, n=3)
62	0.0601 (0.00469, n=5)	2.33 (0.234, n=5)	0.159 (0.0151, n=5)	0.463 (0.0644, n=5)
63	0.0925 (0.0106, n=7)	1.58 (0.156, n=7)	0.190 (0.0195, n=5)	0.386 (0.0466, n=5)
64	0.0916 (0.0104, n=6)	1.57 (0.192, n=6)	0.172 (0.0184, n=5)	0.429 (0.0598, n=5)
65	0.143 (0.0264, n=2)	1.04 (0.295, n=2)	0.289 (0.0215, n=3)	0.233 (0.0144, n=3)
66	0.0743 (0.00740, n=5)	1.89 (0.209, n=5)	0.285 (0.0291, n=5)	0.255 (0.0245, n=5)
67	0.0913 (0.00577, n=2)	1.61 (0.0648, n=2)	0.447 (0.0958, n=2)	0.123 (0.0314, n=2)
68	0.0881 (0.00725, n=2)	1.67 (0.0990, n=2)	0.153 (0.0169, n=2)	0.354 (0.0550, n=2)
69	0.0712 (0.0156, n=4)	2.73 (0.431, n=3)	0.0844 (0.00548, n=4)	0.850 (0.0870, n=4)
70	0.480 (0.0706, n=2)	0.351 (0.0135, n=2)	0.283 (0.0281, n=3)	0.207 (0.0330, n=3)
71	0.166 (0.0417, n=2)	1.02 (0.0668, n=2)	1.02 (0.227, n=3)	0.0604 (0.0170, n=3)
72	0.252 (0.0456, n=2)	0.715 (0.251, n=2)	0.906 (0.127, n=3)	0.0645 (0.0103, n=3)
73	0.979 (0.317, n=2)	0.174 (0.0239, n=2)	2.55 (0.337, n=3)	0.0225 (0.00178, n=3)
74	0.0866 (0.00653, n=2)	1.70 (0.166, n=2)	0.467 (0.00217, n=2)	0.115 (0.00580, n=2)

75	0.214 (0.0234, n=2)	0.690 (0.0905, n=2)	1.49 (0.00142, n=2)	0.0359 (0.00168, n=2)
76	0.124 (0.000853, n=2)	1.24 (0.0255, n=2)	0.125 (0.00942, n=2)	0.630 (0.0992, n=2)
77	135 (22.8, n=2)	0.00102 (0.000331, n=2)	>2000 (n=1/2)	<0.0000325 (n=1/2)
78	0.532 (0.120, n=2)	0.293 (0.0571, n=2)	0.544 (0.0263, n=2)	0.143 (0.00495, n=2)
79	0.0732 (0.0127, n=2)	2.11 (0.305, n=2)	2.02 (0.562, n=2)	0.0410 (0.0142, n=2)
80	0.140 (0.0130, n=2)	1.09 (0.0709, n=2)	0.351 (0.0522, n=2)	0.227 (0.0516, n=2)
81	0.428 (0.0445, n=2)	0.373 (0.0131, n=2)	1.29 (0.00950, n=2)	0.0630 (0.00192, n=2)
82	24.3 (8.06, n=2)	0.00679 (0.00175, n=2)	26.1 (6.81, n=2)	0.00325 (0.000941, n=2)
83	0.182 (0.0176, n=2)	0.804 (0.0637, n=2)	0.387 (0.0648, n=2)	0.166 (0.0265, n=2)
84	0.0915 (0.00451, n=2)	1.59 (0.0514, n=2)	0.374 (0.0762, n=2)	0.173 (0.0337, n=2)
85	1.67 (0.143, n=2)	0.111 (0.00296, n=2)	0.0518 (0.00318, n=2)	1.13 (0.0246, n=2)
86	0.0452 (0.00765, n=2)	3.29 (0.605, n=2)	0.271 (0.0756, n=2)	0.243 (0.0647, n=2)
87	0.0945 (0.0277, n=2)	1.1	0.0801	0.786
88	0.475 (0.00187, n=2)	0.392 (0.0215, n=2)	0.640 (0.00544, n=2)	0.0918 (0.00840, n=2)
89	0.119 (0.0150, n=2)	1.57 (0.107, n=2)	0.335 (0.00771, n=2)	0.175 (0.0105, n=2)
90	0.0361 (0.000915, n=2)	5.17 (0.434, n=2)	0.532 (0.0564, n=2)	0.110 (0.00250, n=2)
91	19.2 (n=1/2)	0.0103 (n=1/2)	>5000 (n=1/2)	<0.0000108 (n=1/2)
92	0.338	0.546	0.257	0.258
93	0.185 (0.0241, n=2)	0.956 (0.292, n=2)	0.115 (0.0143, n=3)	0.498 (0.0199, n=3)
94	0.425	0.434	0.338	0.196

95	1.17 (0.0326, n=2)	0.145 (0.0227, n=2)	1.01 (0.229, n=3)	0.0576 (0.00824, n=3)
96	0.712 (0.0736, n=2)	0.238 (0.0195, n=2)	0.590 (0.0509, n=3)	0.0977 (0.0101, n=3)
97	1.85 (0.214, n=2)	0.0953 (0.0278, n=2)	2.18 (0.347, n=3)	0.0268 (0.00442, n=3)
98	0.0718	2.43	0.157	0.384
99	0.0643 (0.0120, n=5)	2.27 (0.208, n=5)	0.0986 (0.0104, n=4)	0.629 (0.0938, n=4)
100	0.120 (0.0169, n=2)	1.48 (0.191, n=2)	0.0790 (0.00439, n=2)	0.724 (0.0809, n=2)
101	0.0704 (0.00913, n=5)	2.07 (0.138, n=5)	0.0579 (0.00589, n=4)	1.06 (0.131, n=4)
102	0.178	0.983	0.0628 (0.00458, n=2)	0.913 (0.118, n=2)
103	0.0693 (0.0165, n=4)	2.01 (0.183, n=4)	0.101 (0.0132, n=3)	0.655 (0.108, n=3)
104	0.0323 (0.00474, n=8)	4.93 (0.595, n=8)	0.0248 (0.00679, n=6)	1.85 (0.242, n=6)
105	1.85 (0.133, n=2)	0.101 (0.00134, n=2)	0.0401 (0.00740, n=2)	1.51 (0.396, n=2)
106	6.54 (n=1/2)	0.0302 (n=1/2)	0.0413 (0.000823, n=2)	1.42 (0.0898, n=2)
107	0.241 (0.0209, n=5)	0.747 (0.0859, n=5)	0.0539 (0.00678, n=5)	1.10 (0.128, n=5)
108	0.0885 (0.00413, n=2)	2.19 (0.0798, n=2)	0.294 (0.0441, n=2)	0.218 (0.0253, n=2)
109	0.109 (0.0252, n=2)	1.83 (0.397, n=2)	0.350 (0.0142, n=2)	0.182 (0.0134, n=2)
110	0.218 (0.0657, n=2)	0.929 (0.263, n=2)	0.179 (0.0168, n=2)	0.358 (0.0452, n=2)
111	0.141 (0.0253, n=2)	1.1	0.308 (0.0144, n=2)	0.209 (0.0151, n=2)
112	0.124 (0.00217, n=2)	1.53	0.160 (0.0115, n=2)	0.402 (0.0185, n=2)
113	0.166 (0.0364, n=2)	1.39	0.233 (0.0133, n=2)	0.275 (0.0228, n=2)
114	0.133 (0.0220, n=2)	1.65	0.267	0.234
115	0.102 (0.0163, n=5)	1.85 (0.319, n=5)	0.0880 (0.00660, n=4)	0.743 (0.0516, n=4)

-104-

116	0.0867 (0.0141, n=5)	2.13 (0.255, n=5)	0.0703 (0.0111, n=4)	0.956 (0.147, n=4)
117	0.0648 (0.00602, n=7)	2.44 (0.263, n=6)	0.0615 (0.00275, n=7)	0.998 (0.0681, n=7)
118	0.0538 (0.00395, n=7)	3.42 (0.247, n=6)	0.0588 (0.00577, n=6)	1.13 (0.115, n=6)
119	0.216 (0.0107, n=2)	0.901 (0.0541, n=2)	0.0913 (0.00729, n=2)	0.702 (0.0788, n=2)
120	0.122 (0.0397, n=2)	1.67 (0.509, n=2)	0.201 (0.0318, n=2)	0.319 (0.0398, n=2)
121	0.0760 (0.0189, n=2)	1.44	0.0849 (0.0136, n=2)	0.760 (0.128, n=2)
122	0.0923 (0.0122, n=2)	1.73 (0.399, n=2)	0.0760 (0.0221, n=2)	0.856 (0.223, n=2)
123	0.0423 (0.00604, n=8)	4.04 (0.586, n=8)	0.0344 (0.00562, n=5)	1.58 (0.180, n=5)
124	0.0762 (0.00816, n=4)	2.18 (0.283, n=4)	0.0475 (0.00318, n=4)	1.29 (0.0473, n=4)
125	0.0381 (0.00482, n=5)	3.79 (0.152, n=5)	0.0478 (0.00569, n=4)	1.31 (0.229, n=4)
126	0.0685 (0.00653, n=4)	2.53 (0.361, n=3)	0.0715 (0.00249, n=4)	0.869 (0.0332, n=4)
127	0.158 (0.0401, n=2)	0.917	0.145 (0.00951, n=2)	0.443 (0.0176, n=2)
128	0.0694 (0.00856, n=4)	2.46 (0.344, n=3)	0.0924 (0.0147, n=4)	0.700 (0.119, n=4)
129	0.106 (0.00707, n=2)	1.88	0.121 (0.0220, n=2)	0.543 (0.112, n=2)
130	1.55	0.116	0.368	0.182
131	0.183	1.03	0.156	0.425
132	0.0657	2.88	0.26	0.255
133	0.0879 (0.0298, n=2)	1.89 (1.13, n=2)	0.0436	1.52
134	0.104 (0.00639, n=2)	1.43 (0.244, n=2)	0.0654 (0.00394, n=2)	0.942 (0.00985, n=2)
135	0.373	0.482	0.131	0.509
136	3.39	0.0544	0.06	1.1
137	0.0333 (0.00461, n=8)	4.47 (0.381, n=8)	0.0397 (0.00540, n=5)	1.25 (0.114, n=5)
138	0.0581 (0.00498, n=3)	2.18 (0.423, n=3)	0.0471 (0.00784, n=3)	1.12 (0.105, n=3)

-105-

139	0.0370 (0.00460, n=5)	3.61 (0.444, n=5)	0.0417 (0.00760, n=5)	1.13 (0.105, n=5)
140	0.0349 (0.00428, n=5)	3.76 (0.415, n=5)	0.0424 (0.00487, n=5)	1.16 (0.0926, n=5)
141	0.2	0.538	0.0975	0.414
142	0.0489 (0.00436, n=2)	2.84 (0.637, n=2)	0.0426 (0.00626, n=2)	1.22 (0.0942, n=2)
143	0.0515 (0.0105, n=2)	2.78 (0.920, n=2)	0.0745 (0.0109, n=2)	0.714 (0.152, n=2)
144	0.0375 (0.00249, n=3)	3.60 (0.373, n=3)	0.0608 (0.00352, n=3)	0.851 (0.0845, n=3)
145	0.0514 (0.0124, n=3)	2.46 (0.300, n=3)	0.0427 (0.00108, n=2)	1.22 (0.116, n=2)
146	0.0583	1.98	0.0604	0.951
147	0.0304 (0.00146, n=3)	4.14 (0.241, n=3)	0.0527 (0.00623, n=3)	1.13 (0.117, n=3)
148	0.0430 (0.00713, n=3)	2.70 (0.462, n=3)	0.0626 (0.00751, n=3)	0.859 (0.167, n=3)
149	0.0711 (0.0109, n=2)	1.82 (0.0572, n=2)	0.0916 (0.0149, n=2)	0.484 (0.0343, n=2)
150	0.0511 (0.00569, n=2)	2.64 (0.761, n=2)	0.0575 (0.00855, n=2)	0.790 (0.186, n=2)
151	0.41	0.262	1.60 (0.338, n=2)	0.0278 (0.00331, n=2)
152	0.0504 (0.00566, n=2)	2.57 (0.188, n=2)	0.0915 (0.0128, n=2)	0.484 (0.0236, n=2)
153	0.0634	1.7	0.0904 (0.0113, n=2)	0.501 (0.107, n=2)
154	0.0266 (0.00348, n=7)	5.90 (0.513, n=7)	0.0393 (0.00511, n=5)	1.23 (0.117, n=5)
155	0.266	0.584	0.495	0.0978
156	>30.0	<0.00519	0.638	0.0759
157	0.0453 (0.00495, n=6)	3.15 (0.444, n=6)	0.0431 (0.00557, n=4)	1.25 (0.135, n=4)
158	0.0454 (0.0102, n=5)	3.22 (0.527, n=5)	0.0374 (0.00374, n=5)	1.34 (0.0947, n=5)
159	4.6	0.039	0.33	0.176
160	21.0 (0.568, n=2)	0.00712 (0.00165, n=2)	0.0461 (0.00206, n=2)	1.24 (0.0824, n=2)
161	0.254	0.706	4.8	0.0121
162	4.56	0.0393	36	0.00161

-106-

163	0.121	1.29	0.0316	1.54
164	3.09	0.0581	15.6	0.00373
165	1.04	0.172	5.81	0.01
166	0.355	0.504	4.08	0.0143
167	0.617	0.291	1.2	0.0487
168	0.572	0.313	1.8	0.0323
169	0.86	0.122	3.37	0.0136
170	0.569	0.185	10.4	0.00438
171	0.223	0.471	0.75	0.0609
172	1.05	0.1	1.2	0.038
173	0.586	0.179	1.23	0.0373
174	0.217	0.483	0.472	0.0968
175	0.0881	1.19	1.11	0.0412
176	0.523	0.201	1.07	0.0427
177	1.4	0.0749	6.79	0.00673
178	3.08	0.0341	13.1	0.00349
179	1.83	0.0575	2.7	0.0169
180	0.79	0.133	2.16	0.0212
181	0.0459 (0.0122, n=5)	4.10 (0.698, n=5)	0.0592 (0.00966, n=6)	0.718 (0.0586, n=6)
182	0.0442 (0.0133, n=5)	4.37 (0.940, n=5)	0.0463 (0.00578, n=6)	0.873 (0.0433, n=6)
183	0.0615 (0.0175, n=5)	3.10 (0.600, n=5)	0.0551 (0.0125, n=5)	0.843 (0.121, n=5)
184	0.0477	2.45	0.392	0.135
185	0.632	0.185	7.16	0.00739
186			0.0939	0.572
187	0.0371 (0.00593, n=6)	4.61 (0.839, n=6)	0.0577 (0.00695, n=6)	0.702 (0.0431, n=6)
188	0.121	0.969	0.13	0.408
189	0.0775 (0.0140, n=5)	2.41 (0.314, n=5)	0.0608 (0.00976, n=6)	0.668 (0.0450, n=6)
190	0.738	0.158	0.0241	2.2
191	0.0645 (0.0139, n=3)	2.53 (0.131, n=3)	0.0356 (0.00490, n=3)	1.60 (0.182, n=3)
192	0.0615 (0.0139, n=5)	2.83 (0.340, n=5)	0.0289 (0.00261, n=5)	1.73 (0.0510, n=5)
193	0.336	0.538	0.162	0.359
194	0.423	0.427	0.284	0.205
195	0.193	0.936	0.0966	0.602
196	0.277	0.653	0.175	0.332

197	0.211	0.855	0.248	0.189
198	>30.0	<0.00602	0.139	0.337
199	>30.0	<0.00602	0.0422	1.11
200	12.3	0.0146	0.0818	0.573
201	>30.0	<0.00602	0.0385	1.22
202	0.0392 (0.00958, n=3)	4.79 (0.700, n=3)	0.0608 (0.00408, n=2)	0.712 (0.0866, n=2)
203	0.0387 (0.00465, n=4)	4.95 (0.383, n=4)	0.0679 (0.0116, n=3)	0.671 (0.130, n=3)
204	0.0424 (0.0132, n=3)	4.58 (1.01, n=3)	0.0654 (0.0166, n=2)	0.689 (0.207, n=2)
205	0.0281 (0.000581, n=2)	5.71 (0.519, n=2)	0.0261 (0.00703, n=3)	1.46 (0.102, n=3)
206	0.0409 (0.00271, n=2)	4.75 (0.0828, n=2)	0.0270 (0.00477, n=3)	1.42 (0.139, n=3)
207	0.0395 (0.0103, n=3)	4.76 (0.715, n=3)	0.0359 (0.00622, n=2)	1.23 (0.275, n=2)
208	0.0371 (0.00797, n=4)	5.33 (0.808, n=4)	0.0753 (0.00608, n=3)	0.587 (0.0362, n=3)
209	0.0308 (0.00636, n=5)	5.73 (0.721, n=5)	0.0374 (0.00451, n=4)	1.12 (0.108, n=4)
210	0.0383 (0.0124, n=4)	5.40 (1.22, n=4)	0.0432 (0.00554, n=3)	1.03 (0.118, n=3)
211	0.0442 (0.00939, n=5)	4.59 (0.656, n=5)	0.0337 (0.00481, n=4)	1.28 (0.203, n=4)
212	0.0501 (0.0132, n=4)	4.17 (0.999, n=4)	0.0572 (0.00467, n=3)	0.771 (0.0330, n=3)
213	0.0523 (0.0140, n=4)	3.87 (0.721, n=4)	0.0710 (0.0146, n=4)	0.694 (0.110, n=4)
214	0.0251 (0.00459, n=4)	6.92 (0.628, n=4)	0.0221 (0.00364, n=5)	1.74 (0.122, n=5)
215	0.0525 (0.00720, n=3)	3.53 (0.379, n=3)	0.0529 (0.00177, n=2)	0.813 (0.0175, n=2)
216	0.0401 (0.0151, n=3)	4.91 (1.22, n=3)	0.0327 (0.00291, n=2)	1.31 (0.0447, n=2)
217	0.0563 (0.0165, n=3)	3.41 (0.665, n=3)	0.0383 (0.00448, n=2)	1.14 (0.193, n=2)
218	0.0413 (0.00450, n=3)	4.43 (0.113, n=3)	0.0423 (0.00335, n=2)	1.02 (0.137, n=2)

219	0.0341 (0.00595, n=5)	5.86 (0.825, n=5)	0.0403 (0.00221, n=4)	1.03 (0.0601, n=4)
220	0.0315 (0.00564, n=5)	6.30 (0.786, n=5)	0.0312 (0.00267, n=4)	1.36 (0.176, n=4)
221	0.0445 (0.0102, n=4)	4.50 (0.773, n=4)	0.0570 (0.0101, n=3)	0.795 (0.138, n=3)
222	0.0306 (0.00648, n=4)	5.84 (0.924, n=4)	0.0248 (0.00375, n=5)	1.55 (0.110, n=5)
223	0.0670 (0.00561, n=2)	2.93 (0.487, n=2)	0.0363 (0.00532, n=3)	0.962 (0.0435, n=3)
224	0.0545 (0.00995, n=3)	3.52 (0.580, n=3)	0.0349 (0.00788, n=4)	1.06 (0.145, n=4)
225	0.101 (0.0194, n=2)	1.99 (0.536, n=2)	0.0670 (0.0107, n=3)	0.523 (0.0355, n=3)
226	0.0461 (0.00446, n=2)	4.27 (0.762, n=2)	0.0284 (0.00805, n=3)	1.25 (0.167, n=3)
227	0.0414 (0.00954, n=2)	4.73 (0.688, n=2)	0.0329 (0.00627, n=3)	1.07 (0.0870, n=3)
228	0.0503 (0.00265, n=2)	3.86 (0.119, n=2)	0.0282 (0.00274, n=2)	1.10 (0.218, n=2)
229	4.79	0.0298	2.11	0.0139
230	0.0431	3.31	0.0491	0.599
231	0.0253	5.64	0.0611	0.481
232	0.027	5.28	0.0724	0.406
233	0.0288	4.95	0.0549	0.535
234	0.0372	3.83	0.0926	0.317
235	0.0372	3.83	0.136	0.216
236	0.0249 (0.00475, n=5)	6.76 (0.804, n=5)	0.0231 (0.00333, n=5)	1.65 (0.260, n=5)
237	0.0883	2.16	0.0187	2.34
238	0.0296	7.33	0.0241	1.15
239	0.0353 (0.00282, n=4)	5.27 (0.434, n=4)	0.0376 (0.00836, n=4)	0.987 (0.213, n=4)
240	0.0223	9.73	0.0393	0.706
241	0.0257 (0.00164, n=3)	7.12 (0.471, n=3)	0.0175 (0.00373, n=3)	1.89 (0.340, n=3)
242	0.0333 (0.00196, n=3)	5.58 (0.823, n=3)	0.0164 (0.00209, n=3)	1.96 (0.186, n=3)
243	0.0214 (0.00212, n=3)	8.69 (1.21, n=3)	0.0265 (0.00423, n=3)	1.22 (0.158, n=3)

244	0.0225 (0.00136, n=3)	8.27 (1.30, n=3)	0.0252 (0.00415, n=3)	1.29 (0.174, n=3)
245	0.0552	2.82	0.0222	1.55
246	0.0258 (0.00180, n=6)	6.36 (0.340, n=6)	0.0144 (0.00106, n=5)	2.56 (0.216, n=5)
247	0.0622	2.58	0.0491	0.614
248	0.0328 (0.000561, n=2)	5.08 (0.118, n=2)	0.0428 (0.00493, n=2)	0.800 (0.00908, n=2)
249	0.0437 (0.00337, n=2)	3.84 (0.449, n=2)	0.0446 (0.0131, n=2)	0.778 (0.129, n=2)
250	0.0376	4.27	0.0306	0.985
251	0.0292	5.12	0.081	1.37
252	0.093	1.61	0.0483	1.44
253	0.219	0.684	0.109	0.638
254	0.215	0.695	0.0553	1.26
255	0.102	1.47	0.0407	1.71
256	0.643	0.233	0.0506	1.38
257	0.474	0.316	0.0779	0.895
258	2.43	0.0616	0.174	0.401
259	0.257	0.582	0.145	0.482
260	0.617	0.242	0.408	0.171
261	0.16	0.936	0.0948	0.75
262	0.13	1.15	0.0943	0.754
263	0.317	0.473	0.0785	0.906
264	0.0196 (0.00197, n=2)	8.40 (1.51, n=2)	0.0229 (0.00180, n=2)	3.19 (0.327, n=2)
265	0.0229 (0.00918, n=2)	7.56 (2.21, n=2)	0.0223 (0.00115, n=2)	3.27 (0.0894, n=2)
266	0.0442 (0.0109, n=6)	2.82 (0.430, n=6)	0.0883 (0.0104, n=6)	0.627 (0.103, n=6)
267	0.108 (0.0203, n=5)	1.50 (0.0726, n=5)	0.0540 (0.0118, n=5)	0.974 (0.256, n=5)
268	0.239 (0.00366, n=3)	0.851 (0.0652, n=3)	0.0572 (0.0135, n=5)	0.935 (0.247, n=5)
269	0.257 (0.0546, n=3)	0.825 (0.187, n=3)	0.0595 (0.0158, n=3)	0.828 (0.202, n=3)
270	0.328 (0.0226, n=3)	0.627 (0.0795, n=3)	0.128 (0.0355, n=4)	0.400 (0.132, n=4)
271	0.334 (0.0609, n=3)	0.614 (0.0761, n=3)	0.0352 (0.00104, n=2)	1.35 (0.0587, n=2)

-110-

272	0.0464 (0.0119, n=6)	2.97 (0.286, n=6)	0.0435 (0.0117, n=4)	1.19 (0.355, n=4)
273	0.0790 (0.0165, n=5)	2.15 (0.333, n=5)	0.0352 (0.0230, n=3)	1.85 (0.845, n=3)
274	>30.0	<0.00741	14.5 (5.14, n=2)	0.00353 (0.000807, n=2)
275	>30.0	<0.00741	14.0 (0.390, n=2)	0.00357 (0.000336, n=2)
276	0.0757	1.43	0.108 (0.0236, n=2)	0.491 (0.117, n=2)
277	0.0554	2.02	0.133	0.536
278	0.293	0.845	0.123 (0.0121, n=2)	0.517 (0.0592, n=2)
279	0.564	0.439	0.11	0.461
280	0.204	1.53	0.0767	0.663
281	0.166	1.87	0.16	0.318
282	0.323	0.962	0.247	0.23
283	0.301	1.03	0.155	0.329
284	0.113	2.74	0.0462	1.1
285	0.0884	3.52	0.072	0.706
286	0.184	1.69	0.0602	0.845
287	0.15	2.08	0.112	0.455
288	0.0732 (0.0140, n=7)	1.20 (0.268, n=7)	0.172 (0.0288, n=4)	0.393 (0.128, n=4)
289	0.0228 (0.00219, n=5)	4.13 (0.741, n=5)	0.0544 (0.00661, n=6)	1.33 (0.325, n=6)
290	0.0629 (0.0118, n=5)	1.09 (0.176, n=5)	0.179 (0.0336, n=6)	0.279 (0.0844, n=6)

-111-

291	0.118 (0.0226, n=4)	0.746 (0.0858, n=4)	0.150 (0.0253, n=5)	0.188 (0.0294, n=5)
292	0.0682 (0.0192, n=2)	1.10 (0.0631, n=2)	0.183 (0.0328, n=2)	0.143 (0.0191, n=2)
293	0.0562 (0.00736, n=2)	1.36 (0.278, n=2)	0.132 (0.000967, n=2)	0.197 (0.00743, n=2)
294	0.183	0.75	0.185	0.249
295	0.281	0.481	0.116	0.398
296	0.198	0.564	0.0867	0.82
297	0.0451 (0.00597, n=4)	3.00 (0.569, n=4)	0.111 (0.0151, n=5)	0.445 (0.0482, n=5)
298	0.0430 (0.00578, n=6)	2.87 (0.349, n=6)	0.0957 (0.0139, n=7)	0.507 (0.0734, n=7)
299	0.932 (0.507, n=2)	0.146 (0.0780, n=2)	2.54 (0.629, n=4)	0.0244 (0.00551, n=4)
300	0.0234 (0.00482, n=7)	5.38 (1.40, n=7)	0.0867 (0.0105, n=9)	0.636 (0.0568, n=9)
301	0.0346 (0.00764, n=12)	4.11 (0.921, n=11)	0.0441 (0.00684, n=7)	1.61 (0.433, n=7)
302	0.0308 (0.00225, n=8)	3.78 (0.554, n=7)	0.0275 (0.00247, n=6)	1.96 (0.175, n=6)
303	0.0254 (0.00381, n=9)	4.20 (1.10, n=9)	0.104 (0.0157, n=6)	0.602 (0.0702, n=6)
304	0.0296 (0.00440, n=7)	2.68 (0.425, n=7)	0.191 (0.0386, n=5)	0.481 (0.151, n=5)
305	0.0225 (0.00306, n=7)	4.28 (0.953, n=7)	0.107 (0.0149, n=6)	0.685 (0.0980, n=6)
306	0.0191 (0.00502, n=4)	3.97 (0.582, n=4)	0.0711 (0.0202, n=4)	0.912 (0.339, n=4)
307	0.0285 (0.00345, n=5)	2.48 (0.481, n=5)	0.0437 (0.00943, n=4)	1.29 (0.238, n=4)
308	0.0262 (0.00432, n=8)	4.06 (1.01, n=8)	0.0392 (0.00818, n=4)	1.45 (0.307, n=4)
309	0.0389 (0.00473, n=4)	1.64 (0.313, n=4)	0.0330 (0.00555, n=3)	1.27 (0.312, n=3)
310	0.0176 (0.00109, n=4)	5.56 (1.23, n=4)	0.0283 (0.00985, n=3)	1.43 (0.262, n=3)

-112-

311	0.0334 (0.00431, n=4)	3.50 (0.928, n=4)	0.0393 (0.0132, n=3)	1.04 (0.220, n=3)
312	0.0207 (0.00251, n=5)	4.76 (1.32, n=5)	0.0262 (0.00799, n=3)	1.53 (0.342, n=3)
313	0.0233 (0.00223, n=2)	2.87 (0.830, n=2)	0.0388 (0.00647, n=3)	0.867 (0.197, n=3)
314	0.0290 (0.0123, n=2)	2.81 (0.669, n=2)	0.0290 (0.00867, n=3)	1.48 (0.476, n=3)
315	0.0408 (0.00771, n=4)	2.06 (0.452, n=4)	0.0651 (0.0141, n=4)	1.00 (0.245, n=4)
316	0.0240 (0.00478, n=7)	3.75 (0.723, n=7)	0.122 (0.00791, n=6)	0.644 (0.146, n=6)
317	0.0948 (0.0240, n=4)	1.01 (0.478, n=4)	0.172 (0.00643, n=3)	0.333 (0.104, n=3)
318	0.0547 (0.00365, n=4)	1.69 (0.536, n=4)	0.124 (0.0271, n=4)	0.482 (0.188, n=4)
319	0.0540 (0.0220, n=4)	2.77 (2.07, n=4)	0.113 (0.00689, n=3)	0.522 (0.171, n=3)
320	0.161	0.241	0.397	0.224
321	0.0752	0.517	0.204	0.437
322	0.146	0.266	0.711	0.125
323	0.0251 (0.00551, n=4)	3.24 (0.508, n=4)	0.0597 (0.00797, n=4)	1.32 (0.527, n=4)
324	0.0374 (0.00637, n=4)	2.13 (0.185, n=4)	0.0926 (0.0147, n=4)	0.798 (0.264, n=4)
325	0.0301 (0.00366, n=5)	2.65 (0.180, n=5)	0.0586 (0.0119, n=5)	1.16 (0.224, n=5)
326	0.0754	1.5	0.0369	1.4
327	0.0548 (0.0274, n=2/3)	1.47 (0.273, n=2/3)	0.27	0.191
328	0.0965	0.94	0.117	0.575
329	0.132	0.687	0.125	0.535
330	0.0919	0.562	0.199	0.255

-113-

331	0.0547 (0.0162, n=2)	1.40 (0.145, n=2)	0.0929 (0.0237, n=2)	0.808 (0.277, n=2)
332	0.0745 (0.0143, n=3)	0.949 (0.0533, n=3)	0.184 (0.0348, n=3)	0.345 (0.0711, n=3)
333	0.0492	2.31	0.131	0.487
334	0.0718	0.844	0.303	0.151
335	0.0477	1.27	0.122	0.374
336	0.0312	1.95	0.0874	0.523
337	0.0515	1.18	0.173	0.265
338	0.0472	1.29	0.174	0.262
339	0.0219 (0.00722, n=3)	3.18 (0.768, n=3)	0.0986 (0.0180, n=4)	0.574 (0.231, n=4)
340	0.0823 (0.0288, n=3)	0.852 (0.312, n=3)	0.252 (0.00594, n=4)	0.183 (0.0554, n=4)
341	0.238	0.213	0.373	0.0674
342	0.159	0.32	0.127	0.198
343	0.0422	1.84	0.124	0.662
344	0.0433	1.79	0.044	1.86
345	0.0649	2.16	0.035	0.937
346	0.144 (0.0284, n=2)	0.604 (0.00648, n=2)	0.128 (0.0378, n=3)	0.210 (0.0493, n=3)
347	0.0827	0.872	0.102 (0.0247, n=2)	0.245 (0.0142, n=2)
348	0.193	0.373	0.113 (0.00703, n=2)	0.224 (0.0269, n=2)
349	0.117 (0.00129, n=2)	0.756 (0.131, n=2)	0.121 (0.0287, n=3)	0.214 (0.0378, n=3)
350	0.189	0.741	0.107	0.307

-114-

351	0.298	0.47	0.149	0.22
352	0.127 (0.0116, n=2)	0.815 (0.193, n=2)	0.142 (0.0267, n=3)	0.201 (0.0439, n=3)
353	0.497	0.145	1.09 (0.0881, n=2)	0.0231 (0.00235, n=2)
354	0.233 (0.0309, n=2)	0.441 (0.0871, n=2)	0.540 (0.126, n=3)	0.0517 (0.00657, n=3)
355	0.685 (0.318, n=2)	0.111 (0.0498, n=2)	0.896 (0.00185, n=2)	0.0285 (0.00509, n=2)
356	0.386	0.364	0.506	0.0647
357	0.384	0.366	0.181	0.181
358	0.183 (0.0347, n=2)	0.662 (0.0284, n=2)	0.117 (0.0257, n=2)	0.260 (0.0901, n=2)
359	0.172 (0.0235, n=2)	0.706 (0.00679, n=2)	0.131 (0.0201, n=2)	0.227 (0.0647, n=2)
360	0.197	0.53	0.145	0.171
361	0.401	0.261	0.955	0.0259
362	0.302 (n=1/2)	0.347 (n=1/2)	0.365 (0.0425, n=2)	0.0805 (0.0202, n=2)
363	0.145 (0.0185, n=2)	0.835 (0.0159, n=2)	0.208 (0.0485, n=2)	0.146 (0.0522, n=2)
364	0.351 (0.0809, n=2)	0.347 (0.0290, n=2)	1.00 (0.213, n=2)	0.0303 (0.0103, n=2)
365	0.0678	0.784	0.175	0.155
366	0.0889	0.598	0.366	0.074
367	0.0179	5.85	0.0641	0.386
368	0.0757	0.109	0.108	0.299
369	0.166	0.499	0.101	0.319
370	0.117	0.704	0.186	0.172

-115-

371	0.135	0.393	0.132	0.206
372	0.0781	0.68	0.365	0.0741
373	0.185	0.287	0.436	0.0621
374	0.0468	1.76	0.190	0.169
375	0.0471	1.13	0.152	0.178
376	0.0723	0.734	0.170	0.159
377	0.0544	0.976	0.136	0.199
378	0.067	0.793	0.191	0.142
379	0.079	0.672	0.238	0.114
380	0.142	0.374	0.236	0.115

As demonstrated by data in Table 3, Example compounds stimulate cAMP from human GLP-1R and GIPR in the presence of 0.1% casein.

5

IN VIVO STUDIES

Pharmacokinetics in male CD-1 mice

The pharmacokinetics of select Examples are evaluated following a single subcutaneous administration of 200 nMol/kg to male CD-1 mice. Blood samples are collected over 168 hours and resulting individual plasma concentrations are used to calculate pharmacokinetic parameters. Plasma (K₃ EDTA) concentrations are determined using a qualified LC/MS method that measures the intact mass of the Examples. Each Example and an analog as an internal standard are extracted from 100% mouse plasma using immunoaffinity based precipitation with anti-GIP/GLP1 antibodies. Instruments are combined for LC/MS detection. Mean pharmacokinetic parameters are shown in **Table 4**.

15

Table 4. Mean Pharmacokinetic Parameters of peptides Following a Single Subcutaneous Administration of 200 nMol/kg to Male CD-1 mice (N=2/timepoint non-serial sampling).

Example	T _{1/2} (hr)	T _{max} (hr)	C _{max} /D (kg*nmol/L/nmol)	AUCINF_D_obs (hr*kg*nmol/L/nmol)	Cl/F (mL/hr/Kg)
Example 1	17.54	12	4.84	135.61	7.37
Example 2	7.55	6	5.4	77.23	12.95
Example 3	15.04	6	4.42	158.49	6.31

Abbreviations: T_{1/2} = half-life, T_{max} = time to maximal concentration, C_{max} = maximal plasma concentration, AUCINF_D_obs = AUCinf divided by dose, Cl/F =

5 clearance/bioavailability. Notes: Data are the mean, where n=2/timepoint/group.

Results from this study for Examples tested are consistent with an extended pharmacokinetic profile.

10 Pharmacokinetics in male Cynomolgus Monkeys

The pharmacokinetics of select Examples are evaluated following a single subcutaneous administration of 50 nMol/kg to male cynomolgus monkeys. Blood samples are collected over 336 hours and resulting individual plasma concentrations are used to calculate pharmacokinetic parameters. Peptide plasma (K₃ EDTA) concentrations are determined using
 15 a qualified LC/MS method that measured the intact mass of the compound. Each peptide and an analog as an internal standard are extracted from 100% cynomolgus monkey plasma using immunoaffinity based precipitation with anti-GIP/GLG1 antibodies. Instruments are combined for LC/MS detection. Mean pharmacokinetic parameters are shown in **Table 5**.

20 **Table 5.** Mean Pharmacokinetic Parameters of peptides Following a Single Subcutaneous Administration of 50 nMol/kg to Male Cynomolgus Monkeys.

Example	T _{1/2} (hr)	T _{max} (hr)	C _{max} /D (kg*nmol/L/nmol)	AUCINF_D_obs (hr*kg*nmol/L/nmol)	Cl/F (mL/hr/Kg)
---------	-----------------------	-----------------------	---	-------------------------------------	--------------------

-117-

Example 1	125.0	18	6.5	1458	0.69
Example 2	102.1	24	11.7	2059	0.49
Example 3	180.6	30	11.38	3420	0.29

Abbreviations: $T_{1/2}$ = half-life, T_{max} = time to maximal concentration, C_{max} = maximal plasma concentration, $AUC_{INF_D_obs}$ = AUC_{inf} divided by dose, CL/F = clearance/bioavailability. Notes: Data are the mean, where $n=2$ /group. Notes: Data are the mean, where $n=2$ /group. As seen in **Table 5**, results from this study for Example peptides tested are consistent with an extended pharmacokinetic profile.

Pharmacokinetics in male Sprague Dawley rats following subcutaneous or intrajejunal administration

The pharmacokinetics of select Examples are evaluated following a single subcutaneous (SC) administration of 50 nMol/kg (dissolved in PBS, pH 7.4) or single 1 μ mol/kg (mixed with 250 mM sodium decanoate ("C10") and 12 mg/mL soybean trypsin inhibitor (SBTI)) intrajejunal (IJ) administration to male Sprague Dawley rats. Blood samples are collected over 168 hours following SC administration and 72 hours following IJ dosing.

Pharmacokinetic parameters are calculated using individual plasma concentrations. A qualified LC/MS method that measures the intact mass of the Example is used to determine plasma (K_3 EDTA) concentrations. Each Example is tested with an analog peptide as an internal standard. Immunoaffinity based precipitation with anti-GIP/GLP1 antibodies is used to extract each test peptide and analog. Mean pharmacokinetic parameters for the Examples are shown in **Table 6** and **Table 7**.

Table 6. Mean (+/- SD) Pharmacokinetic Parameters of peptides Following a Single Subcutaneous Administration of 50 nMol/kg to Male Sprague Dawley rats.

Example	$T_{1/2}$ (hr)	T_{max} (hr)	C_{max}/D (kg*nmol/L/nmol)	$AUC_{INF_D_obs}$ (hr*kg*nmol/L/nmol)	CL/F (mL/hr/Kg)
Example 1	44.7 (6.2)	21.3 (4.6)	3.34 (0.22)	294.2 (30.0)	3.42 (0.33)

Example 2	20.3 (0.9)	14.7 (2.3)	5.19 (0.20)	231.7 (9.6)	4.32 (0.17)
Example 3	32.1 (1.9)	21.3 (4.6)	4.71 (0.50)	371.8 (21.8)	2.70 (0.16)

Abbreviations: $T_{1/2}$ = half-life, T_{max} = time to maximal concentration, C_{max} = maximal

plasma concentration, $AUC_{INF_D_obs}$ = AUC_{inf} divided by dose, CL/F =

clearance/bioavailability. Notes: Data are the mean, where $n=3$ /group (Table 6) As seen in

table 6, results from this study using these Example peptides are consistent with an extended

5 pharmacokinetic profile.

Table 7. Mean (+/- SD) Pharmacokinetic Parameters of peptides Following a Single Intrajejunal Administration of 1 μ mol/kg to Male Sprague Dawley rats.

Example	T_{max} (hr)	C_{max}/D ($kg \cdot nmol/L/nmol$)	$AUC_{INF_D_obs}$ ($hr \cdot kg \cdot nmol/L/nmol$)
Example 1	1.33 (0.82)	0.08 (0.05)	1.31 (0.85)
Example 2	0.25 (0.13)	0.56 (0.40)	6.6 (4.4)
Example 3	0.33 (0)	0.47 (0.16)	8.45 (3.1)

Data are the mean, where $n=3$ /group $n=6$ /group (Table 7).

10 As illustrated by results in **Table 7**, these Examples are consistent with an exposure following intrajejunal administration. Intrajejunal exposure in this assay supports that the Examples may be suitable for oral formulation and administration.

In Vivo Effect on Insulin Secretion in Male Wistar Rats

15 Male Wistar rats with femoral artery and femoral vein canulas (Envigo, Indianapolis, IN) (280- 320 grams) are single-housed in polycarbonate cages with filter tops. Rats maintained on a 12:12 h light-dark cycle (lights on at 6:00 A.M.) at 21°C and receive food and deionized water ad libitum. Rats are randomized by body weight and dosed 1.5 ml/kg s.c. at doses of 0.04, 0.1, 0.3, 1, 3, and 10 nmol/kg 16 hours prior to glucose administration

20 then fasted. Animals are weighed and anesthetized with sodium pentobarbital dosed i.p. (65 mg/kg, 30 mg/ml). A time 0 blood sample is collected into EDTA tubes after which glucose is administered i.v. (0.5 mg/kg, 5 ml/kg). Blood samples are collected for glucose and insulin levels at time 2, 4, 6, 10, 20 and 30 min post intravenous administration of glucose.

Plasma glucose levels are determined using a clinical chemistry analyzer. Plasma insulin is determined using an electrochemiluminescence assay (Meso Scale, Gaithersburg, MD). Glucose and insulin AUC are examined compared to the vehicle control with n = 5 animals per group. Results are presented (SEM)(N).

5

Table 8: The effect of Example compounds on insulin secretion during intravenous glucose tolerance test.

Example	Dose (nmol/kg, s.c.)						
	0.0	0.04	0.1	0.3	1.0	3	10
1	31.3 (2.8) (5)	32.2 (5.7) (5)	31.5 (4.5) (5)	24.7 (3.0) (5)	35.1 (4.0) (5)	43.5 (4.9) (5)	63.9 (6.5) (5)
2	18.9 (4.3) (5)	32.8 (3.9) (5)	49.1 (4.8) (5)	82.2 (21.1) (5)	110.9 (23.1) (5)	108.2 (20.2) (5)	77.3 (8.8) (5)
3	18.5 (1.0) (5)	26.0 (3.4) (5)	24.6 (3.9) (5)	44.9 (9.6) (5)	60.1 (4.0) (5)	95.5 (18.4) (5)	87.7 (7.9) (5)
4	33.7 (5.3, 5)	34.0 (3.4, 5)	42.0 (3.8, 5)	86.3 (4.5, 5)	90.2 (9.2, 5)	108.7 (9.8, 5)	114.6 (16.1, 5)
5	24.4 (3.0, 5)	28.2 (4.2, 5)	40.2 (6.0, 5)	41.1 (2.7, 5)	44.1 (4.5, 5)	54.3 (11.9, 5)	94.2 (10.1, 5)

The data provided by Table 8 demonstrate a dose dependent increase in insulin secretion.

10

Table 9: ivGTT Insulin Secretion shown by the following data:

Insulin secretion (ivGTT)	
Example	(ED ₅₀ , nmol/kg) (SEM, n)
1	>10
2	0.1 (0.05, 5)

-120-

3	0.7 (0.3, 5)
4	0.2 (0.05, 5)
5	3<ED ₅₀ <10

The data provided by Table 9 demonstrate dose dependent increase in insulin secretion.

5 Studies in Diet-Induced Obese C57/B16 Mice

C57/B16 diet-induced obese (DIO) male mice (Taconic, Germantown, NY) weighing 41-50 g are used. Animals are individually housed in a temperature-controlled (24°C) facility with a 12 hour light/dark photoperiod (lights off at 10:00 AM and lights on at 10:00 PM), with free access to food and water. After 2 week acclimatization to the facility, mice are randomized to treatment groups (n=6/group) based on body weight so each group has similar starting mean body weight.

Mice are treated with either vehicle (40 mM Tris-HCl at pH 8.0) or several peptides between the dose ranges of 0.03 nmol/kg to 10 nmol/kg. Treatments are subcutaneously administered to ad libitum fed DIO mice 30-90 minutes prior to the onset of the dark cycle daily (QD) for 14 days. During the course of the study, body weight and food intake are monitored daily.

All data are expressed as mean $\pm$ SEM of 5-6 rats per group. Statistical analyses are assessed by one-way ANOVA followed by Dunnett's multiple comparison test to compare treatment groups to vehicle group or each other. Significant differences are identified at $p < 0.05$.

$$\text{Percent Body Weight} = \frac{\text{Body weight after 14-day treatment}}{\text{Body weight before treatment started}} \times 100$$

"0" dose group represents the vehicle-treated mice during each study. All data are expressed as mean $\pm$ SEM of 5-6 mice per group. Statistical analyses are assessed by one-way ANOVA followed by Dunnett's multiple comparison test to compare treatment groups to '0' dose (vehicle). *Significant differences are identified at $p < 0.05$. Body weight change after

-121-

treatment with Example compounds after 15 days. “Δ from vehicle” refers to difference between body weight at day 15 between test and vehicle groups. “% change” refers to percent decrease in body weight between days 1 and 15 in test groups. Percent decrease in body weight for animals receiving vehicle is recorded, and is less than about 1% in each study. The Δ from vehicle and % change data are statistically significantly different (p<0.05) than control for all Examples at all doses tested.

Table 10. The effect of GIP/GLP-1 receptor co-agonists on percent body weight in diet-induced obese mice after 14-day of treatment.

	Dose (nmol/kg, s.c., QD)						
Peptide	0	0.03	0.1	0.3	1	3	10
Example 1	99.2 ±0.8	96.2 ±1.2	95.6 ±0.9	86.7 ±1.3*	86.3 ±1.9*	74.0 ±3.8*	64.7 ±2.6*
Example 2	100.5 ±1.4	101.5 ±0.2	95.0 ±1.2	86.5 ±0.8*	76.4 ±4.0*	76.4 ±2.4*	68.1 ±3.1*
Example 3	98.0 ±0.7	99.1± 1.3	95.6 ±1.3	93.0 ±1.1	85.6 ±0.8*	75.9 ±4.3*	73.6 ±1.7*
Example 4	98.3±1. 1	96.6±0. 5	94.7±1. 8	88.5±1. 2*	76.9±1. 4*	66.6±3. 9*	64.5±2. 2*
Example 5	98.3±1. 1	96.0±1. 3	96.7±1. 1	94.1±1. 8	82.4±1. 6*	83.8±1. 6*	74.9±2. 3*
Example 104	99.2±0. 8	94.0±0. 6	94.1±0. 8	89.0±0. 9*	82.7±1. 5*	70.8±4. 2*	71.3±4. 1*
Example 123	99.2±0. 8	94.7±0. 9	90.5±1. 6*	86.5±1. 1*	81.3±2. 0*	75.1±1. 8*	68.6±1. 9*

As illustrated by data provided in Table 10 above, Example compounds tested in the assay dose-dependently reduce body weight in the studies described.

Proteolytic Stability Assay

-122-

The proteolytic stability assay is a useful for assessing potential for oral delivery of peptides. The stability of peptides are compared in 1% rat small intestinal fluid (rSIF). The amount of intact peptide is measured for a sample peptide at 0, 3, 15, and 30 minutes to assess proteolytic stability. The amount of intact peptide for a sample peptide is measured in
5 90% pig small intestinal fluid (pSIF) at 0, 30, 45, and 60 minutes to assess the proteolytic stability.

Sample preparation when rat small intestinal fluid (rSIF) is used:

Peptides are prepared at 0.4 mg/mL in 50mM Tris pH8.0. Rat small intestinal fluid is added at a ratio of 1% (v/v). The mixture is incubated at 37°C at 150 rpm. Thirty µL of each
10 sample are removed and placed into a new tube before the rSIF is added and at 3, 15, and 60 min. At each time point, the reaction was quenched by 1% TFA in 50% ACN at 1:1. The samples are diluted 100 times using dilution buffer (1:1 of 1% TFA in 50% ACN: 50mM Tris pH8) and ready for analysis using mass spectrometry (MS).

Sample preparation when pig small intestinal fluid (pSIF) is used:

15 Peptides are diluted to a concentration of 0.4 mg/mL in 90% pig small intestinal fluid. After the mixing, 20 µL are immediately removed (time 0 for the time point of pre-incubation). The mixture is then incubated at 37°C at 150rpm. Twenty µL of each sample are removed and placed into a new tube at 30, 45, and 60 min. At each time point (0, 30, 45, 60), the reaction is quenched by 1% TFA in 50% ACN at 1:1. The sample is centrifuged at
20 20,000xg for 20 min at 4°C. The supernatant is diluted 100 times using dilution buffer (1:1 of 1% TFA in 50% ACN: 50mM Tris pH 8) and ready for analysis using mass spectrometry (MS).

MS Conditions: The liquid chromatography separation is carried out on a Waters Acquity UPLC using mobile phase A (0.1% formic acid in water) and B (0.1% formic acid in
25 acetonitrile and an ACQUITY UPLC Protein BEH C4 Column (300Å, 1.7 µm, 1 mm X 50 mm) at 40°C. The gradient is 5% of B during 0-1.5, 5-90% of B during 1.5-1.8, 90-95% of B during 1.8-3.0, 95-95% of B during 3.0-3.5, 95-5% of B during 3.5-4.0, and 5-5% of B during 4.0-5.0. The MS analysis is carried out on a Waters Xevo G2-XS QTOF. The data is

acquired using MSe Continuum in the range of 50-2000 m/z in positive and sensitivity mode. The data analysis is performed using MassLynx.

Table 11. The percentage of each peptide not cleaved at different time points using rSIF.

	0 min	3 min	15 min	60 min
Example 1	100	82.4	41.4	1.6
Example 2	100	75.5	18.3	0.3
Example 3	100	68.8	25.8	0.3
Example 4	100	97.9	99.3	89.4
Example 69	100	2.2	0.0	0.0

- 5 The proteolytic peptide results provided in Table 11 suggest that the peptide of Example 4 may be suitable for oral formulation and delivery.

Table 12. The percentage of each peptide not cleaved at different time points using pSIF.

	0 min	30 min	45 min	60 min
Example 4	100	73.4	56.4	60.0
Example 5	100	76.9	56.8	60.7

- 10 The proteolytic peptide results provided in Table 12 suggest that both the peptides of Examples 4 and 5 may be suitable for oral formulation and delivery.

In Vivo Studies

The purpose of this study is to determine the relative potential for clinical immunogenicity of a compound.

15 Methods:

- CD8+ T cell depleted peripheral blood mononuclear cells are prepared and labeled with Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE, Invitrogen) from a cohort of 10 healthy donors. Samples are tested in triplicate with 2.0 mL media control, keyhole limpet hemocyanin ("KLH") (0.33 μ M), anti-chemokine receptor type 4 ("CD4+") (0.33 μ M), and a
20 compound of Examples 1, 2, and 3 (10 μ M). Cultures are incubated for 7 days at 37°C with

5% CO₂. On day 7, samples are analyzed by flow cytometry using High Throughput Sampler (HTS). Data is analyzed using FlowJo® Software (FlowJo, LLC, TreeStar).

Results and Discussion

All donors produce a positive T cell response against KLH (100%). Analysis of the frequency and magnitude of the CD4⁺ T cell response for Example compounds is shown in Table 13.

Table 13: CD4⁺ T Cell Responses for Example compounds and Positive Control (KLH).

	% Donor Response	Median Response Strength in positive donors (CDI)
KLH	100% (n=11)	391 (n=10)
Example 1 (GG-212)	9% (n=11)	0.7 (n=1)
Example 2 (GG-353)	22% (n=9)	3.68 (n=2)
Example 3 (GG-362)	0% (n=9)	NA (n=0)
Example 4 (GG-427)	0% (n=9)	NA (n=0)
Example 288 (GG-709)	10% (n=10)	5.42 (n=1)
Example 289 (GG-731)	0% (n=10)	NA (n=0)
Example 301 (GG-650)	0% (n=10)	NA (n=0)
Example 303 (GG-679)	0% (n=10)	NA (n=0)
Example 316 (GG-698)	0% (n=10)	NA (n=0)

Cell Division Index ("CDI"): proportion of divided CD4⁺ T cells to the total number of CD4⁺ T cells in stimulated versus unstimulated samples.

These data show that the frequency of positive CD⁺ T cell response (CDI>2.5) was low for the compounds of Examples 1, 2, 3, 4, 288, 289, 301, 303 and 316, and the magnitude of the response in the few positive donors was low (CDI<6), indicating a low risk of immunogenicity using the CD4⁺ T cell assay.

GLP-1R HEK293 Cell Membrane [³⁵S]GTPγS Binding Assay

The GLP-1 receptor is a G-protein coupled receptor that increases GTP-bound Gα_s upon ligand induced receptor activation. The potency of peptides to stimulate- GLP-1R induced activation of Gα_s is determined using preparations of purified membranes from

-125-

HEK293 cells expressing the human GLP-1R. The assay is performed similarly to that as previously described (Bueno *et al.*, J. Biol. Chem., (2016) 291, 10700 and Willard *et al.*, Mol. Pharmacol. (2012) 82,1066). The test peptides are solubilized in DMSO and diluted in reaction buffer containing 5 µg of membrane in 20 mM HEPES pH 7.4, 50 mM NaCl, 5 mM
5 MgCl₂, 40 µg/ml saponin, 0.1% BSA, and 500 pM ³⁵S-labeled GTPγS for 30 minutes at room temperature. Reactions are terminated by addition of 0.2% Nonidet P-40 detergent containing rabbit anti-Gα_s polyclonal antibody and 0.5 mg of anti-rabbit polyvinyltoluene beads. Mixtures are developed for 30 minutes, centrifuged at 80 × g for 10 minutes, and counted for 1 minute/well using a MicroBeta TriLux instrument. Peptide concentration-
10 response curves are fit to a four-parameter logistic model to calculate potency as an EC₅₀. Data normalization to % stimulation is performed using DMSO and GLP-1(7-36) as minimum and maximum controls for the receptor (Campbell *et al.*, Assay Guidance Manual 2017). The potency of a sample peptide to stimulate GIPR induced activation of Gα_s is reported in the **Table 14**. Assay results identify a peptide that is a partial agonist on the
15 GLP-1R with respect to GLP-1R induced activation of Gα_s.

GLP-1R CHO Cell β-Arrestin Recruitment Assay

Activated G-protein coupled receptors can interact with the β-arrestin family of signalling proteins. The potency of peptides for GLP-1R induced arrestin recruitment is
20 determined using the PathHunter Enzyme Fragment Complementation approach substantially as described (von Degenfeld *et al.*, FASEB J., 2007 (14):3819-26 and Hamdouchi *et al.*, J. Med Chem., 2016 59(24):10891-10916). CHO-K1 cells expressing Pro-Link-tagged Human GLP-1R and enzyme-acceptor-tagged β-arrestin-2 may be obtained from DiscoverX and prepared as assay-ready frozen cells. Test peptides are solubilized in DMSO and serial
25 dilutions are performed using the Echo acoustic dispenser (LabCyte). Assay media is the PathHunter Cell Assay Buffer (DiscoverX) containing 0.1% w/v hydrolyzed Casein (Sigma). 100 nl of peptide is dispensed into 10 µl of assay media in a 384 well plate and then 10 µl of cells in assay media are added to give 5000 cells per well. Plates are incubated for 90 minutes in a 37°C/5% CO₂ incubator and 10 µl of PathHunter detection reagent is added (DiscoverX)

- and plates are incubated at room temperature for 60 minutes. Luminescence signal is measured. Peptide concentration-response curves fit to a four-parameter logistic model to calculate potency as an EC₅₀. Data normalization to % stimulation is performed using DMSO and GLP-1(7-36) as minimum and maximum controls (Campbell *et al*, Assay Guidance Manual 2017). The potency of a sample peptide to stimulate GLP-1R induced β -arrestin recruitment is reported in **Table 14**. The assay results identify a peptide that is a partial agonist on the GLP-1R with respect to β -arrestin-2 recruitment.

Table 14

Example	hGLP1R GTPγS Rel EC ₅₀ nM (SEM, n)	hGLP1R GTPγS % Top (SEM, n)	hGLP1R B- Arrestin2 Rel EC ₅₀ uM (SEM, n)	hGLP1R B- Arrestin2 % Top (SEM, n)
	0.475 (0.0322, n=115)	99.2 (0.659, n=115)	0.00274 (0.000359, n=42)	104 (3.45, n=42)
1	0.235 (0.0201, n=5)	91.1 (1.77, n=5)	0.005	105
2	0.642 (0.0294, n=2)	95.9 (0.553, n=2)	0.00882 (0.00269, n=2)	96.1 (0.742, n=2)
3	0.421 (0.181, n=2)	95.4 (2.20, n=2)		
4	0.245 (0.0638, n=3)	86.9 (5.93, n=3)	0.00480 (0.000138, n=2)	92.4 (14.0, n=2)
5	0.196 (0.0375, n=3)	91.3 (6.90, n=3)		
266	0.865 (0.328, n=2)	63.4 (1.31, n=2)	0.016	17.1
267	0.867	62.3	0.00901	16.5
272	0.651 (0.0427, n=2)	66.5 (0.741, n=2)	>12.0	ND
298	1.03	57.3		
300	0.405	85.6	0.0054	38.4
301	0.435 (0.0848, n=3)	91.4 (3.63, n=3)	0.00267	93.7
302	0.268	98.6	0.00219	98.4

-127-

303	0.547 (0.0998, n=2)	74.3 (2.99, n=2)	0.0179	47.7
304	0.561	77.1		
305	0.389	76.3		
306	0.378	76.1		
315	0.601	44.2	0.0199	25.4
316	0.766 (0.0469, n=2)	56.7 (3.14, n=2)	0.00608	26.1
317	0.536	53.7		
318	0.415	58.4		
288	0.666 (0.104, n=3)	66.7 (4.09, n=3)	0.00674 (0.00278, n=3)	21.3 (1.94, n=3)
319	0.657	65.7		
323	0.79	81.9		
324	0.475	84.5		
289	0.404 (0.0247, n=3)	83.7 (3.81, n=3)	0.0124 (0.00151, n=3)	51.3 (6.05, n=3)
325	0.414	97.9		
326	0.663	61.6		
327	0.287	75.6	0.00379	41.6
328	0.481	66.3		
329	0.343	83.6	0.00473	63.4
330	1.05 (0.275, n=2)	47.8 (1.16, n=2)	>10.9	ND
331	0.375 (0.0274, n=4)	80.9 (2.54, n=4)	0.0128	44.3
332	0.453 (0.0479, n=4)	81.5 (4.65, n=4)	0.0171	45.6
333	0.442 (0.00535, n=2)	83.4 (0.439, n=2)	0.0548	58.2
334	0.432	70.2	>10.3	ND
335	0.285	89.3	0.00531	73
336	0.377	90.2	0.00778	82.5
290	0.466 (0.0664, n=9)	66.2 (3.12, n=9)	0.0238 (0.00530, n=4)	20.0 (1.15, n=4)
337	0.322	59.5	0.0174	34.1
338			0.0189	47
339	0.326 (0.0357, n=3)	74.1 (7.97, n=3)	0.0107 (0.00238, n=2)	44.0 (2.40, n=2)
340	0.450 (0.0182, n=5)	67.4 (5.12, n=5)	0.0107 (0.00711, n=4)	20.1 (2.31, n=4)
341	0.496	78.9	0.0188	21.9

342	0.414	77.2	0.035	20.7
343	0.522	74.9	0.0455	41.4
344	0.423	85.8	0.0343	46
345	0.684	62	0.00308 (0.000666, n=2)	74.7 (2.86, n=2)
346	0.737 (0.201, n=3)	56.6 (3.94, n=3)	0.00325 (0.00105, n=3)	19.3 (0.767, n=3)
347	0.759	46.9	0.00542 (0.00152, n=2)	24.6 (2.81, n=2)
348	0.66	47.7	0.00346 (n=1/2)	19.8
349	0.464 (0.0290, n=4)	64.5 (1.68, n=4)	0.0151 (0.00111, n=2)	18.4 (0.337, n=2)
350	0.589	64.1	0.0108	21.8
351	0.563	66.5	0.0196	23.5
352	0.552 (0.0267, n=2)	63.5 (1.51, n=2)	0.00421 (n=1/2)	17.4
353	1.96	63.1	0.559 (0.108, n=2)	23.0 (0.408, n=2)
291	0.466 (0.0476, n=6)	65.0 (2.15, n=6)	>10.0 (n=1/4)	ND
354	0.967	53.3	0.255 (n=1/2)	22.7
355	1.76	50.6	0.363	18.3
356			>10.5	ND
357			0.118	18.2
358	0.414 (0.00356, n=2)	72.3 (1.27, n=2)	0.00938 (0.00413, n=3)	21.4 (2.47, n=3)
359	0.496	69.7	0.0841	28.4
360			0.0395	25.8
361			0.269 (n=1/2)	20.2
362			>11.0	ND
363	0.943	69.6	0.135	22.1
364			>12.0	ND
292	0.429 (0.0190, n=4)	71.5 (3.33, n=4)	0.00774 (0.00199, n=4)	29.0 (3.96, n=4)
293	0.368 (0.0304, n=4)	70.6 (0.715, n=4)	0.00719 (0.00168, n=4)	29.5 (6.23, n=4)
365	0.464 (0.0178, n=3)	66.9 (1.35, n=3)	0.00703 (0.00233, n=4)	20.8 (1.78, n=4)
366	0.409 (0.0308, n=3)	67.6 (3.55, n=3)	0.00557 (0.00363, n=2)	21.2 (0.163, n=2)

-129-

367	0.289	89.7	0.00666 (0.00118, n=2)	70.6 (8.61, n=2)
368	0.495	68.9	0.0479 (0.0205, n=2)	21.3 (4.03, n=2)
369	0.381	58.8	0.0414 (n=1/2)	19.9
370	0.428	63.7	0.00990 (0.00149, n=2)	23.0 (0.470, n=2)
371	0.27	62.5	0.0142 (0.00333, n=2)	21.7 (0.711, n=2)
372	0.379	69.1	0.00981 (0.00630, n=2)	32.9 (1.65, n=2)
373	0.336	65.6	0.00954 (0.00348, n=2)	22.9 (5.88, n=2)
374	0.345	67.1	0.0218	34.7
375	0.419	70.4	0.0114	24.2
376	0.326	72.6	0.0123	25.6
377	0.356	68.4	0.00532	16.7
378	0.359	68.6	>10.2	ND
379	0.239	71	0.0181	31.9
380	0.188	66.8	0.0137	35
381	0.273	73.6	0.0155	25.8
Comparator Tirzepatide	0.442 (se=0.0311, n=9)	62.9 (se=1.28, n=9)	>10.5 (n=1/5)	ND

Example	hGLP1R B-Arrestin2 Rel EC50 uM (SEM, n)	hGLP1R B- Arrestin2 % Top (SEM, n)
	0.00274 (0.000359, n=42)	104 (3.45, n=42)
1	0.005	105
2	0.00882 (0.00269, n=2)	96.1 (0.742, n=2)
3		
4	0.00480	92.4

-130-

	(0.000138, n=2)	(14.0, n=2)
266	0.016	17.1
267	0.00901	16.5
272	>12.0	ND
300	0.0054	38.4
301	0.00267	93.7
302	0.00219	98.4
303	0.0179	47.7
315	0.0199	25.4
316	0.00608	26.1
288	0.00674 (0.00278, n=3)	21.3 (1.94, n=3)
289	0.0124 (0.00151, n=3)	51.3 (6.05, n=3)
327	0.00379	41.6
329	0.00473	63.4
330	>10.9	ND
331	0.0128	44.3
332	0.0171	45.6
333	0.0548	58.2
334	>10.3	ND
335	0.00531	73
336	0.00778	82.5
290	0.0238 (0.00530, n=4)	20.0 (1.15, n=4)
337	0.0174	34.1
338	0.0189	47
339	0.0107 (0.00238, n=2)	44.0 (2.40, n=2)
340	0.0107 (0.00711, n=4)	20.1 (2.31, n=4)
341	0.0188	21.9
342	0.035	20.7
343	0.0455	41.4
344	0.0343	46
345	0.00308 (0.000666, n=2)	74.7 (2.86, n=2)
346	0.00325 (0.00105, n=3)	19.3 (0.767, n=3)
347	0.00542 (0.00152, n=2)	24.6 (2.81, n=2)

-131-

348	0.00346 (n=1/2)	19.8
349	0.0151 (0.00111, n=2)	18.4 (0.337, n=2)
350	0.0108	21.8
351	0.0196	23.5
352	0.00421 (n=1/2)	17.4
353	0.559 (0.108, n=2)	23.0 (0.408, n=2)
291	>10.0 (n=1/4)	ND
354	0.255 (n=1/2)	22.7
355	0.363	18.3
356	>10.5	ND
357	0.118	18.2
358	0.00938 (0.00413, n=3)	21.4 (2.47, n=3)
359	0.0841	28.4
360	0.0395	25.8
361	0.269 (n=1/2)	20.2
362	>11.0	ND
363	0.135	22.1
364	>12.0	ND
292	0.00774 (0.00199, n=4)	29.0 (3.96, n=4)
293	0.00719 (0.00168, n=4)	29.5 (6.23, n=4)
365	0.00703 (0.00233, n=4)	20.8 (1.78, n=4)
366	0.00557 (0.00363, n=2)	21.2 (0.163, n=2)
367	0.00666 (0.00118, n=2)	70.6 (8.61, n=2)
368	0.0479 (0.0205, n=2)	21.3 (4.03, n=2)
369	0.0414 (n=1/2)	19.9
370	0.00990 (0.00149, n=2)	23.0 (0.470, n=2)
371	0.0142	21.7

-132-

	(0.00333, n=2)	(0.711, n=2)
372	0.00981 (0.00630, n=2)	32.9 (1.65, n=2)
373	0.00954 (0.00348, n=2)	22.9 (5.88, n=2)
374	0.0218	34.7
375	0.0114	24.2
376	0.0123	25.6
377	0.00532	16.7
378	>10.2	ND
379	0.0181	31.9
380	0.0137	35
381	0.0155	25.8

Composition for Oral Administration

A peptide is dissolved in Tris buffer (pH 8.0, 50 mM). A Permeation enhancer ("PE") is prepared as follows: C10 is dissolved in Tris buffer (pH 8.0, 50 mM), LC, DPC, C12-maltoside and Rhamnolipid are each dissolved in phosphate buffered saline ("PBS") (1X, pH 7.2). A solution of peptide, a PE, and a protease inhibitor is mixed to reach a final peptide concentration of 300 μ M, PE at 100 mM (5% w/v for Rhamnolipid) and 1% (v/v) for the protease inhibitor.

A peptide is incubated at 37 °C in 1% (v/v) rat small intestinal fluid or 50% (v/v) pig small intestinal fluid with and without a peptidase inhibitor. At different time points, samples are taken out, followed by quenching with 1% TFA in 50% ACN/water to stop the enzyme activity. The intact peptide at different time points is analyzed by high-performance liquid chromatography (HPLC) equipped with an ultraviolet (UV) detector or LC-MS/MS and normalized to the amount of peptide before mixing with the enzyme solution. A study using a peptide of Example 2 and a peptide of Example 4 are reported in **Table 15**.

Table 15.

Recombinant protease inhibitor (concentration)	% peptide intact				
	Small intestinal fluid	0 min	15 min	30 min	60 min
rSBTI (5 mg/mL) + Peptide (Example 4)	50% v/v pig	100.00	96.96	96.28	88.57

Peptide Example 4 (no PI; control)	50% v/v pig	100.00	72.52	41.44	18.98
rSBTI (5 mg/mL) + Peptide Example 2	50% v/v pig	100.00	103.02	112.69	87.33
Peptide Example 2 (no PI; control)	50% v/v pig	100.00	2.42	1.90	3.09
rSBTCI (0.5 mg/mL) + Peptide Example 2	50% v/v pig	100.00	131.71	126.53	123.70

Table 15 results support that an oral formulation composition for a peptide of Example 4 may be prepared using a PE and no PI.

Oral Formulation Composition

- Examples of formulation compositions for a peptide of this invention are provided by Table 16. The formulation compositions for peptides of this invention are in no way limited by the examples provided.

Table 16

Formulation	Formulation composition	Concentration
1	Peptide (Example 1; or Example 4 or Example 3)	2.4 mg/mL
	C10	250 mM
	SBTI	75 mg/mL
2	Peptide (Example 1)	2.4 mg/mL
	LC	500 mM
	Citric acid	500 mM
3	Peptide (Example 1)	2.4 mg/mL
	NaTDC	250 mM
	SBTI	75 mg/mL
4	Peptide (Example 1, Example 2, or Example 4)	2.4 mg/mL
	C10	250 mM
	SBTI	12 mg/mL
5	Peptide (Example 1 or Example 2)	2.4 mg/mL
	C10	125 mM
	SBTI	12 mg/mL
	Peptide (Example 1)	2.4 mg/mL

6	C10	125 mM
	SBTI	24 mg/mL
7	Peptide (Example 4)	2.4 mg/mL
	C10	250 mM
	SFTI	12 mg/mL

The effect of formulation composition on a peptide exposure is evaluated in rats via intrajejunal (IJ) administration using liquid formulations. To prepare liquid formulations for a rat IJ administration, a peptide, C10 or NaTDC and SBTI is dissolved in 50 mM Tris buffer pH 8.0 and mixed to achieve final desired concentration. For LC/citric acid formulation, LC and citric acid are dissolved in water and mixed with a peptide dissolved in Tris buffer. Formulation compositions provided in Table 16 may be administered as an oral composition.

Enteric Capsules

An enteric capsule composition may be desired for certain peptides of this invention and may be prepared using methods for example, as set forth by Table 17. Enteric compositions may be prepared by blending ingredients together and filling the blend in enteric capsules.

An enteric composition of Table 17 is prepared adding half of the stated amount of sodium decanoate to a mortar. SBTI (for Examples 382-385) or SFTI (for Examples 386 and 387), and a peptide (peptides of Examples 1-4), as shown in Table 17. A remaining half of the sodium decanoate is added. A mixture is gently blended together using pestle, and spatula. If desired, additional mixing using pestle provides a homogenous blend. A capsule may be manually filled by individually weighing the required amount of blend, filling in capsules, and securely closing the capsule caps to the capsule bodies.

Dissolution testing of a single capsule is completed using known methods. A peptide of this invention may be formulated as an enteric oral composition.

-135-

PeptideComponent	Enteric	Enteric	Enteric	Enteric	Enteric	Enteric
	Example	Example	Example	Example	Example	Example
	382	383	384	385	386	387
Example 2	12.50				12.50	
Example 4		12.50				12.50
Example 1			12.50			
Example 3				12.50		
Sodium decanoate (C10)	250.00	250.00	250.00	250.00	250.00	250.00
SBTI	62.50	62.50	62.50	62.50		
SFTI					62.50	62.50
Total Capsule Fill Weight	325.00	325.00	325.00	325.00	325.00	325.00
Capsule Size	Size 00	Size 00	Size 00	Size 00	Size 00	Size 00

Table 17: Composition of Individual Enteric Capsule for Formulation

-136-

Amino Acid Sequences

SEQ ID NO:1

GIP (Human)

5 YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ

SEQ ID NO:2

GLP-1 (7-36) (Human)

HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH₂

10

SEQ ID NO:3

R₁X₁ X₂ X₃GT X₆TSD X₁₀ X₁₁ X₁₂ X₁₃ X₁₄D X₁₆X₁₇AX₁₉ X₂₀ X₂₁ X₂₂X₂₃ X₂₄ X₂₅ X₂₆ X₂₇
X₂₈ X₂₉ X₃₀X₃₁

15 SEQ ID NO:4

PX₃₂ X₃₃ X₃₄-R₂

SEQ ID NO:5

PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂

20

SEQ ID NO:6

PX₃₂ X₃₃ X₃₄ X₃₅X₃₆ X₃₇ X₃₈ X₃₉ X₄₀-R₂

SEQ ID NO:7

25 K[(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H] X₃₂ X₃₃ X₃₄-R₂

SEQ ID NO:8

K[(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H] X₃₂ X₃₃ X₃₄
X₃₅X₃₆ X₃₇ X₃₈ X₃₉-R₂

30

SEQ ID NO:9

-137-

K[(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H] X₃₂ X₃₃ X₃₄
X₃₅X₃₆ X₃₇ X₃₈ X₃₉ X₄₀-R₂

SEQ ID NO:10

5 **Example 1**

Y-Aib-EGT-αMeF(2F)-TSDYSI-αMeL-LDEK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH₂

SEQ ID NO:11

10 **Example 2**

Y-Aib-EGT-αMeF(2F)-TSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₆-CO₂H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH₂

15 **SEQ ID NO:12****Example 3**

Y-Aib-EGT-αMeF(2F)-TSDYSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-EFI-(D-Glu)-YLIEGGPSSGAPPPS-NH₂

20 **SEQ ID NO:13****Example 4**

Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₆-CO₂H)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGPSSGAPPPS-NH₂

25

SEQ ID NO:14

Example 5

Y-Aib-EGT-αMeF(2F)-TSDVSI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₆-CO₂H)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGPSSGAPPPS-NH₂

30

-138-

SEQ ID NO:297

PSSG-R₂

SEQ ID NO:298

5 PSSGAPPPS-R₂

SEQ ID NO:299

PSSG

10 SEQ ID NO:300

PSSG-NH₂

SEQ ID NO:301

PSSGAPPPS

15

SEQ ID NO:302

PSSGAPPPS-NH₂

WE CLAIM:

1. A compound of the formula:

$$R_1X_1X_2X_3GTX_6TSDX_{10}X_{11}X_{12}X_{13}X_{14}DX_{16}X_{17}AX_{19}X_{20}X_{21}X_{22}X_{23}X_{24}X_{25}X_{26}X_{27}$$

$$X_{28}X_{29}X_{30}X_{31} \text{ (SEQ ID NO:3) wherein:}$$

R_1 is a modification of the N-terminal amino group wherein the modification is selected from the group consisting of Ac and absent;

X_1 is selected from the group consisting of Y, H, D-Tyr, F, desH, and desY;

X_2 is selected from the group consisting of Aib, α MeP, A, P, and D-Ala;

or X_1 and X_2 combine to form desH- ψ [NHCO]-Aib;

X_3 is selected from the group consisting of E, N, Aad, and cTA;

X_6 is selected from the group consisting of F, α MeF, and α MeF(2F);

X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, E, α MeF, α MeF(2F), I, α MeY, Q, D-His, D-Tyr, cTA, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X_{11} is selected from the group consisting of S, α MeS, and D-Ser;

X_{12} is selected from the group consisting of I, S, D-Ile, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X_{13} is selected from the group consisting of Nle, Aib, L, α MeL, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X_{14} is selected from the group consisting of L and K, wherein K is conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally conjugated to said K via a linker;

X_{16} is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, α MeK, R, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X_{17} is selected from the group consisting of K, Q, I, and an amino acid conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally conjugated to said amino acid via a linker;

X_{19} is selected from the group consisting of Q, A, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)_qCO₂H;

X₂₀ is selected from the group consisting of Aib, Q, H, R, K, αMeK, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, I, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

5 X₂₂ is selected from the group consisting of F and αMeF;

X₂₃ is selected from the group consisting of I, L, A, G, F, H, E, V, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₄ is selected from the group consisting of S, Aad, D-Glu, E, Aib, H, V, A, Q, D, P, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

10 X₂₅ is selected from the group consisting of Y and αMeY;

X₂₆ is selected from the group consisting of L, αMeL, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₇ is selected from the group consisting of L, I, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

15 X₂₈ is selected from the group consisting of E, A, S, D-Glu, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₉ is selected from the group consisting of Aib, G, A, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

20 X₃₀ is selected from the group consisting of C, G, G-R₂ and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H;

X₃₁ is absent or is selected from the group consisting of PX₃₂X₃₃X₃₄-R₂ (SEQ ID NO:4), PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5),

PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀-R₂ (SEQ ID NO:6), K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H] X₃₂X₃₃X₃₄-R₂ (SEQ ID NO:7), K[(2-

25 [2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H]

X₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:8), and K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H] X₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀-R₂ (SEQ ID NO:9); wherein:

30 X₃₂ is S or K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

-141-

X₃₃ is S or K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

X₃₄ is selected from the group consisting of G, C, and K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

5 X₃₅ is A or K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

X₃₆ is P or K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

10 X₃₇ is P or K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

X₃₈ is P or K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

X₃₉ is selected from the group consisting of C, S, and K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

15 X₄₀ is selected from the group consisting of C and K[(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H];

q is selected from the group consisting of 14, 15, 16, 17, 18, 19, and 20; and

R₂ is a modification of the C-terminal group, wherein the modification is NH₂ or absent;

20 or a pharmaceutically acceptable salt thereof;

wherein if X₃₀ is G-R₂, then X₃₁ is absent;

wherein no more than one of X₁₀, X₁₂, X₁₃, X₁₄, X₁₆, X₁₇, X₁₉, X₂₀, X₂₁, X₂₃, X₂₄, X₂₆, X₂₇, X₂₈, X₂₉, X₃₀, X₃₁, X₃₂, X₃₃, X₃₄, X₃₅, X₃₆, X₃₇, X₃₈, X₃₉, and X₄₀ may be a substituent that contains a fatty acid; and

25 wherein no more than one of X₃₀, X₃₄, X₃₉, and X₄₀ may be C; and

wherein if one of X₃₀, X₃₄, X₃₉, and X₄₀ is C, then none of X₁₀, X₁₂, X₁₃, X₁₄, X₁₆, X₁₇, X₁₉, X₂₀, X₂₁, X₂₃, X₂₄, X₂₆, X₂₇, X₂₈, X₂₉, X₃₀, X₃₁, X₃₂, X₃₃, X₃₄, X₃₅, X₃₆, X₃₇, X₃₈, X₃₉, and X₄₀ is a substituent that contains a fatty acid.

-142-

2. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein X_1 and X_2 do not combine to form desH- ψ [NHCO]-Aib.
3. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 or Claim 2 wherein X_{17} is an amino acid conjugated to a C_{16} - C_{22} fatty acid.
- 5 4. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 3 wherein:
 - X_1 is Y;
 - X_2 is Aib;
 - X_3 is E;
 - 10 X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, and Y;
 - X_{11} is S;
 - X_{12} is I;
 - X_{14} is L;
 - X_{16} is selected from the group consisting of K, E, Orn, Dab, and Dap;
 - 15 X_{17} is K conjugated to a C_{16} - C_{22} fatty acid wherein said fatty acid is conjugated to K via a linker;
 - X_{19} is Q;
 - X_{20} is Aib;
 - X_{21} is selected from the group consisting of H, Aad, D, Aib, T, A, and E;
 - 20 X_{22} is F;
 - X_{23} is I;
 - X_{24} is selected from the group consisting of S, Aad, D-Glu, and E;
 - X_{26} is L;
 - X_{27} is selected from the group consisting of L and I; and
 - 25 X_{28} is selected from the group consisting of E and A.
5. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 4 wherein:
 - X_{30} is G and X_{31} is $PX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}-R_2$ (SEQ ID NO:5), wherein X_{32} is S, X_{33} is S, X_{34} is G, X_{35} is A, X_{36} is P, X_{37} is P, X_{38} is P and X_{39} is S (SEQ ID
 - 30 NO:298).
6. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1, 2 or 5 wherein X_{17} is K.

7. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 4 wherein the linker comprises one to two amino acids.
8. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 7 wherein the linker comprises from one to two (2-[2-(2-Amino-ethoxy)-ethoxy]-
5 acetyl) moieties.
9. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 8 wherein the linker comprises one to two amino acids independently selected from the group consisting of Glu and γ -Glu.
10. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 9
10 wherein the linker has the following formula:

$$\{(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)_a-(\gamma-Glu)_b\}$$
 wherein a is 1 or 2; and b is 1 or 2.
11. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 10 wherein X_{17} is $K(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)_a-(\gamma-Glu)_b-CO-(CH_2)_q-CO_2H$, wherein: a is 1 or 2; b is 1 or 2; and q is selected from the
15 group consisting of 14 to 20.
12. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 11 wherein a is 1.
13. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 11
20 wherein a is 2.
14. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 11 to 13 wherein b is 1.
15. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 11 to 13 wherein b is 2.
- 25 16. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 11 to 15 wherein q is 18.
17. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 11 to 15 wherein q is 16.
- 30 18. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 11 wherein X_{17} is $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_q-CO_2H$.

-144-

19. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 18 wherein X_{27} is I.
20. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 18 wherein X_{27} is L.
- 5 21. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 19 wherein:
- R_1 is absent;
- X_1 is Y;
- X_2 is Aib;
- 10 X_3 is E;
- X_6 is α MeF(2F);
- X_{10} is selected from the group consisting of Y, 4-PaI, and V;
- X_{11} is S;
- X_{12} is I;
- 15 X_{13} is selected from the group consisting of L, Aib, and α MeL;
- X_{14} is L;
- X_{16} is selected from the group consisting of E, K, and Orn;
- X_{17} is K;
- X_{19} is Q;
- 20 X_{20} is Aib
- X_{21} is selected from the group consisting of E, A, and T;
- X_{22} is F;
- X_{23} is I;
- X_{24} is D-Glu;
- 25 X_{26} is L;
- X_{27} is I;
- X_{28} is E;
- X_{29} is G;
- X_{30} is G; and
- 30 X_{31} is $PX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}$ -R₂ (SEQ ID NO:5), wherein X_{32} is S, X_{33} is S, X_{34} is G, X_{35} is A, X_{36} is P, X_{37} is P, X_{38} is P and X_{39} is S (SEQ ID NO:298).

22. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 21 wherein X_{25} is Y.
23. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 22 wherein X_{13} is α MeL.
- 5 24. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 23 wherein X_{16} is Orn.
25. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 23 wherein X_{16} is E.
26. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
10 of claims 1 to 25 wherein X_{10} is Y.
27. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 25 wherein X_{10} is V.
28. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 25 wherein X_{10} is 4Pal.
- 15 29. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 11 wherein X_{13} is α MeL; a is 2; b is 1; q is 16; and X_{25} is Y.
30. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 11 wherein X_{13} is α MeL; a is 2; b is 1; q is 18; and X_{25} is Y.
31. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 11
20 wherein X_{13} is α MeL; a is 2; b is 1; q is 14; and X_{25} is Y.
32. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 24 wherein X_{10} is Y; and X_{16} is Orn.
33. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 23 wherein X_{10} is Y; and X_{16} is E.
- 25 34. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 23 wherein X_{10} is 4Pal; and X_{16} is Orn.
35. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 23 wherein X_{10} is V; and X_{16} is Orn.
36. A compound as claimed by Claim 1 wherein the compound is selected from the
30 group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, or a pharmaceutically acceptable salt thereof.

37. A compound as claimed by Claim 36 wherein the compound is SEQ ID NO:13, or a pharmaceutically acceptable salt thereof.
38. A compound as claimed by Claim 36 wherein the compound is SEQ ID NO:11, or a pharmaceutically acceptable salt thereof.
- 5 39. A compound, or a pharmaceutically acceptable salt thereof as claimed by Claim 1 wherein:
- X₁₀ is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, αMeF, αMeF(2F), I, αMeY, Q, D-His, E, cTA, and D-Tyr;
- X₁₂ is selected from the group consisting of I, D-Ile, and S;
- 10 X₁₃ is selected from the group consisting of Nle, Aib, L, and αMeL;
- X₁₄ is L;
- X₁₆ is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, αMeK, and R;
- X₁₇ is selected from the group consisting of K, Q, and I;
- 15 X₁₉ is selected from the group consisting of Q and A;
- X₂₀ is selected from the group consisting of Aib, Q, H, R, K, and αMeK;
- X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, and I;
- X₂₃ is selected from the group consisting of I, L, A, G, F, H, E, and V;
- X₂₄ is selected from the group consisting of S, Aad, D-Glu, E, Aib, H, V, A, Q, D, and P;
- 20 X₂₆ is selected from the group consisting of L and αMeL;
- X₂₇ is selected from the group consisting of L and I;
- X₂₈ is selected from the group consisting of E, A, S, and D-Glu; and
- X₂₉ is selected from the group consisting of Aib, G, and A.
- 25
40. A compound, or a pharmaceutically acceptable salt thereof as claimed by Claim 39 wherein:
- X₁ is Y;
- X₂ is Aib;
- 30 X₃ is E;
- X₁₀ is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, and Y;
- X₁₁ is S;

-147-

- X₁₂ is I;
X₁₆ is selected from the group consisting of K, E, Orn, Dab, and Dap;
X₁₉ is Q;
X₂₀ is selected from the group consisting of Aib and K;
5 X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, and E;
X₂₂ is F;
X₂₃ is I;
X₂₄ is selected from the group consisting of S, Aad, D-Glu, and E;
X₂₆ is L; and
10 X₂₈ is selected from the group consisting of E and A.
41. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 39 or 40 wherein one of X₃₀, X₃₄, and X₃₉ is C.
42. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 41 wherein the compound is modified using time-extension technology.
- 15 43. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 39 to 42 wherein q is 18.
44. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 39 to 42 wherein q is 16.
45. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 39 to 44 wherein X₂₇ is L.
- 20 46. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 39 to 45 wherein X₃₁ is PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂.
47. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 39 to 45 wherein X₃₁ is absent.
- 25 48. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 47 wherein R₂ is NH₂.
49. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein:
X₁₄ is L;
30 X₁₇ is selected from the group consisting of K, Q, and I;
X₃₀ is selected from the group consisting of G-R₂ and G; and
q is selected from the group consisting of 16, 18, and 20;

-148-

wherein if X_{30} is G, then X_{31} is selected from the group consisting of:

$PX_{32}X_{33}X_{34}-R_2$ (SEQ ID NO:4), wherein:

X_{32} is S, X_{33} is S, X_{34} is G and R_2 is absent (SEQ ID NO:299) or

X_{32} is S, X_{33} is S, X_{34} is G and R_2 is NH_2 (SEQ ID NO:300);

and

$PX_{32}X_{33}X_{34}X_{35}X_{36}X_{37}X_{38}X_{39}-R_2$ (SEQ ID NO:5), wherein:

X_{32} is S, X_{33} is S, X_{34} is G, X_{35} is A, X_{36} is P, X_{37} is P, X_{38} is P, X_{39} is S

and R_2 is absent (SEQ ID NO:301) or

X_{32} is S, X_{33} is S, X_{34} is G, X_{35} is A, X_{36} is P, X_{37} is P, X_{38} is P, X_{39} is S

and R_2 is NH_2 (SEQ ID NO:302); and

wherein one of X_{10} , X_{12} , X_{13} , X_{14} , X_{16} , X_{19} , X_{20} , X_{21} , X_{23} , X_{24} , X_{26} , X_{27} , X_{28} , and X_{29} is $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-\gamma Glu-CO-(CH_2)_qCO_2H$.

50. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 49 wherein:

X_1 is Y;

X_2 is Aib;

X_3 is E;

X_{10} is selected from the group consisting of A, L, H, 3Pal, 4Pal, V, Y, E, cTA, and $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_qCO_2H$;

X_{11} is S;

X_{12} is selected from the group consisting of I, D-Ile, and $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_qCO_2H$;

X_{14} is selected from the group consisting of L and $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_qCO_2H$;

X_{16} is selected from the group consisting of K, E, Orn, Dab, Dap, and $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_qCO_2H$;

X_{17} is selected from the group consisting of K and I;

X_{19} is selected from the group consisting of Q and $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_qCO_2H$;

X_{20} is selected from the group consisting of Aib and $K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_2-(\gamma-Glu)-CO-(CH_2)_qCO_2H$;

X₂₁ is selected from the group consisting of H, Aad, D, Aib, T, A, E, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₂ is F;

X₂₃ is I;

5 X₂₄ is selected from the group consisting of S, Aad, D--Glu, E, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₆ is selected from the group consisting of L, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₂₇ is selected from the group consisting of L and I;

10 X₂₈ is selected from the group consisting of E, A, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_qCO₂H;

X₃₀ is G; and

X₃₁ is selected from the group consisting of PX₃₂X₃₃X₃₄-R₂ (SEQ ID NO:4),

PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5),

15 X₃₂ is S;

X₃₃ is S;

X₃₄ is G;

X₃₅ is A;

X₃₆ is P;

20 X₃₇ is P;

X₃₈ is P; and

X₃₉ is S.

51. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 49 to 50 wherein X₂₀ is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H.

52. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 49 to 51 wherein PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ is selected from the group consisting of PSSGAPPPS (SEQ ID NO:301) and PSSGAPPPS-NH₂ (SEQ ID NO:302).

53. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 49 to 52 wherein q is 18.

-150-

54. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 49 to 52 wherein q is 16.
55. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein:
- 5 X₁ is selected from the group consisting of Y, F, D-Tyr, and desY,
X₆ is F; and
X₁₃ is selected from the group consisting of Aib, L, and αMeL.
56. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 55
- 10 wherein
- R₁ is absent;
X₂ is Aib;
X₃ is E;
X₁₀ is Y;
- 15 X₁₁ is S;
X₁₂ is I;
X₁₄ is L;
X₁₆ is selected from the group consisting of K, E, Orn, Dab, Dap, S, T, H, Aib, αMeK, and R
- 20 X₁₇ is an amino acid conjugated to a C₁₆-C₂₂ fatty acid wherein said fatty acid is optionally conjugated to said amino acid via a linker;
X₁₉ is Q;
X₂₀ is selected from the group consisting of Aib, Q, H, and K;
X₂₁ is selected from the group consisting of H, D, T, A, and E;
- 25 X₂₂ is F;
X₂₃ is I;
X₂₄ is selected from the group consisting of D-Glu and E;
X₂₆ is L;
X₂₇ is I;
- 30 X₂₈ is selected from the group consisting of E, A, S, and D-Glu;
X₂₉ is selected from the group consisting of Aib, G, and A;
X₃₀ is selected from the group consisting of C, G, and G-R₂;

-151-

X₃₁ is absent or is selected from the group consisting of PX₃₂X₃₃X₃₄-R₂ (SEQ ID NO:4), PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5), and PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀-R₂ (SEQ ID NO:6); wherein:

- 5 X₃₂ is S;
 X₃₃ is S;
 X₃₄ is selected from the group consisting of G and C;
 X₃₅ is A;
 X₃₆ is P;
 X₃₇ is P;
 10 X₃₈ is P;
 X₃₉ is selected from the group consisting of C and S; and
 X₄₀ is C.
57. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
 15 of Claims 55 to 56 wherein X₁₇ is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)_q-CO₂H.
58. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
 of Claims 55 to 57 wherein PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ is selected from the
 group consisting of PSSGAPPPS (SEQ ID NO:301) and PSSGAPPPS-NH₂ (SEQ
 20 ID NO:302).
59. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of
 Claims 55 to 58 wherein
 X₂₈ is A;
 X₂₉ G;
 25 X₃₀ is G;
 X₃₁ is PX₃₂X₃₃X₃₄X₃₅X₃₆X₃₇X₃₈X₃₉-R₂ (SEQ ID NO:5)
 X₃₄ is G; and
 X₃₉ is S.
- 30 60. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of
 Claims 55 to 59 wherein

-152-

X₁ is selected from the group consisting of Y and D-Tyr; and X₁₃ is αMeL.

61. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 55 to 60 wherein q is 16.
62. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of
5 Claims 55 to 60 wherein q is 18.
63. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein the compound is selected from the group consisting of SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, and SEQ ID NO:392.
- 10 64. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 63 wherein the compound is SEQ ID NO:305.
65. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 63 wherein the compound is SEQ ID NO:307.
66. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 63
15 wherein the compound is SEQ ID NO:308.
67. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 63 wherein the compound is SEQ ID NO:392.
68. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of
20 Claims 1 to 67 wherein the compound is a partial agonist on the GLP-1R.
69. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 68 wherein the compound stimulates GLP-1R induced activation of Gα_s in the GIPR and GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTPγS) Binding Assay.
- 25 70. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 68 or 69 wherein the compound is a partial agonist on the GLP-1R with respect to the β-arrestin-2 recruitment assay.
71. A method for treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis, dyslipidemia, and
30 metabolic syndrome, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70.

72. A method for treating obesity, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70.
73. A method for providing therapeutic weight loss, comprising administering to a
5 subject in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70.
74. A method for treating type 2 diabetes mellitus comprising administering to a subject in need thereof, an effective amount of the compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70.
- 10 75. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70 and at least one pharmaceutically acceptable carrier, diluent, or excipient.
76. A pharmaceutical composition as claimed by Claim 75 wherein the composition is administered as a subcutaneous injection.
- 15 77. A pharmaceutical composition as claimed by Claim 75 wherein the composition is administered orally.
78. A pharmaceutical composition as claimed by Claim 77 wherein the composition comprises a permeation enhancer and at least one pharmaceutically acceptable carrier, diluent, or excipient.
- 20 79. A pharmaceutical composition as claimed by Claim 78 wherein the permeation enhancer is selected from the group consisting of sodium decanoate ("C10"), sodium taurodeoxycholate ("NaTDC"), lauroyl carnitine ("LC"), dodecyl maltoside ("C12-maltoside"), dodecyl phosphatidylcholine ("DPC"), sodium taurodeoxycholate ("NaTDC"), and a Rhamnolipid.
- 25 80. A pharmaceutical composition as claimed by Claim 79 wherein the permeation enhancer is selected from the group consisting of C10 and LC.
81. A pharmaceutical composition as claimed by Claim 80 wherein the permeation enhancer is C10.
82. A pharmaceutical composition as claimed by any one of Claims 77 to 81 wherein
30 the composition comprises a permeation enhancer and a protease inhibitor, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

83. A pharmaceutical composition as claimed by Claim 82 wherein the protease inhibitor is selected from the group consisting of soybean trypsin inhibitor ("SBTI"), soybean trypsin-chymotrypsin inhibitor ("SBTCT"), ecotin, sunflower trypsin inhibitor ("SFTI"), leupeptin, citric acid, ethylenediaminetetraacetic acid ("EDTA"), sodium glycocholate and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride ("AEBSF").
84. A pharmaceutical composition a claimed by Claim 83 wherein the protease inhibitor is selected from the group consisting of SBTI, SBTICI, and SFTI.
85. A pharmaceutical composition as claimed by Claim 84 wherein the protease inhibitor is SBTI.
86. A pharmaceutical composition as claimed by any one of Claims 77 to 85 wherein the composition is a monolithic formulation.
87. A pharmaceutical composition as claimed by any one of Claims 77 to 85 wherein the composition is a multiparticulate formulation.
88. A pharmaceutical composition as claimed by any one of Claims 77 to 85 wherein the composition is a capsule or tablet.
89. A pharmaceutical composition as claimed by Claim 86 wherein the composition is an enteric capsule or tablet.
90. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70 for use as a medicament.
91. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70 for use in treating a disease selected from the group consisting of treating type 2 diabetes mellitus, obesity, NAFLD, NASH, dyslipidemia and metabolic syndrome.
92. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70 for use in treating treating type 2 diabetes mellitus.
93. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70 in the manufacture of a medicament for treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, NASH, dyslipidemia and metabolic syndrome.

94. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 70 in the manufacture of a medicament for treating type 2 diabetes mellitus.
95. A method for treating diabetes comprising administering an effective amount of a compound showing partial agonism of 75% or less in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTP γ S) Binding Assay, and an effective amount of a compound that is a GIP agonist.
96. A method as claimed by Claim 95 wherein the diabetes is type 2 diabetes.
97. A method as claimed by any one of Claims 95 or 96 wherein a compound showing partial agonism in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTP γ S) Binding Assay is co-administered with a compound having GIP agonist activity.
98. A method as claimed by any one of Claims 95 to 97 wherein a compound showing partial agonism in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTP γ S) Binding Assay is co-administered with a compound of a compound showing 35% or less in the GLP-CHO Cell β -Arrestin Recruitment Assay.
99. A method as claimed by any one of Claims 95 to 98 wherein a compound showing partial agonism in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTP γ S) Binding Assay is administered as an active agent within one week before or after a compound having GIP agonist activity.
100. A method as claimed by any one of Claims 95 to 98 wherein a compound showing partial agonism in the GLP-1R HEK293 Cell Membrane Guanosine 5'-(gamma-thio) Triphosphate-[³⁵S] (GTP γ S) Binding Assay is administered as an active agent within one week before or after a compound having GIP agonism and showing showing 35% or less in the GLP-CHO Cell β -Arrestin Recruitment Assay.